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 These studies investigated the impact of intensity and body temperature on 
performance and cardiovascular regulation during high intensity and prolonged 
exercise. In study 1, polyphenol antioxidant supplementation proved to have no effect 
on exercise performance and related variables (gross efficiency, perceived exertion, 
maximal power) during exercise in the heat. Furthermore, there were no differences 
between the cardiovascular or thermoregulatory responses between control and 
antioxidant treatments. Study 2 utilized an integrative approach to investigate a classic 
topic in exercise physiology, namely, is the cardiac output to oxygen consumption 
relationship linear across a wide range of exercise intensities? The slope of the CO vs. 
VO2 relationship was significantly reduced from 70 to 100% of VO2max when compared 
to the slope from 40 to 70% of VO2max (2.0 ± 0.4 vs. 4.4 ± 0.3 l/min, p = 0.025).  This 
finding, in combination with the plateau and eventual reduction in stroke volume at 
high intensity exercise compared to moderate intensity exercise (146.0 ± 16.6 vs. 138.5 
± 14.9 ml/beat, p = 0.015), argues in favor of a cardiac limitation to high intensity 
vi
exercise. This study also showed that the pattern of oxygen extraction at the whole 
body level (arterial venous O2 difference) and the muscle level (deoxygenated 
hemoglobin) is not similar and that muscle specific differences exist regarding oxygen 
extraction. Study 3 determined that hyperthermia (elevation of skin temperature by 
4.3ºC and core temperature by 0.8ºC) did not reduce SV independent of the increase in 
HR. Even under conditions of moderate hyperthermia the reduction in SV is due to the 
increase in HR and temporally unrelated to increases in cutaneous blood flow.  In 
summary, antioxidant supplementation had no effect on performance, cardiovascular, 
or thermoregulatory responses to exercise in the heat in well trained subjects. High 
intensity exercise is associated with a reduced rate of increase in the CO vs. VO2 
relationship. Finally, hyperthermia does not reduce SV during exercise when HR is 
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CHAPTER 1: INTRODUCTION 
 
During exercise the cardiovascular system is responsible for delivering 
oxygenated blood to the active muscle in order to meet the energetic demands of 
muscular activity. Similarly, during passive heating a severe strain, second only to 
exercise, is placed on the cardiovascular system as blood is directed from central to 
peripheral sites in an attempt to maintain thermal homeostasis (Rowell et al., 1969a; 
Rowell et al., 1969c; Johnson & DW, 1996; Crandall, 2008). Blood flow to active muscle 
and skin is ultimately limited by cardiac output (CO) as CO cannot continue to increase 
without end. Mean arterial blood pressure must be maintained in order to perfuse 
critical tissues such as the brain and heart. During maximal small muscle exercise, blood 
flow to active muscle can be as high as 250 to 400 ml/100g/min (Richardson et al., 1993; 
Saltin et al., 1998). Total skin blood flow, second only to skeletal muscle in terms of 
vasodilation capacity, can increase to as high as 8 l/min under severe heat stress (Rowell 
et al., 1969a). If muscle and skin were to maximally vasodilate, CO would have to exceed 
50 l/min. Most endurance trained athletes possess a CO in the 25 to 30 l/min range with 
a few elite individuals reaching a CO of 35 to 40 l/min (Ekblom & Hermansen, 1968). A 
reduction in muscle blood flow will limit the intensity and duration of exercise, whereas 
a reduction in skin blood flow will reduce heat dissipation, both of which are intimately 
linked to exercise tolerance and fatigue (Gonzalez-Alonso et al., 2008).  
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CHAPTER II: STATEMENT OF THE PROBLEM 
 
Study 1 focused on antioxidant supplementation and exercise performance in 
the heat. The specific aims of study 1 were: 
1. Determine if exercise performance in the heat is improved by antioxidant 
supplementation. 
2. If exercise performance is improved, is this improvement related to a reduction 
in cardiovascular strain and improved thermoregulatory control during exercise? 
 
Study 2 examined the cardiac output and stroke volume responses to high 
intensity exercise. The specific aims of study 2 were: 
1. Use a series of steady state intervals to determine if the cardiac output to VO2 
relationship is linear across a wide range of exercise intensities. 
2. To investigate the SV response to high intensity exercise. 
3. Compare central (cardiac output, stroke volume, heart rate, arterial venous O2 
difference) and peripheral cardiovascular responses (deoxygenated hemoglobin) 
from moderate to high intensity exercise. 
 
Study 3 focused on the independent effect of hyperthermia on the stroke 
volume response to moderate intensity exercise. The specific aims of study 3 were: 
2
1. Use a low dose of cardio-selective beta blockade (atenolol) to determine the 
effect of hyperthermia on SV independent of HR. 
2. Determine if the reduction in SV during prolonged exercise in the heat is 

















CHAPTER III: EXPERIMENTAL DESIGN 
Study 1: A placebo controlled randomized cross over design was used to determine if 
antioxidant supplementation improved exercise performance in the heat. Twelve well 
trained endurance athletes consumed twice daily supplements of either placebo or 
polyphenol antioxidant (POM) for one week. On day 6 of supplementation subjects 
performed a one hour bout of exercise in the heat (31.5ºC, 55% RH) which included 
determination of gross cycling efficiency, 30 minutes of cycling at 5% below lactate 
threshold, and a 10 minute time trial. During exercise measures of cardiovascular 
responses (HR, SV, CO, BP) and body temperatures (core and skin) were made. On day 7 
subjects returned to the laboratory and exercised in the heat at VO2max until 
exhaustion during which cardiovascular and body temperature measurements were 
made. Near infrared spectroscopy (NIRS) was used in a subset of subjects (n=5) to 
determine if the antioxidant treatment had any effect on muscle oxygenation / 
deoxygenation status during exercise.  
 
Study 2: This experiment focused on cardiovascular responses to high intensity exercise. 
Ten well trained cyclists performed a series of preliminary tests (incremental and 
discontinuous VO2max tests) to determine the minimal workrate needed to attain 
VO2max.  Following these preliminary tests interval cycling was performed. The 
intervals included exercise bouts at 40, 50, 60, 70, 80, 90 and 100% of VO2max. Cardiac 
output and stroke volume were measured during each interval and the CO vs. VO2 
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relationship and the SV response was established across a full range of exercise 
intensities.  Near infrared spectroscopy (NIRS) was used to determine the 
deoxygenation status of the vastus lateralis and the gastrocnemius. 
 
Study 3: In order to determine the effect of hyperthermia on SV independent of HR, 
eleven moderately trained subjects performed 1 hour of moderate intensity exercise 
(57% VO2max) under four experimental conditions; normothermia and placebo 
(NormoPL), normothermia and beta blockade (Normo βB), hyperthermia and placebo 
(HyperPL), and hyperthermia and beta blockade (Hyper βB). Hyperthermic conditions 
resulted in higher core and skin temperatures (0.8ºC and 4.3ºC, respectively). In order to 
prevent the normal increase in HR during exercise a low dose (0.2mg/kg) of the β1 
cardioselective beta blocker atenolol was ingested immediately prior to exercise. Beta 
blockade resulted in a nearly identical HR response for the NormoPL and Hyper βB 
thereby allowing for a direct comparison of SV under conditions of hyperthermia 










CHAPTER IV: STUDY 1 
EFFECT OF POLYPHENOL SUPPLEMENTATION ON PERFORMANCE AND 
CARDIOVASCULAR RESPONSES TO EXERCISE IN THE HEAT 
Abstract:           
 Dietary supplementation with antioxidants has gained popularity in recent years; 
however, the effects of antioxidants on exercise performance in the heat have not been 
well described. The purpose of this study was to determine if supplementation with 
polyphenol antioxidants (POM) improves exercise performance in the heat (31.5ºC, 55% 
RH) by altering the cardiovascular and thermoregulatory responses to exercise. Near 
infrared spectroscopy was measured in a subset of subjects (n = 5) to determine if 
POMS had any effect on muscle oxygenation and deoxygenation. Twelve well trained 
endurance athletes ingested POM or placebo (PLA) for 7 days. Consecutive days of 
exercise testing were performed at the end of the supplementation periods (i.e.; Day-1 
and Day-2 of testing). Performance during a 10 minute time trial (TT) on Day-1 was not 
different between treatments (PLA; 292 ± 33 W and POM; 279 ± 38 W, p = 0.12). 
Similarly, gross efficiency (GE), blood lactate (La), maximal neuromuscular power 
(Pmax), and ratings of perceived exertion (RPE) were not different between treatments. 
Furthermore, time to fatigue at VO2max on Day-2 was not different between 
treatments (PLA; 377 ± 117 sec vs. POM; 364 ± 128 sec, p = 0.61). The overall 
cardiovascular and thermoregulatory responses to exercise were not different between 




did not alter the cardiovascular or thermoregulatory response to exercise and 



























High intensity exhaustive exercise is associated with an increase in oxidative 
stress and free radical production (Davies et al., 1982; Bailey et al., 2004; Powers & 
Jackson, 2008). Furthermore, heat stress during exercise has also been shown to 
exacerbate the increase in oxidative stress during exercise (Flanagan et al., 1998; 
McAnulty et al., 2005). Therefore, the combination of exhaustive exercise and heat 
stress yields an ideal situation to test if antioxidant supplementation can improve 
exercise performance. To date, the results from experiments using antioxidants are 
equivocal as some investigators have found an increase (Medved et al., 2004a; Medved 
et al., 2004b; MacRae & Mefferd, 2006; McKenna et al., 2006; McKenna et al., 2008; 
McKenna & Hargreaves, 2008; Davis et al., 2009), no change (Cheuvront et al., 2009; 
Nieman et al., 2009; Utter et al., 2009), or decrease in performance (Gomez-Cabrera et 
al., 2008). 
Rather compelling evidence for the beneficial role of antioxidant 
supplementation and exercise performance has been shown with intravenous infusion 
of the free radical scavenger n-acetylcysteince (NAC) (Travaline et al., 1997; Bailey et al., 
2004; Medved et al., 2004a; Medved et al., 2004b; Matuszczak et al., 2005; McKenna et 
al., 2006; McKenna et al., 2008; McKenna & Hargreaves, 2008). NAC has been shown to 
delay fatigue during high intensity exercise by improving antioxidant status and ion (K+) 
regulation (Bailey et al., 2004; Medved et al., 2004a; Medved et al., 2004b; McKenna et 




and administered the dose via intravenous infusion. Contrary to these findings, most 
studies using oral administration of quercetin (a polyphenol antioxidant) have found no 
beneficial effect on exercise performance (Cheuvront et al., 2009; Nieman et al., 2009; 
Utter et al., 2009) while only one study in humans has shown improved exercise 
performance with oral quercetin ingestion (MacRae & Mefferd, 2006). Further 
investigation is required to determine if physiological dosages of antioxidants increase 
performance in healthy individuals.   
The antioxidant supplement used for this study is a mixture of high potency 
polyphenols found in pomegranate juice (POM).  Previous work has shown POM to 
possess higher antioxidant potency when compared to other polyphenol rich fruits and 
pharmacokinetic analysis revealed that plasma levels of the active antioxidants peak 1 
to 2 hours after consumption and are present in the urine for 48 hours (Seeram et al., 
2006; Seeram et al., 2008a; Seeram et al., 2008b). Furthermore, POM has been shown 
to increase nitric oxide (NO) bioavailability by protecting the molecule from oxidative 
destruction (Ignarro et al., 2006). Given the important roles of NO in cutaneous blood 
flow (Kellogg et al., 1998), thermoregulatory control of sweating (Welch et al., 2009), 
and skeletal muscle blood flow (Boushel et al., 2002; Mortensen et al., 2007), we 
thought POM would be an ideal antioxidant supplement to test for ergogenic properties 




The primary purpose of this study is to determine if POM supplementation 
improves exercise performance in the heat. We hypothesized that POM would increase 
performance in the heat and that this increase in performance would be associated with 
reduced cardiovascular strain and improved thermoregulation during exercise. 
Secondly, by performing exhaustive exercise on consecutive days, we were able to test 
















Subjects: Twelve healthy and well trained male cyclists (26.8 ± 5.0 yr of age) 
provided written informed consent to participate in this study. The protocol, 
experimental design, and informed consent were approved by the Institutional Review 
Board at The University of Texas at Austin. The subjects’ stature, body mass, and 
maximal oxygen consumption (VO2max) (means ± SD) were as follows: 1.80 ± 0.08 m, 
74.4 ± 8.8 kg, 4.459 ± 0.305 l/min, respectively.    
Experimental design: A double blind placebo controlled randomized cross over 
design consisting of two testing periods each lasting seven days was utilized. During 
each of the testing periods subjects performed exercise tests on days six and seven of 
supplementation or placebo control (Day-1 and Day-2 of testing, respectively). 
Consecutive (back-to-back) days of testing allowed us to determine whether or not 
supplementation with POM aided in recovery from exhaustive exercise performed on 
the previous day. In order to match diet from one treatment to the next subjects kept 
dietary logs for days four, five, and six and an overnight fast of at least 10 hours was 
performed prior to testing on days six and seven (i.e.; Day-1 and Day-2). All testing was 
performed at the same time of day. Prior to the start of the experimental trials subjects 
reported to the laboratory on three separate occasions to perform preliminary and 




Experimental protocol: Preliminary and familiarization testing was performed 
over the course of three visits to the laboratory (Sessions 1, 2, and 3). Session 1 included 
a submaximal exercise test on a cycle ergometer (Excalibur Sport, Lode, Groningen, The 
Netherlands) to determine lactate threshold and oxygen cost of loaded cycling and an 
incremental test to exhaustion to determine VO2max. Position on the ergometer was 
matched to the subject’s road bicycle and kept constant throughout the study. The 
submaximal test included 5 stages each lasting 5 minutes. Workrate was progressively 
increased by 20 to 40 watts depending on the fitness level of the subject. Lactate 
samples were collected during the final minute of each stage by a finger stick and 
analyzed with a portable lactate meter (Lactate Pro, Arkray Inc, Kyoto, Japan). Lactate 
threshold (LT) was determined as the 1 mmol increase above baseline. Oxygen 
consumption (VO2) was collected continuously during this test.  VO2 data was averaged 
over the final minute of each stage to determine the oxygen of cost of cycling at each 
workrate. Following the submaximal test subjects rested for 10 minutes before 
performing an incremental VO2max test, which lasted 8 to 12 minutes. Initial workrate 
for the VO2max test was set at a workrate that elicited approximately 80% of subject’s 
reported maximal heart rate (HRmax).  Session 1 was performed in the environmental 
chamber under moderate temperature conditions (24ºC and 50% relative humidity 
(RH)).    
Familiarization sessions 2 and 3 were performed on consecutive days. The 




timeline is described in Figures 1A and 1B. The purpose of the familiarization trials was 
twofold; first, acquaint subjects with the testing procedures and the demands of the 
exercise tests, and second, determine the appropriateness of the workrates for each of 
the exercise tests. Upon arrival at the laboratory subjects were asked to void their 
bladder and obtain a nude bodyweight (Lifesource UC-321 precision scale, Lifesource). 
Nude bodyweight was also obtained after exercise. Subjects then inserted a rectal 
temperature probe (model 401, Yellow Springs Instrument) 12 cm past the anal 
sphincter.  Subjects were then instrumented and escorted to the environmental 
chamber and asked to sit quietly on the ergometer for 5 minutes while resting blood 
pressure measurements were made (STBP-680, Colins). Subjects then performed a 5 
minute warm-up at 60% of their VO2max. Immediately following the warm-up subjects 
exited the environmental chamber and performed 4 maximal power sprint tests on an 
inertial load ergometer. After the maximal power tests subjects reentered the 
environmental chamber and began the 1 hour bout of exercise.  During the first 20 
minutes of the 1 hour test subjects cycled at 40, 50, 60, and 70% of VO2max for 5 
minutes for the determination of gross cycling efficiency (APPENDIX A). At minute 20 
workrate was adjusted to 5% below LT. At minute 50 a 10 minute time trial (TT) began. 
The TT began at a workrate that would elicit approximately 90% of VO2max. After the 
first 2 minutes of the TT the subject was able to change the workrate every 30 seconds. 
The power output was changed by a member of the research team as instructed by the 




research team. The goal of the TT was to perform as much work as possible during the 
10 minute period. A similar protocol has been successfully used by our lab (Below et al., 
1995).    
On Day-2 of the experimental testing (and familiarization session 3) subjects 
performed the same warm-up and series of maximal power tests as previously 
described (Figure 1B). After completion of the maximal power test subjects entered the 
environmental chamber and began a 10 minute exercise bout which consisted of 5 
minutes of cycling at 60% and 5 minutes at 70% of VO2max. At min 10 an open-ended 
ride to fatigue began. Workrate for this performance test was set so as to elicit 100% of 
VO2max. Previous work from our lab has shown that well trained endurance athletes 
were able to cycle for 5 to 9 min at this workrate (Dingwell et al., 2008).  Subjects were 
verbally encouraged to give a maximal effort during all trials. All trials except session 1 
(preliminary submaximal and VO2max tests) were performed in the environmental 
chamber under warm conditions (dry bulb temperature: 31.5ºC, RH: 55.1%)  
Supplementation: Supplements of POM or PLA (500 mL) were taken twice daily 
at 12 hour increments over the seven-day testing period.  On day 6 (Day-1 of testing) 
and day 7 (Day-2 of testing), subjects consumed the supplement approximately 30 
minutes before the start of the exercise test. POM and PLA drinks were provided by 
POM Wonderful, LLC (Los Angeles, CA).  Products were shipped frozen and were stored 




95.5% eligatanins (22.5% as punicalins and punicaligans), 3.5% ellagic acid, and 1% 
anthocyanins.  Both POM and PLA contained a very low amount of carbohydrate (4 
grams maltodextrin and sucralose) with additional coloring and flavoring to blind the 
treatments. Subjects were reminded verbally and through e-mail communication to 
consume the experimental supplements at the required times.  
Respiratory measurements: Oxygen consumption was determined using a 
commercially available metabolic cart (Max II Modular Metabolic System, AEI 
Technologies, Pittsburg, PA) while subjects cycled on an electromagnetically braked 
ergometer. Gas analysis was performed using oxygen and carbon dioxide analyzers 
(Applied Electrochemistry, Models S-3A/I and CD-3A, respectively) while the subjects 
breathed through a one-way valve (Hans Rudolph, Kansas City, MO).  Ventilation was 
measured with an inspiratory pneumotachometer (Hans Rudolph, Kansas City, MO). 
Cardiovascular measurements: An impedance cardiography device (Physioflow 
Type PF05L1, Manatec Biomedical, Macheren, France) was used to measure heart rate 
(HR), stroke volume (SV), and cardiac output (CO). The Physioflow unit uses changes in 
transthoracic impedance (dZ) in response to an administered electrical current during 
cardiac ejection to calculate SV. The Physioflow emits a high frequency (75 kHz) and very 
low-amperage (3.8 mA peak-to-peak) alternating electrical current via skin electrodes 
(Series 810 electrodes, S&W Healthcare). Two pairs of electrodes, one transmitting and 




clavicular fossa at the left base of the neck and at the midpoint of the thoracic region of 
the spine. An additional pair of electrodes was used to monitor a single ECG lead (V1/V6 
position).  The physioflow impedance cardiograph has been validated against the direct 
Fick method (Charloux et al., 2000) and mean differences between CO as measured by 
the direct Fick and the physioflow were not found to be significantly different at rest, 
during submaximal exercise, or during incremental maximal exercise (Richard et al., 
2001). Prior to placement of electrodes, the skin was cleaned with isopropyl alcohol and 
a gauze sponge. Subjects wore a spandage® shirt around their torso and coban® tape 
around their neck to reduce movement of electrode wires and to insure that electrodes 
were kept in place throughout the duration of the exercise tests.  
Blood pressure (BP) was collected using an automated blood pressure device 
(STBP-680, Colins). Resting measurements were made while the subject sat quietly on 
the cycle ergometer with their right arm relaxed on the handlebars of the ergometer. 
During the 1 hour exercise bout of Day-1 BP was measured with the subject’s arm 
relaxed on the handlebars during the final minute of each submaximal stage, at min 30 
and 45, and again at two minute intervals during the 10 min TT.      
Body temperatures and rating of perceived exertion: Core temperature (Tcore) 
was measured using a rectal temperature probe inserted 12 cm past the anal sphincter.  
Skin Temperature (Tskin) was measured using skin thermistors (model 409A, Yellow 




Tskin was calculated based on the equation of Hardy and Dubios (Hardy et al., 1938). 
Body temperature (Tbody) was calculated using the equation of Baum et al. (Baum et 
al., 1976) (Tbody = .87*Tcore + .13*Tskin).  All temperature data was collected 
continuously on a personal computer using Tracer-Daq (Measurement Computing) 
software interfaced with an A/D board (USB Temp, Measurement Computing). Ratings 
of perceived exertion (RPE) were collected using the Borg 6 to 20 point scale (Borg, 
1975) at min 30 and 45 of the one hour exercise bout on Day-1.    
Near Infrared Spectroscopy: Muscle oxygenation was determined by a 
frequency-domain multi-distance NIRS system (Oxiplex TS, ISS, Champaign, IL) in a 
subset of subjects (n = 5). The principles of operation and algorithms used by this NIRS 
system have been previously described (Gratton et al., 1997). For this experiment the 
NIRS probe was positioned longitudinally on the belly of the vastus lateralis 
approximately 12 cm above the lateral border of the patella. The probe was held in 
place by a Velcro strap provided by the manufacturer and the subject’s cycling shorts 
were pulled over the probe to minimize movement of the probe. The NIRS system was 
calibrated prior to each test after a warm-up of at least 30min. The calibration was done 
with the optical probe placed on the calibration block with absorption and reduced 
scattering coefficients previously measured and correction factors were determined and 
automatically implemented by the equipment’s software for the calculation of the 
absorption coefficient (μa) and reduced scattering coefficient (μs) for each wavelength 




absolute concentration of oxyhemoglobin (HbO) and deoxyhemoglobin (HHb) 
(expressed in μM). The HHb reported in the present study was calculated incorporating 
the continuous measurement of μs made throughout the exercise test, i.e.; without 
assuming a constant for scattering.  All NIRS data was averaged over 30 seconds.  
Maximal neuromuscular power: Maximal neuromuscular power (Pmax) was 
determined by the inertial load ergometry. Validation and reliability of the inertial load 
has been previously described in detail (Martin et al., 1997). Briefly, the inertial load 
ergometer uses the resistance created by the moment of inertia of a flywheel to 
represent the force that the subject accelerates during the test. Power is calculated as 
the product of inertia, angular velocity and angular acceleration.  Flywheel angular 
velocity and acceleration are determined by an optical sensor and micro-controller 
based computer interface which measures time (± 0.5 microsecond) and allows power 
to be calculated instantaneously every 3 degrees of pedal crank revolution and averaged 
over one complete revolution of the pedal cranks (Pmax). The coefficient of variability 
with this technique is ± 2.5% and this high degree of reliability has allowed mean 
treatment differences in maximal power of 2-3% within a population to become 
statistically significant (Trinity et al., 2006; Trinity et al., 2008). The measurement of 
Pmax requires maximal effort over 2 to 3 seconds with 60 seconds of passive recovery 
between efforts. Subjects performed familiarization with the inertial load ergometer 




experimental trials. All Pmax values were obtained after a 5 minute warm-up and prior 
to the prolonged exercise tests.    
Statistics:  All statistical analyses were performed using SPSS version 14.0. Data 
are presented as mean ± standard deviation of the mean.  For the purpose of clarity 
data presented in figures is presented as mean ± standard error. A two-way (trial x time) 
repeated measures ANOVA analyses was used to test for significant differences. A priori 
analyses of sequential time points was employed following a significant main effect of 
time. The number of a priori comparisons was limited to k-1 for each variable measured, 
where k is equal to the number of means compared. If the interaction (treatment x 
time) was found to be significant, pairwise comparisons were made using a paired 
samples T-test.  If Mauchly’s test of sphericity was violated, the Greenhouse-Geisser 
correction was used to correct for this violation. Average power during the TT (D-1) and 
time to fatigue (D-2) were analyzed using a paired samples T-test. For statistical analysis 
data from Day-1 was separated into two groups; data from rest to 50 minutes of 











DAY - 1: 
Subject characteristics and environmental factors: BW prior to exercise was not 
different for both treatments (Table 1.1). BW post exercise was similar indicating that 
the reduction in BW was not different for both treatments. The reduction in BW from 
pre to post exercise (PLA; -0.7% and POMS; -0.6%) was significant (p < 0.01); however, 
dehydration of less than 1% is minor and not expected to be a confounding variable in 
the study.          
Dry bulb temperature (DB), black globe temperature (BG), and relative humidity 
(RH), were held constant over the course of each trial and no differences existed 
between trials. DB averaged 31.5 ± 0.7ºC while BG averaged 31.6 ± 0.5ºC with an 
average RH of 55.1 ± 3.7%.   
Exercise intensity and respiratory responses: Actual exercise intensity during the 
first 50 minutes of exercise is reported in Table 1.2. During the first 20 minutes of 
exercise subjects cycled at workrates that elicited 41, 53, 63, and 74% of VO2max. VO2 
increased to the same extent at each of the 4 stages for both treatments indicating that 
GE was not influenced by the POMS supplementation (Table 1.2). GE increased as 
workrate increased with the highest GE occurring at approximately 74% of VO2max. 
From minute 20 to 50, workrate was adjusted to 5% below lactate threshold which 




Exercise performance: There was no difference in average power output during 
the 10 minute TT. Subjects averaged 292 ± 33 W and 279 ± 38 W (p = 0.12) for the PLA 
and POMS trials, respectively (Figure 1.2). Workload, when divided into quartiles (2.5 
minute periods), was not different between trials at any time point (Table 1.3). 
Workrate was significantly reduced from the first to second quartile of the TT and 
continued to fall from the second to third quartile for both PLA and POMS. Workrate 
significantly increased during the final quartile during POMS but not during PLA. 
However, despite this end spurt during the POMS trial, average workrate during the last 
2.5 minutes of the TT was not different between the trials. Lactate levels at minutes 5, 
30, and post TT were not different between trials, similarly RPE was not different 
between trials (Table 1.4). 
Measures of maximal power (Pmax), instantaneous power (IP), and velocity at 
maximal power (RPM) were not different between day-1 and day-2 or between 
treatments (Table 1.5).   
Thermoregulatory responses: There were no pairwise differences between 
treatments for Tcore, Tskin, or Tbody during the one hour bout of exercise. Tcore 
increased with each increase in workload during the first 20 minutes of exercise and 
continued to increase from minute 20 to 50 as well as during the 10 minute TT reaching 
a peak value at the end of the TT (PLA; 38.90 ± 0.34ºC and POMS; 38.87 ± 0.28ºC). The 




minute 20 to 50 was slightly higher for POMS than PLA (PLA; 0.64ºC [rate = 0.021ºC/min] 
vs. POMS; 0.74ºC [rate = 0.025ºC/min], p < 0.01) (Table 1.6). Tskin was slightly higher 
prior to exercise during the POMS trials; however, by minute 5 of exercise this 
difference was abolished. Tskin was maintained between 32.0 and 32.3ºC from minute 5 
to minute 20 and reduced by 1.1ºC (PLA) and 0.8ºC (POMS) from minute 20 to minute 
50 (p < 0.05). Similar to Tcore, the increase in Tbody from minute 20 to 50 was greater 
for POMS than PLA (PLA; 0.41ºC vs. POMS; 0.54ºC, p < 0.01). Overall, there were no 
pairwise differences between trials at any time point during exercise for Tcore, Tbody, 
and Tskin. However, the increase in Tcore and Tbody from minute 20 to minute 50 was 
significantly greater during POMS than PLA.   
Cardiovascular responses: The HR response to the first 50 minutes of exercise 
was similar for PLA and POMS (Figure 1.4). Significant HR drift of 9 bpm (PLA; 5.6%, p 
<0.01) and 11 bpm (POMS; 7.4%, p <0.01) occurred from minute 20 to 50. HR increased 
to the same extent during the TT for both treatments (Figure 1.4). Due to the slightly 
lower (non-significant) power output during the POMS trial the overall treatment by 
time interaction for HR was significant during the TT; however, there were no pairwise 
difference between the treatments. The SV response to exercise was similar for PLA and 
POMS (Table 1.6). SV plateaued between 60 and 70% of VO2max, furthermore SV was 
not significantly increased during the TT despite increases in HR and CO. As with HR and 
SV, CO was not different between treatments (Table 1.6). CO increased by 1 to 1.5 l/min 




50 and peaked at minute 58 and minute 60 for PLA (23.5 ± 3.8l/min) and POMS (23.6 ± 
4.1l/min), respectively.  
There were no differences between trials for SBP, DBP, and MABP (Table 1.6). 
SBP increased with each increase in exercise intensity and peaked at minute 20. SBP was 
maintained between minute 20 and 50 and increased during the TT, reaching peak 
values at minute 58 and 60 for PLA and POMS, respectively. DBP was reduced over the 
course of the first 20 minutes of exercise and reached a minimum at minute 20. DBP 
gradually increased from minute 20 to minute 50, and overall (effect of time 
independent of treatment) this increase was significant (p = 0.003). MABP increased 
with exercise and reached a peak value at minute 50. MABP was not different from 
minute 20 to minute 50.  SVR was reduced by 50% with the onset of exercise and 
continued to decrease as exercise intensity increased.      
Overall, no differences between treatments were observed for any CV related 
variable. HR and CO increased linearly as exercise intensity increased. Significant HR 
drift occurred between minute 20 and minute 50. This HR drift was accompanied by an 
increase in CO; however, SV, MABP, and SVR were all maintained during this period.   
NIRS and muscle oxygenation: There were no differences between PLA and 
POMS for any of the NIRS related variables (Table 1.7). OxSat was reduced by 11.5% 
(PLA) and 7.6% (POMS) from minute 5 to 20 and continued to decline by 5% during the 




TT. HbO showed no change during the first 50 minutes of exercise but was reduced by 
5% (POMS) and 6% (PLA) during the TT. HHb increased 19.7% and 21.5% from 41 to 74% 
of VO2max for PLA and POMS, respectively and continued to increase by 7% (PLA) and 
7.5% (POMS) during the TT. 
DAY - 2: 
Exercise performance and respiratory responses: During the fatigue test subjects 
cycled at a constant workrate of 338 ± 27 W. There was no difference in time to fatigue 
between the two treatments (PLA; 377 ± 117 sec vs. POM; 364 ± 128 sec, p = .61) 
(Figure 1.3). Based on the design of the study (i.e.; back to back days of exhausting 
exercise) we were able to ascertain that the treatment had no effect on aiding recovery 
from Day-1 to Day-2 as performance on Day-2 was not different between treatments. 
During the fatigue test, VO2 peaked at 60% of completion time for POMS and at 80% of 
completion time for PLA. The highest VO2 obtained during the fatigue trial 
corresponded to 99% of VO2max that was achieved during preliminary testing (Table 
1.8).  
Thermoregulatory responses:  Tcore, Tskin, and Tbody were not different 
between trials. Tcore at the start of the fatigue trial was 37.7 ºC for both trials and 
increased to 38.3ºC. Tcore increased at a rate of approximately 0.1ºC/min. Tskin was 




decreased by 0.4ºC until the final portion of the trial. Tbody, like Tcore, increased 
throughout the course of the trial and was 0.5ºC higher at fatigue than start (Table 1.8).  
Cardiovascular responses:  There were no significant differences in HR, SV, or Q 
for the two treatments (Table 1.8). The HR response was nearly identical for both trials. 
Over the course of the fatigue trial HR increased to 181.2 and 181.5 bpm for PLA and 
POMS, respectively. No significant change in SV was observed during the fatigue trial. 
This finding is in agreement with Day-1 data and indicates that SV did not significantly 
increase beyond 74% of VO2max. CO peaked just prior to fatigue (i.e.; at the final time 
point) and was increased by 4 l/min at this time point when compared to the starting 
value (Table 1.8). 
NIRS and muscle oxygenation: There was no effect of treatment on any of the 
NIRS variables measured (Table 8). However, significant changes over time did occur for 
OxSat and HHb. OxSat declined over the duration of the fatigue trial with final values at 
fatigue being 5% lower than starting values. HHb increased 8.5% (PLA) and 9.7% (POMS) 
over the course of the fatigue trial with most of the increase (~ 60%) in HHb occurring 
during the final 40% (i.e.; during the last 2.5 minutes) of the exercise bout. The time 
course with which VO2 and HHb increased during the fatigue trial is not similar as most 
of the increase in VO2 (~90%) occurred during the first 40% (i.e.; during the first 2.5 
minutes) of the fatigue bout. This mismatch in VO2 and HHb may have implications for 





The purpose of this study was to determine if oral antioxidant supplementation 
can improve exercise performance in the heat and aid in recovery from exhaustive 
exercise. We hypothesized that antioxidant supplementation might improve exercise 
performance and that this improvement would be associated with alterations in 
cardiovascular and thermoregulatory function during exercise. The primary finding of 
this study is that antioxidant supplementation did not improve performance during 
prolonged exhaustive exercise (one hour exercise including 10 minute time trial) or 
during high intensity exercise (time to fatigue at VO2max) in the heat. Another novel 
finding afforded by the back to back days of high intensity exhaustive exercise showed 
that antioxidant supplementation did not aid in recovery from an exhaustive bout of 
exercise as there was no difference in performance from Day-1 to Day-2. Furthermore, 
variables associated with performance; gross cycling efficiency, blood lactate 
accumulation, maximal neuromuscular power, and rating of perceived exertion were 
not altered by POM supplementation. Accordingly, the cardiovascular and 
thermoregulatory responses were not different between the treatments.  
This study is important as the use and popularity of antioxidant supplements has 
dramatically increased in recent years. Despite a rapid growth in popularity, scientific 
validation of the ergogenic benefits of antioxidants remains scarce. Antioxidants have 
been shown to improve (Medved et al., 2004a; Medved et al., 2004b; MacRae & 




2008; Davis et al., 2009), have no effect (Cheuvront et al., 2009; Nieman et al., 2009; 
Utter et al., 2009), or decrease (Gomez-Cabrera et al., 2008) exercise performance. 
Similarly, adaptations associated with exercise have been shown to be improved (Davis 
et al., 2009), not changed (Gomez-Cabrera et al., 2008), or decreased, with exercise 
(Lescaudron et al., 1999; Richardson et al., 2007; Gomez-Cabrera et al., 2008; Wray et 
al., 2009). The efficacy of antioxidant supplementation is complex and will undoubtedly 
be dependent on the population (healthy vs. diseased, young vs. old) (Kirby et al., 2009) 
and the mode of exercise testing/training (endurance vs. resistance).   
The rationale behind our focus on the cardiovascular and thermoregulatory 
function during exercise originated from the finding that POMS has been shown to 
increase NO bioavailability by protecting NO from oxidative destruction (Ignarro et al., 
2006). Given that NO has important roles in cutaneous blood flow (Kellogg et al., 1998), 
thermoregulatory control of sweating during exercise (Welch et al., 2009), and skeletal 
muscle blood flow (Boushel et al., 2002; Mortensen et al., 2007), we hypothesized that 
POMS would reduce the CV strain and improve thermoregulation during exercise in the 
heat. This was apparently not the case for our well trained subjects as there were no 
differences in CV or thermoregulatory function between the treatments.    
During exercise there is an increase in reactive oxygen species (ROS) and free 
radical production (Davies et al., 1982; Powers & Jackson, 2008). Originally the increase 




biochemistry; however, free radicals are now becoming recognized as important 
molecules necessary for maintaining cellular homeostasis (Richardson et al., 2007). 
Oxidative stress may play a necessary or regulatory role in many physiological processes 
and functions; mitochondrial biogenesis, vascular function, muscle regeneration, and 
inflammation. Based upon this theory, disrupting or reducing the normal increase in 
oxidative stress caused by exercise may reduce or attenuate the adaptations associated 
with exercise. That being said there are situations in which oxidative stress is chronic 
(e.g.; aging, disease) and normal function is diminished as a result of this chronic 
oxidative stress. This study was designed in order to increase the oxidative stress that is 
associated with exercise by performing high intensity exercise with the addition of a 
heat stress. Both high intensity exercise and heat stress have been shown to induce an 
elevation in oxidative stress beyond normal conditions (McAnulty et al., 2005; Tyldum et 
al., 2009). In order to test the efficacy of the antioxidant supplement it is important to 
create a situation in which the oxidative stress was elevated.    
The antioxidants found in the POMS supplement contain high concentrations of 
polyphenols, specifically elligatannis, which have been shown to possess higher 
antioxidant potency when compared to other polyphenol rich fruits (Seeram et al., 
2008a; Seeram et al., 2008b). Pharmacokinetic analysis revealed that plasma levels of 
ellagic acid, a metabolite of the POMS supplement, peaked 1 and 2 hours post 
consumption and was present in some urine samples 48 hours after initial ingestion 




demonstrated that POM supplementation (identical composition as that used in the 
current study) was successful at attenuating the muscle weakness and soreness 
experience following eccentric exercise. Given that subjects consumed the supplement 
twice daily for 7 days and consumed the supplement approximately 30 minutes before 
exercise we are confident that the active antioxidants from the supplement were in the 
system during exercise. Furthermore, similar polyphenol antioxidants (POM specifically) 
have been shown to have high biological activity and potent treatment effects in clinical 
conditions associated with oxidative stress and/or vascular dysfunction such as type 2 
diabetes (Rosenblat et al., 2006), atherosclerosis (Aviram et al., 2004), cancer (Adams et 
al., 2006), and rheumatoid arthritis (Shukla et al., 2008).    
While the antioxidant supplementation used in the current study did not have 
any effect on performance, cardiovascular, and thermoregulatory function, there is 
evidence supporting the role of such supplementation during conditions of disease or 
dysfunction. The present study used highly trained endurance athletes which may have 
an up-regulated endogenous antioxidant enzyme system capable of coping with the 
increase in oxidative stress brought about by high intensity exercise in the heat. 
Trombold et al. (Trombold et al., in press) showed that following damaging eccentric 
exercise both novice and experienced resistance trained individuals exhibited an 
accelerated rate of muscle strength recovery at 48 and 72 hours post exercise. A recent 
study (Nieman et al., 2009) showed that quercetin (flavanoid antioxidant) 




days of prolonged cycling exercise but did not affect mitochondrial biogenesis. Chronic 
supplementation with polyphenols has been shown to improve endothelial nitric oxide 
synthase (eNOS) and vasoreactivity in response to shear stress in patients with 
cardiovascular disease (de Nigris et al., 2007).  A possible mechanism for the increased 
vascular function may be due to an increase in NO bioavailability as POMS has been 
shown to augment the biological action of NO by protecting the molecule from oxidative 
destruction (Ignarro et al., 2006). Ignarro et al.  (Ignarro et al., 2006) showed that POMS 
was only effective at upregulating eNOS expression and endothelial function in 
dysfunctional endothelial cells and not in healthy endothelial cells. This might be a 
possible reason why we showed no difference in CV and thermoregulatory function in 
our healthy, well trained subjects. Other studies (Plotnick et al., 2003; Barringer et al., 
2008) created an acute state of metabolic dysfunction in humans via consumption of a 
high fat meal and showed that polyphenol supplementation was effective at preventing 
vascular dysfunction following the meal.  Similarly, mice fed a high fat diet in 
combination with resveratrol showed improved insulin sensitivity and reduced mortality 
despite increased bodyweight (Baur et al., 2006).  Additionally, the resveratrol fed mice 
displayed reduced hepatic pathology, preserved mitochondria content, and improved 
motor coordination over their lifespan when compared to control mice on the high fat 
diet. These findings along with the present study provide support for the idea that 




(cardiovascular, metabolic), disuse (inactivity, sedentary lifestyle), and dysfunction 
(inflammation, metabolic).     
Despite the previously described argument against the ergogenic benefits of 
antioxidant supplements, there are a few studies that have shown dramatic 
improvements in exercise performance following administration of antioxidants. 
However, we are aware of only one study that showed improved exercise performance 
with oral antioxidant supplementation in healthy individuals (MacRae & Mefferd, 2006). 
This was the impetus for performing the current study. Collectively, investigations into 
the effectiveness of supplementation with antioxidant vitamins E and C show that these 
vitamins do not improve human exercise performance (Clarkson, 1995; Kanter & 
Williams, 1995; Powers et al., 2004). However, rather compelling evidence has been 
gathered showing the ergogenic effect of the free radical scavenger, N-acetylcysteine 
(NAC) (Travaline et al., 1997; Medved et al., 2004a; Medved et al., 2004b; Matuszczak et 
al., 2005; McKenna et al., 2006; McKenna et al., 2008; McKenna & Hargreaves, 2008). 
Pertinent to the present study, a series of studies (Medved et al., 2004a; Medved et al., 
2004b; McKenna et al., 2006; McKenna & Hargreaves, 2008; Murphy et al., 2008) was 
performed investigating the effects of NAC infusion on time to fatigue and the 
mechanisms responsible for the observed improvements in performance. Medved et al. 
(Medved et al., 2004b) infused NAC prior to and during prolonged cycle exercise and 
showed a 26% improvement in performance (time to fatigue at 92% of VO2max). The 




availability. A follow-up study (Medved et al., 2004a) revealed that the improvement in 
time to fatigue was correlated with VO2max, indicating that the most fit individuals are 
most likely to benefit from the NAC supplementation and that the improvement was 
also associated with improved K+ regulation. McKenna et al. (McKenna et al., 2006) 
showed that NAC attenuates muscle fatigue during cycling exercise by preserving 
Na+/K+ pump activity leading to the improved K+ regulation. Discrepancies between the 
aforementioned studies and the present study may be due to a multitude of factors; 1) 
method of administration (intravenous infusion vs. oral consumption), 2) the amount of 
antioxidant administered (physiological vs. supraphysiological), 3) the type of 
antioxidant provided (NAC vs. polyphenol), and 4) the environmental conditions under 
which exercise was performed (warm vs. moderate). While all four of these differences 
may contribute to the discrepancies, the most likely are the manner in which and the 
amount of the antioxidant that was administered. The use of an intravenous infusion of 
NAC prior to and during the exercise bout allowed for the delivery of a 
supraphysiological dose of the antioxidant. While the NAC infusion studies provided 
valuable information regarding mechanisms related to muscle fatigue and the role of 
ROS and free radicals on muscle fatigue, they do not, from a practical and application 
oriented viewpoint, provide information regarding the ergogenic benefit of oral 
antioxidant supplementation.            
Oral supplementation with physiological dosages of the antioxidant quercetin 




Mefferd, 2006) found a small but significant 3% increase in 30 kilometer time trial 
performance after 6 weeks of quercetin supplementation. Davis et al. (Davis et al., 
2009) fed mice quercetin for 7 days and showed improved exercise tolerance (time to 
fatigue on a treadmill) and mitochondrial biogenesis. However, in support of the 
findings of the current study, Cheuvront et al. (Cheuvront et al., 2009) reported that 
quercetin supplementation (2,000 mg) did not affect total work performed during a 15 
minute time trial in the heat (40 C; 20 to 30% RH) or alter the pacing strategy during the 
time trial. In agreement with the current study, quercetin did not have any impact on 
physiological or perceptual measures during exercise. Neiman et al. (Nieman et al., 
2009) found no difference between quercetin and placebo in any performance related 
measurement. These previous findings, coupled with the results of the present study, 
indicate that antioxidant supplementation, in general, does not improve exercise 
performance in healthy individuals.        
Exercise performance in the present study was maintained during POMS 
supplementation. However, recent findings argue that acute and chronic antioxidant 
supplementation in healthy individuals may disrupt or have a negative impact on 
physiological function and may attenuate or reduce the positive outcomes associated 
with exercise training.  Richardson et al. (Richardson et al., 2007) reduced free radical 
production in healthy subjects via an oral antioxidant cocktail. This reduction in free 
radicals disrupted the balance between pro and antioxidant forces and negatively 




pressure in slightly hypertensive elderly men yet when exercise was combined with 
antioxidant administration the beneficial improvements yielded from the exercise 
training was blunted (Wray et al., 2009). Recent findings (Gomez-Cabrera et al., 2008) 
on rats showed that vitamin C administration attenuated adaptations to exercise 
training. Endurance trained rats improved exercise time to exhaustion nearly 3 fold (99 
to 284 min; 187% increase) whereas the group that also consumed vitamin C exhibited a 
marked reduction in improvement of endurance capacity (101 to 128 min; 26% 
increase). Adaptations associated with resistance exercise training may also be 
negatively influenced as the normal inflammatory response to muscle damage appears 
to have a stimulatory effect on skeletal muscle adaptations, specifically muscle 
hypertrophy (Lescaudron et al., 1999). In the present study, the 7 day period of 
supplementation may have been short enough to not negatively impact exercise 
performance. Although not directly measured in the current study there is no indication 
that skin blood flow was negatively affected as skin temperature, sweat rate, and the 
cardiovascular and thermoregulatory responses were not altered by the treatment.  
Exercise in healthy individuals produces acute increases in oxidative stress that 
ultimately leads to an up-regulation of the body’s natural defense mechanisms against 
ROS and free radicals making supplementation with antioxidant unnecessary.  
Antioxidant supplementation may be warranted in situations in which oxidative stress is 




antioxidants appear to compensate for the inability of the endogenous antioxidant 
systems to combat the persistent increase in oxidative stress.  
Another novel and important finding of the present study is the manner in which 
HHb changed over the course of the fatigue trial. During the fatigue trial the majority of 
the increase in oxygen consumption occurred during the first 40% of the exercise bout 
and was maintained until 60% of completion time until fatigue (Figure 1.5). Breath by 
breath measurements of VO2 were not made therefore exact calculation of the oxygen 
uptake kinetics cannot be made. HHb, which can be used to estimate muscle O2 
extraction (Barstow & Mole, 1991; Grassi et al., 1996; DeLorey et al., 2003; Ferreira et 
al., 2005; Harper et al., 2006; Ferreira et al., 2007; Boone et al., 2009; Krustrup et al., 
2009), increased slightly during the first 60% of the exercise bout but did not increase 
significantly until just prior to fatigue. Whole body VO2 can be integrated with HHb to 
give an estimation of capillary blood flow (Qcap) to the active muscle tissue (Ferreira et 
al., 2005; Harper et al., 2006; Ferreira et al., 2007; Boone et al., 2009). Estimated Qcap 
plateaued after 40% of the exercise bout is completed and is reduced just prior to 
fatigue (Figure 1.5). Studies examining leg blood flow during similar fatiguing exercise 
bouts have shown that leg blood flow plateaus at approximately 50% of completion 
time (Gonzalez-Alonso & Calbet, 2003; Gonzalez-Alonso et al., 2004; Mortensen et al., 
2005). A reduction in leg blood flow has not been previously reported, however, the 
techniques previously used measured flow across a whole limb. Therefore, flow to 




measurement (Harper et al., 2006). It is conceivable that blood flow does not increase 
to the same extent to the different muscle groups of the leg (glutes, quadriceps, 
hamstrings) during upright cycling. The current finding that Qcap of the vastus lateralis 
is reduced during fatigue should be interpreted with caution as the NIRS measurements 
were made on only 5 subjects. Despite the low subject number, such a reduction in 
capillary blood flow may provide insight into peripheral muscle fatigue during high 
intensity exercise.       
Based on the findings of this study exercise performance in the heat was not 
improved by POMS supplementation. Accordingly, POMS had no effect on the 
cardiovascular or thermoregulatory response to exercise or any variable related to 
performance (oxygen consumption, gross efficiency, and rating of perceived exertion). 
There is a growing body of literature indicating that antioxidant supplementation in 
healthy individuals may result in negative outcomes by altering the balance between 
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Figure 1.2: Average workrate during the 10 minute time trial performed on Day-1 for 
both PLA and POMS. Individual data of the 12 subjects and the mean response, 
represented by solid black line, is presented. There was no difference in average 






Figure 1.3: Time to fatigue during the constant load performance test performed on 
Day-2 for both PLA and POMS. Individual data of the 12 subjects and the mean 
response, represented by solid black line, is presented. There was no difference in time 





Figure 1.4: Values are mean ± SE for 12 subjects. Heart rate response for POMS and PLA 
during one hour exercise bout on Day - 1. * Indicates significant difference from 
previous value for PLA and † indicates significant difference from previous value for 





Figure 1.5: Mean responses for normalized oxygen consumption (% VO2), deoxygenated 
hemoglobin (% HHb), and estimated capillary blood flow (%Qcap). Data was normalized 
based on the following equation range; % normalized value  = [( value of interest - min) / 
(max - min)] (Belardinelli et al., 1995). 
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Pre Bodyweight, kg 74.2 ± 9.1 74.4 ± 9.1








PLA 99 ± 11 144 ± 12* 189 ± 15* 234 ± 19* 229 ± 17
POM 99 ± 11 144 ± 12* 189 ± 15* 234 ± 19* 229 ± 17
VO2, ml/min
PLA 1807 ± 147 2347 ± 240* 2760 ± 218* 3271 ± 224*
POM 1882 ± 171 2354 ± 192* 2839 ± 235* 3324 ± 284*
% VO2max
PLA 40.6 ± 3.7 52.6 ± 3.7* 62.0 ± 3.8* 73.5 ± 4.4*
POM 42.4 ± 4.3 52.9 ± 4.2* 63.8 ± 4.6* 74.6 ± 5.1*
VCO2, l/min
PLA 1517 ± 92 2031 ± 188* 2398 ± 162* 2886 ± 159*
POM 1580 ± 143 2023 ± 144* 2465 ± 190* 2940 ± 245*
RER
PLA 0.84 ± 0.03 0.87 ± 0.03* 0.87 ± 0.03 0.88 ± 0.04*
POM 0.84 ± 0.03 0.86 ± 0.03* 0.87 ± 0.03* 0.89 ± 0.04*
GE, %
PLA 16.2 ± 1.5 18.1 ± 1.4* 20.1 ± 1.0* 20.9 ± 1.2*





5 10 15 20 20 to 50
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Time
0 to 2.5 min 310.6 ± 32.0 307.5 ± 30.3
2.5 to 5 min 290.5 ± 41.6* 271.8 ± 44.9*
5 to 7.5 min 277.6 ± 36.6* 259.5 ± 44.6*











PLA 1.3 ± 0.3 2.6 ± 0.9* 8.2 ± 2.4*
POM 1.4 ± 0.4 2.7 ± 0.9* 8.1 ± 3.3*
RPE
PLA 13.3 ± 1.2 13.5 ± 1.3







Pmax, watts 1250 ± 231 1240 ± 229 1240 ± 214 1243 ± 258
IP, watts 2027 ± 384 2029 ± 362 2027 ± 336 2046 ± 415
RPM 120.9 ± 8.7 120.7 ± 8.6 119.6 ± 9.1 116.7 ± 8.1












PLA 37.30 ± 0.30 37.37 ± 0.32* 37.50 ± 0.27* 37.65 ± 0.25* 37.84 ± 0.25* 38.48 ± 0.28* 38.52 ± 0.29* 38.61 ± 0.30* 38.71 ± 0.31* 38.81 ± 0.32* 38.90 ± 0.34*
POM 37.27 ± 0.22 37.31 ± 0.21 37.44 ± 0.20* 37.60 ± 0.21* 37.79 ± 0.23* 38.53 ± 0.27* 38.58 ± 0.29* 38.65 ± 0.29* 38.73 ± 0.29* 38.80 ± 0.28* 38.87 ± 0.28*
Tskin , ºC
PLA 32.00 ± 0.91 32.22 ± 0.49 32.25 ± 0.45 32.31 ± 0.49 32.14 ± 0.67 31.03 ± 0.76* 31.14 ± 0.79 31.08 ± 0.68 30.89 ± 0.71 31.02 ± 0.75 31.05 ± 0.96
POM 32.56 ± 0.71† 32.37 ± 0.63 32.21 ± 0.52 32.03 ± 0.40 32.05 ± 0.39 31.25 ± 1.04* 31.07 ± 1.07 30.98 ± 1.05 30.94 ± 0.91 30.76 ± 1.00 30.58 ± 1.21
Tbody , ºC
PLA 36.61 ± 0.25 36.70 ± 0.32* 36.82 ± 0.28* 36.96 ± 0.24* 37.10 ± 0.25* 37.51 ± 0.29* 37.56 ± 0.28* 37.63 ± 0.27* 37.70 ± 0.28* 37.79 ± 0.31* 37.88 ± 0.35*
POM 36.65 ± 0.22 36.67 ± 0.22 36.76 ± 0.21* 36.88 ± 0.21* 37.04 ± 0.22* 37.59 ± .28* 37.60 ± 0.29 37.65 ± 0.28* 37.72 ± 0.29* 37.75 ± 0.28 37.80 ± 0.31
HR, bpm
PLA 64.6 ± 8.9 111.2 ± 9.1* 126.1 ± 10.2* 138.6 ± 11.7* 152.0 ± 12.8* 160.5 ± 11.9* 172.5 ± 13.7* 177.9 ± 11.3* 179.3 ± 12.4 180.9 ± 13.1* 184.2 ± 12.5*
POM 66.2 ± 6.8 111.2 ± 9.9* 125.8 ± 10.8* 139.2 ± 12.1* 153.5 ± 13.6* 164.8 ± 14.1* 175.9 ± 12.3* 177.0 ± 14.9 177.2 ± 15.3 179.2 ± 14.6 183.7 ± 14.4*
SV, ml/beat
PLA 88.4 ± 11.1 115.6 ± 12.8* 118.3 ± 12.9* 121.4 ± 13.4* 122.8 ± 13.9 123.0 ± 14.3 124.8 ± 15.3 127.4 ± 17.6 128.6 ± 19.0 130.1 ± 21.7 127.6 ± 15.0
POM 88.8 ± 12.1 115.6 ± 16.8* 118.4 ± 16.6* 121.5 ± 16.4* 124.2 ± 17.1* 125.1 ± 17.2 125.2 ± 17.5 127.6 ± 17.7 125.9 ± 18.1 127.6 ± 17.2 128.6 ± 19.2
CO, l/min
PLA 5.8 ± 1.1 12.8 ± 1.7* 14.9 ± 1.8* 16.8 ± 2.1* 18.6 ± 2.2* 19.7 ± 2.0* 21.4 ± 2.5* 22.6 ± 2.7* 23.0 ± 3.3 23.5 ± 3.8 23.4 ± 2.6
POM 5.9 ± 0.8 12.8 ± 1.8* 14.8 ± 2.0* 16.8 ± 2.0* 19.0 ± 2.5* 20.5 ± 2.5* 22.0 ± 3.0* 22.6 ± 3.5 22.3 ± 3.8 22.9 ± 3.8 23.6 ± 4.1
SBP, mmHg
PLA 122.4 ± 5.7 158.4 ± 17.5* 173.8 ± 15.7* 181.7 ± 15.9* 193.1 ± 16.* 191.7 ± 15.1 205.5 ± 14.4* 211.3 ± 20.2 203.8 ± 18.1 211.5 ± 22.5* 205.8 ± 16.6
POM 125.7 ± 5.4 157.4 ± 16.8* 175.8 ± 14.9* 181.8 ± 17.3 197.1 ± 14.7* 191.6 ± 20.0 196.7 ± 15.0 200.8 ± 12.2 200.8 ± 13.7 199.1 ± 20.3 203.1 ± 20.0
DBP, mmHg
PLA 83.0 ± 6.5 82.3 ± 13.4 78.4 ± 11.4 73.4 ± 12.4* 71.3 ± 12.5 74.6 ± 10.5 77.1 ± 10.2 79.8 ± 10.9 73.9 ± 11.6 76.9 ± 14.0 71.8 ± 13.6
POM 84.8 ± 8.6 80.3 ± 12.0 76.4 ± 12.1 73.8 ± 10.0 70.9 ± 11.1 77.9 ± 14.9 72.7 ± 13.4 76.4 ± 13.8 78.5 ± 11.7 74.2 ± 11.6 78.4 ± 11.0
MAP, mmHg
PLA 96.1 ± 4.9 107.6 ± 10.8 110.2 ± 10.3 109.5 ± 10.7 111.9 ± 9.7* 113.7 ± 8.2 119.9 ± 6.6 123.7 ± 9.3 117.2 ± 9.7 121.8 ± 10.8 116.5 ± 10.1
POM 98.4 ± 6.4 106.0 ± 11.0 109.6 ± 11.0 109.8 ± 10.1 113.0 ± 8.6 115.8 ± 11.7 114.0 ± 9.6 117.9 ± 10.9 119.3 ± 9.7 115.8 ± 12.1 119.9 ± 11.2
TPR, pru
PLA 17.30 ± 3.54 8.56 ± 1.64* 7.54 ± 1.35* 6.65 ± 1.20* 6.13 ± 1.11* 5.83 ± 0.71 5.68 ± 0.87 5.56 ± 0.86 5.19 ± 0.91 5.29 ± 0.82 5.04 ± 0.86*
POM 17.12 ± 2.79 8.46 ± 1.75* 7.58 ± 1.71* 6.64 ± 1.21* 6.08 ± 1.17* 5.77 ± 1.19 5.30 ± 1.02* 5.39 ± 1.31 5.52 ± 1.24 5.20 ± 1.16 5.22 ± 1.04









PLA 60.9 ± 4.1 59.6 ± 4.3* 56.1 ± 4.7* 53.9 ± 4.4 54.9 ± 3.4 52.6 ± 4.3* 51.8 ± 5.4 51.6 ± 5.6 51.6 ± 5.6 52.0 ± 5.7
POM 61.7 ± 5.4 60.8 ± 8.0 58.2 ± 7.7* 57.0 ± 5.9 55.1 ± 4.8* 54.2 ± 4.8 53.5 ± 4.7 52.5 ± 3.8 52.2 ± 3.0 52.2 ± 3.1
THC, um
PLA 62.1 ± 5.2 64.1 ± 6.8 63.8 ± 7.9 64.2 ± 8.4 66.8 ± 8.5 67.2 ± 8.0 66.4 ± 8.7 66.5 ± 8.9 66.8 ± 8.8 67.1 ± 9.2
POM 63.7 ± 4.8 67.2 ± 6.1 67.9 ± 6.3 67.7 ± 5.5 67.1 ± 5.8 67.0 ± 7.0 66.9 ± 7.1 67.2 ± 6.2 67.4 ± 6.2 67.6 ± 6.2
HbO, um
PLA 37.9 ± 5.0 38.3 ± 5.9 36.0 ± 7.0 34.8 ± 6.8 36.7 ± 5.7 35.5 ± 6.0* 34.5 ± 7.1 34.4 ± 7.2 34.6 ± 6.8 35.0 ± 7.2
POM 39.4 ± 5.0 41.0 ± 8.1 39.7 ± 8.1 38.6 ± 5.3 36.9 ± 3.7 36.2 ± 4.3 35.7 ± 4.4 35.2 ± 3.1 35.1 ± 2.4 35.1 ± 1.4
HHb, um
PLA 24.2 ± 2.5 25.8 ± 2.9* 27.8 ± 2.4* 29.4 ± 3.1 30.1 ± 4.1 31.7 ± 3.9* 31.8 ± 4.2 32.0 ± 4.5 32.2 ± 4.9 32.1 ± 4.9










PLA 3383 ± 287 3877 ± 414* 4233 ± 316* 4248 ± 295 4399 ± 336* 4232 ± 459
POM 3426 ± 412 3957 ± 433* 4286 ± 409* 4396 ± 430* 4343 ± 383 4239 ± 347
HR, bpm
PLA 154.5 ± 14.5 165.7 ± 13.2* 172.6 ± 12.5* 176.3 ± 12.9* 179.4 ± 12.3* 181.2 ± 12.2*
POM 155.9 ± 14.3 165.9 ± 13.9* 172.8 ± 13.3* 176.5 ± 12.7* 179.0 ± 12.3* 181.5 ± 12.6
SV, ml/beat
PLA 127.3 ± 13.4 129.4 ± 13.5 130.4 ± 15.8 130.2 ± 14.6 129.6 ± 15.2 130.5 ± 16.0
POM 129.6 ± 13.0 132.2 ± 17.1 132.9 ± 17.1 133.0 ± 14.9 132.9 ± 14.8 132.7 ± 16.7
CO, l/min
PLA 19.6 ± 1.9 21.4 ± 2.0* 22.4 ± 2.4* 22.9 ± 2.2 23.2 ± 2.6 23.5 ± 2.9
POM 20.1 ± 1.9 21.8 ± 2.7* 22.9 ± 2.7* 23.4 ± 2.6* 23.7 ± 2.6 24.0 ± 3.1
Tcore, º C
PLA 37.69 ± 0.19 37.74 ± 0.18* 37.84 ± 0.18* 37.97 ± 0.20* 38.10 ± 0.26* 38.25 ± 0.32*
POM 37.71 ± 0.22 37.77 ± 0.22 37.88 ± 0.24* 38.01 ± 0.28* 38.16 ± 0.34* 38.31 ± 0.39*
Tskin, º C
PLA 32.27 ± 0.36 32.30 ± 0.37 32.09 ± 0.41* 31.93 ± 0.42* 31.89 ± 0.52 31.95 ± 0.43
POM 32.07 ± 0.66 32.15 ± 0.68 31.94 ± 0.68 31.87 ± 0.65 31.86 ± 0.67 31.74 ± 0.73
Tbody, º C
PLA 36.98 ± 0.18 37.04 ± 0.17* 37.09 ± 0.16* 37.18 ± 0.17* 37.30 ± 0.21* 37.43 ± 0.27*
POM 36.97 ± 0.22 37.04 ± 0.22* 37.11 ± 0.25* 37.22 ± 0.27* 37.34 ± 0.29* 37.46 ± 0.34*
OxSat, %
PLA 58.8 ± 6.6 57.8 ± 6.9 57.8 ± 5.9 57.4 ± 5.1 56.5 ± 5.7 55.9 ± 5.4
POM 62.9 ± 6.0 62.3 ± 6.2 61.7 ± 6.9 61.2 ± 7.4 60.5 ± 7.5 59.6 ± 7.6
THC, μm
PLA 64.2 ± 5.5 64.1 ± 5.3 64.1 ± 5.2 64.0 ± 5.7 64.4 ± 5.9 65.0 ± 5.2
POM 66.7 ± 6.6 66.8 ± 6.1 66.8 ± 5.9 66.5 ± 5.3 66.8 ± 5.9 67.2 ± 5.7
HbO, μm
PLA 37.7 ± 4.7 37.0 ± 4.7 37.0 ± 4.2 36.6 ± 3.6 36.3 ± 4.5 36.3 ± 3.8
POM 42.0 ± 6.1 41.6 ± 5.5 41.2 ± 5.8 40.7 ± 5.6 40.4 ± 6.3 40.0 ± 6.0
HHb, μm
PLA 26.5 ± 4.9 27.1 ± 5.2 27.1 ± 4.7 27.4 ± 4.6 28.1 ± 4.6* 28.7 ± 4.6
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CHAPTER V: STUDY 2 
 
CARDIAC OUTPUT DURING INTENSE EXERCISE 
 
Abstract:  
Recent findings have challenged the traditional belief that the cardiac output 
(CO) and oxygen consumption (VO2) relationship is linear from rest to maximal exercise. 
The purpose of this study was to determine the CO and stroke volume (SV) response to 
a full range of exercise intensities. In order to integrate central and peripheral 
cardiovascular responses to exercise, near infrared spectroscopy was used to determine 
muscle deoxygenation (HHb) of two leg muscles, the vastus lateralis (VL) and the 
gastrocnemius (GAS). Ten well trained cyclists performed a series of discontinuous 
intervals to establish the CO vs. VO2 and the SV response to exercise across a wide 
range of exercise intensities (40 to 100% of VO2max). The increase in CO from 70 to 
100% of VO2 was reduced when compared to the slope from 40 to 70% of VO2max (2.0 
± 0.4 vs. 4.4 ± 0.3 l/min, p = 0.025). CO did not increase significantly from 90 to 100% 
VO2max (23.9 ± 2.2 to 24.6 ± 2.6 l/min, p = 0.12). SV during high intensity exercise was 
reduced when compared to moderate intensity exercise (146.0 ± 16.6 vs. 138.5 ± 14.9 
ml/beat, p = 0.015) whereas whole body arterial venous O2 difference (AVO2 
difference) increased as intensity increased.  The pattern of change in HHb was different 
between the VL and the GAS as VL-HHb plateaued at 80% of VO2max and GAS-HHb 
increased from 90 to 100% of VO2max. Overall, the increase in CO was attenuated as 
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exercise intensity increased as evidenced by the reduced rate of increase in CO per VO2 
is reduced from 70 to 100% of VO2. At the micro-vascular level the pattern of muscle 







































The cardiac output (CO) vs. oxygen consumption (VO2) relationship is thought to 
be linear from rest to maximal exercise as CO is increased by 4 to 6 liters per minute for 
every 1 liter per minute increase in VO2 (Rowell, 1986). While this relationship may hold 
true for low and moderate intensity exercise (< 70 to 80% of VO2max), debate exists as 
to whether or not the same relationship can be applied to high intensity exercise.  
Examination of the CO vs. VO2 relationship has been performed by either 
discontinuous interval exercise or incremental exercise from rest to VO2max. Typically, 
investigators utilizing a discontinuous exercise protocol measured CO and VO2 during a 
series of submaximal exercise intensities and then performed a bout of exercise at or 
near maximal intensity (Astrand et al., 1964; Ekblom et al., 1968; Ekblom & Hermansen, 
1968). Linear regression of such data is biased towards the lower exercise intensities 
and therefore may not accurately portray the CO vs. VO2 relationship during high 
intensity exercise. Incremental exercise, in which a given workrate is performed for only 
a few minutes and a steady state is not achieved, may underestimate the true CO vs. 
VO2, especially at high levels of exertion and VO2.     
Evidence for a reduced rate of increase in CO is most compelling from studies 
that have implemented an incremental protocol. Stringer et al. (Stringer et al., 1997; 
Stringer et al., 2005) used the direct Fick method to calculate CO and observed a linear 
relationship between AVO2 difference and VO2 and an attenuated increase in CO 
beginning at the lactic acidosis threshold. Similarly, Beck et al. (Beck et al., 2006) used 
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the open circuit acetylene washin method to measure CO in a large sample of subjects 
(n = 73) and showed an attenuated increase in the CO vs. VO2 relationship which was 
most prominent in subjects with an above average fitness level. Mortensen et al. 
(Mortensen et al., 2005) and Calbet et. al (Calbet et al., 2007) showed that CO increased 
curvilinearly from rest to approximately 84% of maximal workrate and from 84 to 100% 
of maximal workrate the increase in CO was only 1.2L/min. However, the dynamic 
nature of the incremental exercise test may yield different results when compared to a 
protocol that establishes a steady state response. In support of a cardiac limitation to 
VO2max and maximal exercise is the finding that CO is reduced prior to fatigue during 
constant load maximal exercise (Gonzalez-Alonso & Calbet, 2003; Gonzalez-Alonso et 
al., 2004; Mortensen et al., 2005). This reduction in CO is due to a reduction in SV as HR 
is maintained at near maximal levels and leads to an impairment in systemic O2 
delivery. Heat stress, resulting in an increased demand for the limited CO, accelerates 
fatigue and strengthens the argument in favor of CO limiting VO2max (Gonzalez-Alonso 
et al., 2004).  
In order to better understand and integrate the whole body response to a wide 
range of exercise intensities, near infrared spectroscopy (NIRS) was used in the present 
study to determine the muscle oxygenation status of two leg muscles (vastus lateralis 
and gastrocnemius) during exercise. Deoxygenated hemoglobin (HHb) is thought to be 
proportional to O2 extraction and the result of the relationship between oxygen delivery 
and oxygen consumption in the region of interest (Grassi et al., 2003; Ferreira et al., 
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2005b; Ferreira et al., 2007). This technique coupled with whole body oxygen 
consumption has been used to gain insight into the matching of oxygen delivery, oxygen 
consumption, and blood flow during exercise (DeLorey et al., 2003; Grassi et al., 2003; 
Ferreira et al., 2005b; Harper et al., 2006; Ferreira et al., 2007; Boone et al., 2009).  
  The purpose of this study was to determine if the increase in CO is reduced at 
high exercise intensities. In order to answer this question, CO was measured during a 
series of discontinuous intervals across a wide range of exercise intensities (10% 
increments from 40 to 100% of VO2max). We hypothesized that as exercise intensity 
increases the rate of increase in CO per increase in VO2 would be reduced. In 
conjunction with this reduced rate of increase in CO we hypothesized that stroke 
volume would plateau during moderate intensity exercise and would be reduced during 
high intensity exercise. Regarding muscle deoxygenation, we hypothesized that HHb of 
the vastus lateralis and the gastrocnemius would increase linearly reflecting the linear 










Subjects: Ten healthy, well trained male cyclists (31 ± 8 yr of age, range 18 to 45) 
provided written informed consent to participate in this study. The protocol, 
experimental design, and informed consent form were approved by the Institutional 
Review Board at The University of Texas at Austin. The subjects’ stature, body mass, and 
VO2max (means ± SD) were as follows: 1.79 ± 0.07m, 74.9 ± 7.9kg, 4.70 ± 0.33 l/min, 
respectively.  
Experimental design and protocol: The entire experimental protocol was 
completed over 4 visits to the laboratory. The first visit served to establish the 
submaximal VO2 vs. workrate relationship, lactate threshold, and VO2max. The second 
visit was performed to familiarize the subject with the open circuit acetylene 
measurement and to verify that the workrates for the intervals were appropriate. 
Furthermore, a discontinuous VO2max protocol consisting of three high intensity 
intervals was performed during the second visit to ensure a true VO2max had been 
established. The third and forth visits to the laboratory involved moderate intensity (40, 
50, 60, and 70% of VO2max) and high intensity intervals (80, 90, and 100%). Briefly, 
subjects performed the 40, 50, 60, and 70% intervals in sequential order and then 
performed the 80, 90, and 100% intervals in random order. Moderate intensity intervals 
were performed once per visit whereas high intensity intervals were performed twice 
per visit. This protocol yielded 4 measurements of CO per subject for each moderate 
intensity interval and 8 measurements of CO per subject for each high intensity interval. 
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The order of the high intensity intervals was randomized so as to not display an ordering 
effect and to remove the influence that fatigue may have on performance. Visits three 
and four were separated by one week and all experimental testing was performed at 
the same time of day.  
Experimental procedures: Submaximal VO2 vs. workrate relationship was 
determined during a continuous incremental protocol on a cycle ergometer (Excalibur 
Sport, Lode, The Netherlands). Seat and handlebar position on the ergometer were 
matched to the subject’s road bicycle and kept constant throughout the study. The 
submaximal test included 5 stages, each lasting 5 minutes. Workrate was progressively 
increased by 20 to 40 watts depending on the fitness level of the subject. Lactate 
samples were collected during the final minute of each stage by a finger stick and 
analyzed with a portable lactate meter (Lactate Pro, Arkray Inc, Kyoto, Japan). Lactate 
threshold (LT) was determined as the 1 mmol increase above baseline. Oxygen 
consumption (VO2) and HR were collected continuously during this test.  VO2 was 
averaged over the final minute of each stage to determine the oxygen cost of cycling at 
each workrate. Following a 10 minute rest subjects performed an incremental VO2max 
test lasting 8 to 12 minutes. Initial workrate for the VO2max test was set to elicit 
approximately 80% of subject’s reported maximal heart rate (HRmax). In order to verify 
a plateau in VO2max subjects rested again for 10 minutes before performing a constant 
load exercise bout at either the workrate they fatigued at during the incremental 
protocol or 25 watts higher than that workrate. The criteria for determining the 
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workrate during this VO2 verification trial depended on the duration of the final stage of 
the incremental test (Taylor et al., 1955; Lafrenz et al., 2008). If subjects lasted less than 
1 minute during the final stage the same workrate was used for the constant load test. If 
subjects lasted longer than 1 minute during the final stage the workrate was increased 
by 25 watts for the constant load VO2 verification test. Average time to fatigue during 
the VO2 verification trial was 156 ± 28 seconds. 
One week after initial testing, subjects returned to the laboratory for a second 
day of VO2max verification trials. This second day of testing was performed to 
determine if a true VO2max had been achieved during the first visit. Based on the 
submaximal VO2 vs. workrate relationship, linear regression was used to determine the 
minimal workrate needed to elicit VO2max. Following a 20 minute warm-up (5 minutes 
at 40, 50, 60, 70% of VO2max) subjects performed 3 high intensity intervals at 100%, 
100% minus 25 watts (W), and 100% plus 25W of VO2max. Each interval was performed 
for 4 minutes or until exhaustion. Five minutes of passive recovery and 5 minutes of 
active recovery (easy spinning at 30W) separated the intervals. The order of the 100%, 
100% minus 25W, and 100% plus 25W intervals was randomized. Using this method in 
combination with the incremental exercise test and constant load verification trials from 
visit one all subjects exhibited a clear leveling off of VO2 (i.e.; a true VO2max).  
 Visits three and four consisted of interval cycling at 40, 50, 60, 70, 80, 90, and 
100% of VO2max. Each submaximal stage (i.e.; 40 – 70% VO2max) lasted 5 minutes and 
was separated by 6 minutes of cycling at 30W. The high intensity intervals (i.e.; 80 – 
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100% of VO2max) were performed for 4 minutes and separated by 6 minutes of cycling 
at 30W (similar to unloaded cycling). Breath by breath VO2 measurements commenced 
at least 2 minutes prior to each interval, cardiac output was measured at min 3 and 4.5 
of each submaximal stage and at min 2 and 3.5 of each high intensity interval. The 1.5 
minute time period between CO measurements was selected based on pilot data that 
showed adequate washout of acetylene. CO was not measured during the primary 
phase of VO2 response.       
Approximately 30 minutes prior to exercise subjects consumed 400 ml of water. 
During exercise subjects drank a 6% CHO-electrolyte beverage (Powerbar Endurance 
Formula, Nestle). Subjects were allowed to drink ad libitum during visit 3. Fluid intake 
(timing and volume) were recorded and matched during visit 4. On average, 1.2 ± 0.3 L 
of fluid was consumed. The overall change in bodyweight from pre to post exercise was 
less than 0.25 kg indicating that hydration was maintained. 
On arrival, subjects dressed in cycling shorts and shoes. Before testing 
commenced on visits two, three and four, subjects inserted a rectal temperature probes 
and voided their bladder. A subset of subjects (n = 7) inserted an esophageal 
temperature probe. Following probe placement, subjects were instrumented and 
resting measures were made. After all baseline measures were made subjects 
performed the series of intervals as previously described.      
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Respiratory and cardiovascular measurements: Oxygen consumption was 
measured breath by breath using open-circuit spirometry according to the calculation 
described by Beaver et al. (Beaver et al., 1981). Subjects breathed through a two-way 
non rebreathing valve connected to a pneumotachometer (Hans Rudolph, Kansas City, 
MO). Oxygen and carbon dioxide concentration of inspired and expired gases were 
determined by a mass spectrometer (Perkin-Elmer MGA 1100, St. Louis, MO). Gas 
samples were collected at the mouthpiece via a 6 foot capillary tube connected directly 
to the mass spectrometer. CO was determined by open circuit acetylene washin as 
described by Johnson et al. (Johnson et al., 2000). Briefly, at the end of normal 
expiration, the participants breathed for a minimum of 8 breaths through a mouthpiece 
connected to a bag filled with mixed gases, including 0.7% acetylene, 9.0% helium, 21% 
oxygen, and balance nitrogen. The concentrations of acetylene and helium were 
monitored by continuous sampling at the mouthpiece and data was viewed in real time 
on a personal computer. CO was calculated from the washin curve of the acetylene 
according to a single alveolar one compartment lung model. The iterative method as 
described by Johnson et al. (Johnson et al., 2000) was used for the calculation of CO. 
Custom software (Beck Integrated Physiological Systems) was used to determine breath 
by breath oxygen consumption and to calculate CO. The mass spectrometer was 
calibrated prior to each experimental trial using gases of known concentration. Volume 
was calibrated using a 3 l syringe (Hans Rudolph) at low, moderate, and high flow rates. 
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Heart rate was measured continuously (Physioflow) and average HR corresponding the 
CO measurement was used for the calculation of SV (SV = CO/HR).   
Core body temperature: Core temperature (Tcore) was measured using a rectal 
temperature probe inserted 12 cm past the anal sphincter (model 401, Yellow Springs 
Instrument). A subset of subjects (n = 7) also performed esophageal core temperature 
measurements (Teso). The esophageal probe (model 4491, Yellow Springs Instruments) 
was inserted through the nasal passage and swallowed to depth of one-fourth of the 
subject’s standing height (Mekjavic & Rempel, 1990).  As stated earlier, fluid was 
consumed prior to and during exercise (i.e.; between intervals). In order to not affect 
the Teso measurements all subjects consumed fluid that was warmed to approximately 
37ºC.            
 Near Infrared Spectroscopy (NIRS):  Muscle oxygenation was evaluated by a 
frequency-domain multi-distance NIRS system (Oxiplex TS, ISS, Champaign, IL). The 
principles of operation and algorithms used by this NIRS system have been previously 
described (Gratton et al., 1997). For this experiment two NIRS probes were positioned 
longitudinally on the belly of the vastus lateralis approximately 12 cm above the lateral 
border of the patella and the other on the belly of the lateral head of the 
gastrocnemius. The probe was held in place by a Velcro strap provided by the 
manufacturer. A latex glue (Skin Bond®) was used to adhere the probe to the skin and to 
reduce movement of the probe during exercise. The subject’s cycling shorts were pulled 
over the quadriceps probe and a spandex sleeve was placed over the calf probe to 
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further minimize movement of the probes. The NIRS system was calibrated prior to each 
test after a warm-up of at least 30 minutes. The calibration was done with the optical 
probe placed on calibration block with absorption and reduced scattering coefficients 
previously measured and correction factors were determined and automatically 
implemented by the equipment’s software for the calculation of the absorption 
coefficient (μa) and reduced scattering coefficient (μs) for each wavelength during the 
data collection. The NIRS system provides a continuous measurement of absolute 
concentration of oxyhemoglobin ([HbO2], and deoxyhemoglobin ([HHb]) (expressed in 
μM). The HHb reported in the present study was calculated incorporating the 
continuous measurement of μs made throughout the exercise test, i.e.; without 
assuming a constant for scattering.  NIRS data was exported from the manufacturer’s 
software at 1 Hz to provide second by second data. Baseline HHb was obtained during 
30W cycling. The final HHb value was the average of the final 30 seconds of each 
interval. The change in HHb was calculated and then normalized using the following 
equation; % HHb = [(value of interest – min)/(max – min)] *100 (Belardinelli et al., 
1995).  Due to technical problems in one subject, HHb is reported for 9 subjects.
 Statistics: All statistical analyses were performed using SPSS version 14.0. Data 
are presented as mean ± standard deviation of the mean. Selected figures are presented 
as mean ± standard error for the purpose of clarity.  A one-way repeated measures 
ANOVA analysis was used to test for significant differences between exercise intensities. 
When appropriate, an a priori analyses of sequential exercise intensities (40% to 50%, 
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50% to 60%, 60% to 70%, 80% to 90%, or 90% to 100% of VO2max) was employed 
following a significant main effect of condition. The number of a priori comparisons was 
limited to k-1 for the selected variable, where k is equal to the number of means 
compared. If Mauchly’s test of sphericity was violated, the Greenhouse-Geisser 
correction was used to correct for this violation and to ensure that the main effect was 
significant. All non-sequential pairwise comparisons were corrected using the Sidak 
correction for multiple comparisons (i.e.; 40% to 60% or 80% to 100% of VO2max). 

















Workrate, exercise intensity and ventilation: Exercise was performed at 
workrates eliciting 42, 51, 60, 70, 83, 91, and 99% of VO2max. For the purpose of clarity 
further discussion of the aforementioned intervals will be referred to as 40, 50, 60, 70, 
80, 90, and 100% of VO2max. Absolute VO2 and corresponding workrates are reported 
in Table 2.1. Ventilation increased in an exponential manner as intensity increased. 
During high intensity exercise, the increase in VE per increase in VO2 was approximately 
twice as great during high intensity (56 l/min per 1 l/min) exercise compared to low and 
moderate intensity exercise (27.7 l/min per 1 l/min) (Table 2.1).  
Cardiovascular responses: HR for each interval is reported in Table 2.2. Each 
increase in workrate was accompanied by a significant increase in HR with one 
exception. The random order of the intervals elevated HR at 80% thereby making the 
difference between 80 and 90% not significant (p = 0.87) despite the 41 watt and 0.299 
LO2/min difference between the stages.    
From rest to 70% of VO2max the increase in CO vs. VO2 was 5.0 ± 0.4 l/min. 
However, for the purpose of comparing slopes, only values during exercise were 
analyzed. The slope of the CO vs. VO2 relationship was significantly reduced as exercise 
intensity increased (Figure 2.2). The slope of CO vs. VO2 from 70 to 100% VO2max was 
significantly reduced when compared to the slope from 40 to 70% of VO2max (2.0 ± 0.4 
vs. 4.4 ± 0.3 l/min, p = 0.025). The CO values for each workrate are reported in Table 2.2. 
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CO increased significantly from one workrate to the next until 90% of VO2max (Figure 
2.1). The increase in CO from 90 to 100% of VO2max was not significant (23.9 ± 2.2 to 
24.6 ± 2.6 l/min, p = 0.12). The reduced increase in CO vs. VO2 at high exercise 
intensities coupled with the non-significant increase from 90 to 100% of VO2 max 
indicates a CO limitation during high intensity exercise.  
The SV response to exercise is reported in Table 2.2. SV increased significantly 
from rest to exercise (112.0 ± 20.5 to 138.6 ± 17.3 ml/beat, p < 0.01) and again from 40 
to 50% VO2max (138.6 ± 17.2 to 144.8 ± 17.2ml/beat, p < 0.01). SV peaked at 70% of 
VO2max (147.8 ± 15.9) and was reduced by approximately 7% (p < 0.05) at 80% and 
100% of VO2max. SV was not different from 50% to 70% or from 80% to 100% and when 
pooled together the SV was significantly lower during high intensity exercise (80, 90, and 
100% of VO2max) compared to moderate intensity exercise (50, 60, and 70% of 
VO2max) (138.5 ± 14.9 vs. 146.0 ± 16.6 ml/beat, p = 0.015).  
AVO2 difference increased as exercise intensity increased with the only 
exception being from 40% to 50% of VO2max. AVO2 difference is reported in Table 2.2. 
The slope of the AVO2 difference from 70 to 100% of VO2max was slightly higher than 
the slope from 40 to 70% of VO2max; however, this difference was not significant (2.9 ± 
1.1 vs. 2.0 ± 1.0 ml/dl, p = 0.14). 
Core temperature: From 40 to 70% of VO2max Tcore increased on average 
0.24ºC per stage (p < 0.05) (Table 2.1). Tcore was elevated during maximal exercise: 
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however, there were no differences between 80, 90, and 100% VO2max.  In order to 
verify that the rectal temperature measurement was able to accurately measure the 
change in core temperature during the brief bouts of high intensity exercise (4 min), 
esophageal temperature was measured in conjunction with the rectal temperature 
measurement in 7 of the 10 subjects. Rectal temperature was significantly lower at rest 
and 40% of VO2max compared to esophageal temperature; however, there were no 
significant differences between the two methods from 50 to 100% of VO2max 
(APPENDIX I: Table 2.4 Rectal vs. Esophageal core temperature measurements)  
Muscle deoxygenation: Prior to the start of each interval (ie; during 30W cycling), 
HHb was not different between exercise intensities for either the vastus lateralis (VL) or 
the gastrocnemius (GAST) (Table 2.3). There were no significant increases in normalized 
VL-HHB (% VL-HHb) beyond 80% of VO2max, indicative of a plateau in oxygen extraction 
for the vastus lateralis. In contrast, normalized GAST-HHb (% GAST-HHb) showed a 
significant increase from 90 to 100% of VO2 (p = 0.037) (Figure 2.3). Given that HHb 
approximates tissue O2 extraction, this finding has direct implications regarding muscle 
specific differences in O2 extraction and blood flow during cycle exercise. A qualitative 
analysis of Qcap revealed that Qcap-VL continued to increase as exercise intensity 





The main finding of the present study was that during moderate to high intensity 
exercise (70 to 100% VO2max) the slope of the CO vs. VO2 relationship is reduced when 
compared to the slope from low to moderate exercise (40 to 70% VO2max) (2.0 ± 0.4 vs. 
4.4 ± 0.3 l/min, p =0.025). Furthermore, CO only increased by 1.5 l/min from 80 to 100% 
of VO2max, a finding similar to what has been reported for incremental exercise 
(Mortensen et al., 2005; Calbet et al., 2007).  Another main finding of the study was that 
SV plateaued at approximately 50% of VO2max and was reduced during high intensity 
exercise when compared to low and moderate intensity exercise. The attenuated 
increase in the CO to VO2 relationship coupled with the plateau and decline in SV 
provides strong evidence to support the concept of a cardiac limitation to high intensity 
exercise (Gonzalez-Alonso & Calbet, 2003; Mortensen et al., 2005; Beck et al., 2006; 
Saltin et al., 2006; Gonzalez-Alonso, 2008b). An additional novel finding was that the 
pattern of change in deoxygenated HHb (approximated O2 extraction) was different 
between the vastus lateralis and the gastrocnemius during upright cycle exercise. The 
vastus lateralis exhibited a plateau in HHb from 80 to 100% of VO2max whereas the 
gastrocnemius showed a significant increase in HHb at 100% VO2max. This finding has 
possible implications regarding capillary blood flow heterogeneity to the muscles of the 
leg during cycling exercise.  
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Previous investigations have found a curvilinear or reduced increase in the CO to 
VO2 relationship (Bevegard et al., 1963; Astrand et al., 1964; Hanson & Tabakin, 1965; 
Grimby et al., 1966; Ekblom & Hermansen, 1968; Hermansen et al., 1970; Stringer et al., 
1997; Stringer et al., 2005; Beck et al., 2006). However, the majority of these studies 
used incremental ramp exercise (Stringer et al., 1997; Mortensen et al., 2005; Stringer et 
al., 2005; Beck et al., 2006; Calbet et al., 2007) while those that did implement steady 
state discontinuous exercise typically measured CO during 1 to 4 submaximal work 
bouts and then again at maximum (Astrand et al., 1964; Grimby et al., 1966; Ekblom & 
Hermansen, 1968).  The present study is the only study to date that implemented a 
series of high intensity steady state intervals to assess the CO vs. VO2 relationship. The 
use of interval exercise of at least 4 minutes in duration allowed us to make duplicate 
measures of CO at each intensity after the primary phase of the VO2 response was 
complete. While a slow VO2 component was present during our measures of CO, the 
majority (approximately 86%) of this slow component is caused by factors arising in the 
exercising legs (Poole et al., 1991; DeLorey et al., 2003; Ferreira et al., 2005a). Previous 
studies that used discontinuous interval type exercise to determine CO generally only 
performed a few bouts of exercise at submaximal intensities and a final bout at near 
maximal or maximal intensity (Bevegard et al., 1963; Astrand et al., 1964). This type of 
protocol cannot assess the CO to VO2 relationship at high intensities as only one 
measure of CO was made at maximal workrates. The focus of the present study was to 
measure CO over a wide range of intensities with special attention to workrates greater 
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than 80% VO2max. Due to the dynamic non-steady state nature of incremental exercise 
measures of CO and VO2 may not be generalized to steady state exercise (Stringer et al., 
2005). Other studies that have shown a reduction in CO at maximal effort made CO 
measurements just prior to fatigue when cardiovascular function was at its limit 
(Gonzalez-Alonso & Calbet, 2003; Gonzalez-Alonso et al., 2004; Mortensen et al., 2005; 
Mortensen et al., 2008). While a reduction in SV and subsequent drop in CO prior to 
exhaustion argues in favor of a cardiac limitation to maximal exercise (Gonzalez-Alonso 
& Calbet, 2003; Mortensen et al., 2005; Beck et al., 2006; Saltin et al., 2006; Gonzalez-
Alonso, 2008b, a; Warburton & Gledhill, 2008b, a) it does not add to the description of 
the overall CO to VO2 relationship from rest to maximal exercise.    
Establishing the CO vs. VO2 relationship across a wide range of exercise 
intensities is important as this approach allows for the determination of when the 
attenuated increase in CO begins to manifest. As discussed by Beck et al. (Beck et al., 
2006) if the attenuation in CO becomes more pronounced (i.e.; a more prominent 
negative curvature in the CO vs. VO2 relationship) with exercise training a mechanical 
cardiac limitation would be suggested. Similarly investigating the CO vs. VO2 
relationship in individuals with a known cardiac limitation may be insightful as the shape 
of the CO vs. VO2 relationship would depend on how well the cardiac pump could 
increase SV as HR and venous return increase but filling time decreases (Beck et al., 
2006). From a practical perspective, most competitive endurance events occur at 
intensities above 70% of VO2max and based on the results of this study the reduction in 
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the slope of CO vs. VO2 begins at approximately 70% of VO2max.  The malleability of 
this relationship through exercise training is not known and is worthy of future 
investigation.          
 It is important to address the manner in which CO was measured in the current 
study in order to be certain that the reduction in CO is not an artifact of the open circuit 
acetylene washin technique. The open circuit acetylene washin method for determining 
CO has been compared with thermodilution in anesthetized and ventilated dogs, the 
acetylene rebreathing technique in humans, and the direct Fick method in humans 
during submaximal and maximal exercise (Stout et al., 1975; Gan et al., 1993; Nielsen et 
al., 1994; Johnson et al., 2000). As addressed by Johnson et al. (Johnson et al., 2000), 
ventilation inhomogeneity and ventilation-to-perfusion ratio mismatching will cause CO 
and lung volumes to be underestimated when using the open circuit or any rebreathing 
technique.  The open circuit technique is clearly dependent on the ventilation-to-
perfusion ratio and is not appropriate to measure CO in individuals with pulmonary 
disease (Kallay et al., 1987). This precaution was not a factor in the present study as all 
subjects were healthy and free of pulmonary disease. Another factor that could 
potentially contribute to an underestimation of CO when using the open circuit method 
or any ventilatory dependent method for assessing CO is the presence of anatomic 
shunts. However, studies (Hopkins et al., 1998; Hopkins et al., 2008) using the multiple 
inert gas technique have shown that such an intrapulmonary shunt is always less than 1 
% of CO.  
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Another often debated topic focusing on the central limitation to exercise is the 
manner in which SV responds to increasing exercise intensity (Vella & Robergs, 2005). 
Classic studies by Bevegard et al. (Bevegard et al., 1963) and Astrand et al. (Astrand et 
al., 1964) showed an initial increase in SV from rest to upright exercise and then a 
constant SV from moderate to maximal exercise, a finding that has been repeated 
numerous times (Higginbotham et al., 1986; Flamm et al., 1990; Seals et al., 1994; 
Stringer et al., 1997; Proctor et al., 1998; McCole et al., 1999; Gonzalez-Alonso & Calbet, 
2003; Gonzalez-Alonso et al., 2004; Stringer et al., 2005). The present study supports 
this finding as SV did not increase beyond 50% of VO2max. Furthermore, the 10 ml/beat 
reduction in SV at high intensity exercise as observed in the present study is partially 
responsible for the reduced increase in CO as HR continued to increase as intensity 
increased. Previous investigations have found a reduction in SV at peak exercise during 
both constant load and incremental exercise in well trained endurance athletes and 
moderately trained individuals (Flamm et al., 1990; Spina et al., 1992; Seals et al., 1994; 
Mortensen et al., 2005; Stringer et al., 2005). A fortuitous finding of the present study 
was the elevation in HR during the 80% VO2max interval and the outcome that this 
tachycardia had on SV. Due to the randomized design of the intervals, the HR during the 
80% interval was elevated and only 3 bpm lower than the 90% interval.  Despite this 
elevation in HR, CO and VO2 were appropriate (i.e.; linear increase in VO2 with 
workrate). Therefore, the tachycardia associated with this workrate resulted in a 
reduced SV, most likely due to a reduction in diastolic filling time and reduced end 
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diastolic volume presumably due to a lower left ventricular filling pressure when 
compared to the higher workload interval (Fritzsche et al., 1999).   
The plateau and reduction in SV during high intensity exercise is a finding that 
has not been corroborated by all investigators. Other investigators have found that SV in 
highly trained individuals continues to increase as exercise intensity increases and that 
almost all endurance athletes achieve their highest SV during maximal exercise while 
untrained or moderately trained individuals exhibit a plateau or drop in SV at peak 
exercise (Gledhill et al., 1994; Vella & Robergs, 2005; Warburton & Gledhill, 2008b, a). 
The reason for the continual increase in SV is thought to be due to improved diastolic 
function as the result of chronic exercise training (Gledhill et al., 1994). Recent work by 
Faisal et al. (Faisal et al., 2009) examined the SV kinetic response to moderate and high 
intensity exercise and found that SV exhibits a substantial overshoot during the first few 
minutes of exercise and then decreases and eventually levels off as exercise duration 
progresses. The manner in which cardiac function is determined (HR matched vs. VO2 
matched) and the timing of the CO and SV measurement coupled with the protocol 
employed (incremental vs. discontinuous, short duration maximal or supramaximal 
effort) may confound the SV finding and lead to overestimation of CO and SV. The low 
maximal (a-v)O2diff ( < 130 ml/l) observed by Gledhill et al. (Gledhill et al., 1994) may 
also explain the overestimated Q and SV measurements. Furthermore, maximal CO as 
measured by Gledhill et al. (Gledhill et al., 1994) was 34.8 l/min at a VO2 of 4.4 l/min. A 
similar CO (36 l/min) was observed by Ekblom and Hermansen (Ekblom & Hermansen, 
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1968) in elite athletes; however, the corresponding VO2 was much higher at nearly 6.2 
L/min. 
Near infrared spectroscopy provides a noninvasive measure of muscle 
oxygenation (or O2 extraction) in the microcirculation (Grassi et al., 2003; DeLorey et al., 
2005; Ferreira et al., 2005b; Harper et al., 2006; Ferreira et al., 2007; Boone et al., 2009). 
Furthermore, although the muscle oxygenation signal from NIRS does not allow for 
specific assessment of intracellular oxygenation, the HHb is the result of the relationship 
between oxygen delivery and oxygen consumption in the region of interest (Grassi 
2003). Therefore, as the NIRS originates in the microcirculation (Liu et al., 1995), HHb is 
considered to reflect the balance between muscle oxygen consumption and blood flow 
at the capillaries (DeLorey et al., 2003; Grassi et al., 2003; DeLorey et al., 2004b, a, 2005; 
Ferreira et al., 2005a; Ferreira et al., 2005b; Ferreira et al., 2006; Harper et al., 2006; 
Ferreira et al., 2007; Boone et al., 2009). Although not well understood, the slow 
component of the HHb signal most likely resembles a muscle response, given that 
approximately 86% of the pulmonary VO2 slow component arises from the active 
muscle (Poole et al., 1991; Grassi et al., 2003; Ferreira et al., 2005a).  NIRS cannot 
distinguish between the myoglobin (Mb) and hemoglobin (Hb) signal; however, the Mb 
contribution appears to be minimal and contribute less than 10% to the total signal in 
humans. Furthermore, the deoxygenated Mb signal did not change from 50 – 60% to 
100% of work max (Richardson et al., 1995), whereas the HHb continued to increase up 
to VO2max (Grassi et al., 1999). Given that the Mb signal is less than 10% of the total 
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signal and changes little from 50 to 100% of VO2 max, the HHb appears to be a 
reasonable estimate of O2 extraction (Seiyama et al., 1988; McCully & Hamaoka, 2000).  
 The present study is the first, to our knowledge, to examine HHb in two leg 
muscles during cycling exercise. The vastus lateralis is commonly measured with NIRS as 
this muscle is the primary contributor to force production during upright cycling. 
However, other muscle groups of the lower body (gluteus, hamstrings, and calf muscles) 
are recruited and contribute to force production and joint stabilization during cycling 
(Dingwell et al., 2008).  Based on the findings of this study, the vastus lateralis and 
gastrocnemius exhibited somewhat different patterns of muscle deoxygenation during 
cycling exercise. The vastus displayed a plateau in HHb starting at approximately 80% of 
VO2max with no increase from 90 to 100%. A similar pattern of vastus HHb has been 
seen during incremental exercise while cycling (Ferreira et al., 2007; Boone et al., 2009). 
The gastrocnemius, however, showed an increase in HHb from 90 to 100%. Given that 
HHb resembles O2 extraction this finding indicates that the pattern of O2 extraction also 
differs in leg muscles during cycling. This dissimilar pattern in HHb (Figure 2.3) has 
implications for blood flow distribution to the active muscle during cycling. Capillary 
blood flow (Qcap) to the vastus lateralis has been estimated during cycling by using HHb 
(~ O2 extraction) and VO2 during cycling. Based upon the findings of the current study 
and the data presented on highly trained cyclists (Boone et al., 2009), the rate of Qcap 
to VO2 appears to increase from approximately 90 to 100% of maximal workrate 
(Wmax) at least the in microcirculation near the vastus lateralis. Despite the difference 
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in protocols (discontinuous vs. incremental ramp) between Boone et al. (Boone et al., 
2009) and the present study the Qcap to muscle VO2 (pulmonary VO2 used as a 
surrogate for muscle VO2, (Ferreira et al., 2007; Boone et al., 2009)) relationship 
appears similar. Based on the different HHb response between the VL and GAST the 
inferred Qcap to VO2m relationship for the VL and GAST was markedly different from 90 
to 100% of VO2max as Qcap for the VL increased from 90 to 100% whereas Qcap for 
GAST plateaued at 90% of VO2max (Figure 2.4). This difference between the Qcap to 
VO2m relationship for the two muscle groups may indicate that the blood flow to the 
smaller muscle group (gastrocnemius) does not increase from 90 to 100% of VO2max 
whereas blood flow to the primary muscle of force production (vastus lateralis) 
continues to increase up to 100% of VO2max. We are unaware of any studies that have 
made direct measurements of vastus lateralis and gastrocnemius oxygen consumption 
and blood flow during cycling as this would require isolation of venous outflow from the 
respective muscle beds. The observed differences in muscle deoxygenation and 
estimated Qcap may be explained by differences in mean transit time, diffusing area, 
and diffusing distance, in small verse large muscle groups (Calbet et al., 2005). This 
interpretation must be made with caution as the assumption is made that VO2m 
increases to the same degree in both the gastrocnemius and vastus lateralis during 
cycling exercise.  
By revisiting a classic topic in exercise physiology new insights regarding 
limitations to high intensity exercise have been gained. The increase in CO was 
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attenuated as exercise intensity increased beyond 70% of VO2max. Furthermore, SV 
plateaued during moderate intensity exercise and was reduced at high intensity 
exercise. Whole body AVO2 difference continued to increase as exercise intensity and 
VO2 increased, however, at the level of the microcirculation, oxygen extraction at the 
vastus lateralis plateaued during high intensity exercise which has direct implications 
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Figure 2.1: Values are mean ± SE of 10 subjects. * Indicates significant difference from 








Figure 2.2: Values are mean ± SE of 10 subjects. Slope was determined from each 
individual Q vs. VO2 relationship. * Indicates significant reduction in slope from 40 to 






Figure 2.3: Values are means ± SE of 9 subjects. Closed circles (•) represent vastus 
lateralis (VL) and open circles (ᴏ) represent gastrocnemius (GAST). Normalized 
deoxygenated hemoglobin (HHb) was calculated based on the change in HHb from 
baseline 30W cycling to the HHb value obtained during the final 30 seconds of each 
workrate. Peak HHb was determined for each subject and then converted to 100%. The 
following equation was used for the calculation of % HHb; % HHb = [(value of interest – 
min)/(max – min)] *100 (Belarandani et al). * Indicates significant increase from 
previous value for VL, † indicates significant difference from previous value for GAST, p 
<0.05.   
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Figure 2.4: Values are means ± SE of 9 subjects. Closed circles (•) represent vastus 
lateralis (VL) and open circles (ᴏ) represent gastrocnemius (GAST). Qcap was calculated 
in a qualitative way by solving the Fick equation in which deoxygenated hemoglobin 
(HHb) was used as an expression of (a-v)O2 difference and pulmonary VO2 as surrogate 
of muscle VO2 (VO2m). Normalized capillary blood flow (Qcap) was calculated based on 
the change in HHb from baseline 30W cycling to the HHb value obtained during the final 
30 seconds of each workrate. Peak HHb was determined for each subject and then 
converted to 100%. The following equation was used for the calculation of % Qcap; % 
Qcap = [(value of interest – min)/(max – min)] *100 (Belarandani et al). * Indicates 
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significant increase from previous value for VL, † indicates significant difference from 





Workrate, watts 0 ± 0 132 ± 15* 174 ± 18* 216 ± 23* 257 ± 27* 300 ± 31* 341 ± 35* 383 ± 38*
VO2, l/min 0.416 ± 0.050 1.997 ± 0.140* 2.402 ± 0.176* 2.821 ± 0.175* 3.312 ± 0.212* 3.914 ± 0.356* 4.213 ± 0.330* 4.507 ± 0.360*
% VO2max 9 ± 1 42 ± 3 51 ± 3 60 ± 2 70 ± 3 83 ± 4 91 ± 2 99 ± 1
VE, l/min 15.6 ± 3.0 49.1 ± 4.9* 59.3 ± 6.1* 70.4 ± 7.7* 85.5 ± 10.8* 115.0 ± 21.1* 128.9 ± 16.6* 148.3 ± 17.9*
Rectal Tcore, ºC 37.23 ± 0.27 37.24 ± 0.25 37.43 ± 0.23* 37.68 ± 0.22* 37.87 ± 0.22* 38.20 ± 0.27* 38.17 ± 0.28 38.26 ± 0.28
Table 2.1: Exercise intensity, respiratory, and core temperature responses to exercise




HR, bpm 69.5 ± 12.7 116.2 ± 9.2* 126.7 ± 10.6* 136.5 ± 11.3* 148.7 ± 10.1* 168.2 ± 8.2* 171.2 ± 8.2 179.1 ± 9.0*
% HRmax 37.3 ± 6.6 62.4 ± 4.7* 68.0 ± 5.1* 73.3 ± 5.3* 79.8 ± 4.3* 90.3 ± 3.3* 91.9 ± 3.2 96.1 ± 3.3*
CO, l/min 7.6 ± 0.9 16.0 ± 16* 18.2 ± 1.8* 19.7 ± 1.7* 21.9 ± 1.8* 23.1 ± 2.2* 23.9 ± 2.2* 24.6 ± 2.6
SV, ml/beat 112.0 ± 20.5 138.6 ± 17.3* 144.8 ± 17.2* 145.3 ± 17.5 147.8 ± 15.9 137.9 ± 15.5† 139.9 ± 14.9 137.7 ± 16.2†




Rest 40% 50% 60% 70% 80% 90% 100%
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BL VL‐HHb, μm 35.14 ± 8.49 34.77 ± 8.28 35.23 ± 8.48 35.42 ± 8.74 36.44 ± 10.02 36.10 ± 9.45 36.29 ± 9.94
% VL‐HHB 34.82 ± 18.98 46.17 ± 9.29* 62.02 ± 9.15* 78.44 ± 12.63* 88.11 ± 6.90* 94.14 ± 7.50 94.76 ± 9.71
BL GAST‐HHb, μm 19.11 ± 7.74 18.86 ± 7.74 19.19 ± 7.69 19.27 ± 7.80 20.98 ± 8.62 20.65 ± 8.47 19.82 ± 8.41







40% 50% 60% 70% 80%
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CHAPTER VI: STUDY 3 
STROKE VOLUME RESPONSE TO LOW DOSE BETA BLOCKADE DURING 
NORMOTHERMIC AND HYPERTHERMIC CONDITIONS 
Abstract: 
The effect of hyperthermia on stroke volume (SV) independent of heart rate (HR) 
has not been described. Therefore, the purpose of this study was to determine if 
hyperthermia independent of an increase in HR reduces SV. Eleven active men 
performed 60 minutes of exercise at ~ 57% of VO2max after receiving placebo control 
(PL) or a low dose (0.2mg/kg) of the β1 adrenoreceptor beta blocker (βB), atenolol. Four 
experimental conditions were performed; normothermia and PL (NormoPL), 
normothermia and βB (NormoβB), hyperthermia and PL (HyperPL), and hyperthermia 
and βB (HyperβB). Hyperthermia increased skin and core temperature by 4.3ºC and 
0.8ºC, respectively. HR at minute 60 was not different between NormoPL (154.6 ± 11.0) 
and HyperβB (153.8 ± 13.3 bpm) (p > 0.05) and SV was slightly increased during the 
latter portion of the exercise bout (6 to 7% increase from minute 40 to 60) during Hyper 
βB when compared to NormoPL (treatment x time interaction, F =3.234, p = 0.03). The 
increase in SV appears to be due to the higher CO during hyperthermic conditions 
(minute 60: Hyper; 21.0 ± 2.5 vs. Normo 18.9 ± 2.6, p < 0.01). When the progressive 
increase in HR was not prevented by βB, SV was reduced by 9% and 14% for NormoPL  
and HyperPL, respectively (p < 0.01). Although hyperthermia increased cutaneous blood 
flow (CBF) and forearm blood flow (FBF) by ~40% (p < 0.05), these increases were not 
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temporally related to the decrease in SV as CBF and FBF did not increase after min 15 of 
exercise. In conclusion, when matched for HR, hyperthermia does not lower SV. 
Furthermore, the reduction in SV during exercise under both normothermic and 




















During moderate intensity prolonged exercise, heart rate (HR) normally 
increases by 10 to 20 beats per minute from minute 10 to 60 of exercise. This HR drift is 
accompanied by a significant reduction in stroke volume (SV). Previous work from our 
laboratory used a low dose of beta blockade (βB) (cardioselective β1 adrenergic 
receptor blockade; 0.1mg/kg atenolol) to prevent the normal increase in HR which 
attenuated the reduction in SV without affecting thermoregulation, blood pressure, or 
cutaneous blood flow (CBF) (Fritzsche et al., 1999). Based on the results of this study, it 
was believed that the increase in HR leads to a reduction in diastolic filling time which 
then causes the decrease in SV (Ross et al., 1965; Bevegard et al., 1967; Sheriff et al., 
1993). Furthermore, increases in CBF were shown to be temporally unrelated to the 
reduction in SV (Fritzsche et al., 1999) which is in direct contradiction to classic studies 
of CV drift (Rowell, 1974, 1986) that posited a redistribution of blood volume from 
central to peripheral sites and a gradual and progressive increase in cutaneous blood 
flow caused the increase in HR and decrease in SV. 
Whether or not a similar attenuation of the reduction in SV would be observed 
during exercise with severe heat stress has yet to be determined. During exercise in the 
heat the magnitude of the increase in HR is substantially greater than during moderate 
conditions as increased demand is placed on the cardiovascular system to deliver blood 
to the working muscles and to the skin to aide in thermoregulation (Shaffrath & Adams, 
1984; Gonzalez-Alonso et al., 2008). Under such conditions both HR and CBF are 
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increased leading to a substantially greater reduction in SV when compared to normal 
conditions (Shaffrath & Adams, 1984). The contribution that the elevation in HR and CBF 
independently exert on the reduction in SV is unknown.  
Cardiac function appears to be reduced during exercise in the heat. 
Hyperthermia independent of dehydration reduced SV by 11 ml/beat; however, 
hyperthermia was associated with an 8 bpm higher HR (Gonzalez-Alonso et al., 1997). In 
a follow-up study (Gonzalez-Alonso et al., 1999a) supine exercise restored two thirds of 
the reduction in SV and prevented one third of the increase in HR. Since SV was still 
reduced it appeared that a factor associated with hyperthermia and not dehydration 
was associated with the reduction in SV.   
The purpose of this study was to determine if hyperthermia, independent of an 
increase in HR, reduces SV. In order to answer this question a low dose of βB was used 
to prevent the normal increase in HR during exercise under normothermic and 
hyperthermic conditions. We hypothesized that hyperthermia would reduce SV when 
HR was matched. Furthermore, we were also able to determine if the progressive 
increase in HR and reduction in SV associated with exercise in the heat is temporally 
unrelated to peripheral hemodynamics as has been previously determined during 






Subjects: Eleven healthy and active men (24 ± 5 yr of age; range 18 - 34) provided 
written informed consent to participate in this study. The protocol, experimental design, 
and informed consent form were approved by the Institutional Review Board at The 
University of Texas at Austin. The subjects’ stature, body mass, peak O2 uptake 
(VO2peak), and maximal HR (means ± SD) were as follows: 1.767 ± 0.056 m, 77.8 ± 12.4 
kg, 3.885 ± 0.541 l/min, and 192.9 ± 8.2 beats/min, respectively.     
 
Experimental protocol and design:  
Preliminary testing: The submaximal VO2 vs. workrate relationship was 
determined during a continuous incremental cycle ergometer protocol.  Subjects rested 
while seated on the cycle ergometer (Excalibur Sport, Lode) for 5 minutes while VO2 
and HR were monitored to determine baseline resting values. Subjects then cycled for 
20 minutes (4 by 5 minutes stages) at a constant pedal rate (freely chosen by subject). 
Five minutes at each submaximal work rate allowed for a steady state VO2 and HR 
response. Following a 10 min rest, subjects returned to the cycle ergometer and 
VO2max and maximal HR were determined during a continuous, incremental cycle 
ergometer protocol.  
Familiarization trials: Subjects performed two familiarization trials. The first 
familiarization trial was performed under normothermic conditions while the second 
was performed under hyperthermic conditions. Subjects pedaled for 60 minutes at a 
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constant workrate that elicited approximately 60% of VO2max.  All measurements 
except venous blood draws were made during these familiarization trials, thereby 
allowing subjects to practice the acetylene wash-in (cardiac output) and venous 
occlusion plethysmography (forearm blood flow) techniques.  During these 
familiarization trials subjects ingested 12 ml/kg of a 6% CHO-electrolyte beverage 
(Gatorade, Quaker Oats) and sweat rate was calculated for both conditions (sweat rate 
equal to change in nude body mass pre to post exercise minus ingested fluid volume). 
Fluid was ingested prior to exercise (water only) and at min 15, 30, and 45 of exercise 
(Gatorade).  
Experimental Trials:  Subjects cycled for 60 min at a constant work rate that 
elicited approximately 57% of VO2max under normothermic and hyperthermic 
conditions. Three minutes before the exercise bout subjects ingested: 1) 0.2 mg/kg of 
the β1 (cardioselective)-adrenoreceptor blocker atenolol (βB) or 2) placebo control 
(PLA). βB was in liquid oral suspension (2 mg/ml). One hundred milliliters of a calorie 
free diet cherry soda was used to mask the βB and to match the flavor of the placebo 
(100ml of diet cherry soda). The target amount of βB was measured using a precision 
scale (XP-105, Mettler-Toledo).  The dosage of βB was chosen based on pilot work and 
previous work from our laboratory (Fritzsche et al., 1999). Previously, Fritzsche et al. 
(Fritzsche et al., 1999) gave subjects 0.1mg/kg atenolol and showed that this dosage 
was effective at blocking the normal increase in HR that occurs with prolonged exercise 
under moderate environmental conditions (dry bulb temp 27ºC, wet bulb temp 18ºC, RH 
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< 40%). However, based on pilot work, this dosage (0.1mg/kg) was not effective at 
preventing the increase in HR under hyperthermic conditions, therefore a slightly higher 
dosage (0.2mg/kg) was used for this study. This dosage (0.2mg/kg) resulted in a nearly 
identical HR response between the NormoPL and HyperβB trials (see results section). A 
set volume of water (specific to trial and subject) was ingested prior to exercise. A 6% 
CHO-electrolyte beverage (Gatorade, Quaker Oats) was ingested at min 15, 30, and 45. 
The total volume of water and the CHO-electrolyte beverage equaled the sweat volume 
as determined during the familiarization trials. 
  Experimental trials were performed in a random order with at least 48 hours 
separating the trials. Subjects were blinded as to whether or not they were performing a 
βB or PLA trial. All trials were performed at the same time of day to avoid any 
confounding effects of circadian rhythm on core temperature. Subjects were instructed 
to drink 500 ml of water upon waking to insure adequate hydration and to eat the same 
breakfast prior to each trial. Trials commenced at least 2 hours post-prandial.   
 
Experimental procedures:  
Upon arrival to the laboratory, subjects were escorted to a restroom adjacent to 
the laboratory where they voided their bladder, recorded their nude body mass, and 
inserted the rectal temperature probe. Subjects then dressed in cycling shorts and 
returned to the main laboratory to begin instrumentation.  Subjects sat quietly in a chair 
while their skin was cleaned with 70% isopropyl alcohol for placement of ECG 
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electrodes. Following placement of electrodes the subjects put on a spandage shirt 
which held all wires and electrodes in place during exercise. An antecubital vein was 
catheterized for blood sampling. Following catheterization, subjects moved to the cycle 
ergometer and final instrumentation was performed (forearm blood flow strain gauge 
and laser Doppler probe placement). Resting measures of forearm blood flow (FBF), 
cutaneous blood flow (CBF), oxygen consumption (VO2), cardiac output (CO), and blood 
pressure (BP) were made prior to exercise.  In order to achieve the hyperthermic 
conditions, subjects were dressed with a vinyl rain jacket and nylon/spandex leg 
coverings and two parabolic electric heaters (Heatdish, Presto) were directed at the 
subject, one from the front and the other from the back. The combination of the jacket, 
leg coverings, and heaters was successful at reducing heat dissipation as evidenced by 
the higher core (Tcore) and skin (Tskin) temperatures during hyperthermia trials. 
Normothermic conditions were achieved without fan cooling with an environmental 
temperature of 23ºC and 35% RH. Following instrumentation and baseline measures the 
subjects received their experimental treatment and started the 60 minute exercise bout.  
Respiratory and cardiovascular measurements: Oxygen consumption was 
measured breath by breath using open-circuit spirometry. Subjects breathed through a 
two-way non rebreathing valve connected to a pneumotachometer (Hans Rudolph, 
Kansas City, MO). Oxygen and carbon dioxide concentration of inspired and expired 
gases were determined by a mass spectrometer (Perkin-Elmer MGA 1100, St. Louis, 
MO). Gas samples were collected at the mouthpiece via a 6-foot capillary tube 
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connected directly to the mass spectrometer. CO was determined by open circuit 
acetylene washin as described by Johnson et al. (Johnson et al., 2000). Briefly, at the 
end of full expiration, the participants breathed for a minimum of 8 breaths through a 
mouthpiece connected to a bag filled with mixed gases, including 0.7% acetylene, 9.0% 
helium, 21% oxygen, and balance nitrogen. The concentrations of acetylene and helium 
were monitored by continuous sampling at the mouthpiece and data was viewed in real 
time on a personal computer. CO was calculated from the washin curve of the acetylene 
according to a single alveolar one compartment lung model. The iterative method as 
outlined in Johnson et al. (1999) was used for the calculation of CO. Custom software 
(Beck Integrated Physiological Systems) was used to determine breath by breath oxygen 
consumption and to calculate CO. The mass spectrometer was calibrated prior to each 
experimental trial using gases of known concentration. Volume was calibrated using a 3 
l syringe (Hans Rudolph) at low, moderate, and high flow rates. During exercise VO2 was 
measured continuously from min 0 to 15, 18 to 22, 28 to 32, 38 to 42, 48 to 60. CO was 
measured prior to exercise and at min 5, 10, 15, 20, 30, 40, 50, and 60.  
HR was measured continuously (Physioflow) and 1 minute averages were 
reported for the corresponding time period during which the CO measurement was 
made. The HR during this 1 minute average was used for the calculation of SV (SV = 
CO/HR). SBP and DBP were determined by auscultation on the right arm with use of a 
microphone under a blood pressure cuff (Tango+, Suntech). During the measurement of 
blood pressure the subject was instructed to relax his right arm and rest his right hand 
104
on the handlebars of the cycle ergometer. Mean arterial pressure (MAP) was calculated 
as DBP + 1/3(SBP-DBP). Total peripheral resistance (TPR) was calculated during each 
determination of CO as TPR = MAP/CO. 
Hematocrit and hemoglobin: Blood samples (totaling ~15 ml/treatment) were 
withdrawn prior to exercise and heating (hyperthermia trials) and during exercise at min 
5, 15, 30, 45, and 60. The catheter was kept patent by flushing 5 ml 0.9% saline after 
each blood draw. Hemoglobin (Hb) concentration was analyzed in duplicate with the 
cyanmethemoglobin method. Hematocrit (Hct) was measured in duplicate after 
microcentrifugation for 15 min. The changes in blood volume and plasma volume 
(percent change from rest) were calculated from the changes in Hb and Hct according to 
the equations of Dill and Costill (Dill & Costill, 1974). Complete data for Hb and Hct is 
reported for 9 subjects due to technical problems with the 60 minute blood draw in 1 
subject.  
Cutaneous blood flow and forearm blood flow: Cutaneous blood flow (CBF) was 
measured continuously by laser-Doppler flowmetry (MoorLab, Moor Instruments 
Limited) on the ventral side of left forearm. Location of the laser-Doppler probe was 
kept consistent across trials by marking the site with an indelible marker. Forearm blood 
flow (FBF) was measured by venous occlusion plethysmography (EC6 plethysmograph, 
Hokanson) according to the procedures outlined by Whitney (Whitney, 1953). During 
this measurement, a flexible mercury in silastic tubing strain gauge was placed over the 
largest circumference of the right forearm. The placement of the gauge was kept 
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consistent within a trial as well as across trials by marking the location of the gauge with 
an indelible marker. An occlusion cuff was placed at the wrist and inflated to 250 mmHg 
to restrict blood flow to the hand for 2 minutes. A second cuff was placed around the 
upper arm and rapidly inflated to 50 mmHg which occludes venous outflow while 
arterial inflow continues. The increase in forearm volume, measured by the strain 
gauge, was plotted with data acquisition software (NIVP3, Hokanson). During the 
measurements the arm was suspended just above heart level in a custom made sling 
that was able to support the weight of the arm. In order to reduce movement artifact a 
member of the research team stabilized the sling. FBF was measured prior to exercise 
and heating and during exercise at min 12, 35, and 55. A series of at least 6 FBF 
measurements were performed for each time period.   
Body temperatures and rating of perceived exertion: Rectal temperature (Tcore) 
was recorded using a thermistor (model 401, Measurement Specialties) inserted 12 cm 
past the anal sphincter. Skin temperature (Tskin) was recorded from skin thermistors 
(model 409A, Measurement Specialties) attached to plastic holders and placed at six 
skin sites; chest, back, upper arm, forearm, thigh, and calf. All skin thermistors were 
placed on the left side of the body and held in place with spandage and tape. Mean skin 
temperature was calculated based on the weighted average of the six sites (Hardy et al., 
1938). Body temperature was calculated based on the following equation; Tbody = 
(0.87*Tcore) + (0.13*Tskin) (Baum et al., 1976). All temperature measurements were 
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made continuously and were interfaced to a PC. Rating of perceived exertion (RPE) was 
recorded on the 6 to 20 Borg scale (Borg, 1975) at min 5, 10, 15, 20, 30, 40, 50, and 60. 
 
Statistics: A two-way (treatment x time) repeated measures ANOVA was used to 
determine significant differences between means. According to our original statistics 
plan, changes from min 10 to 60 (effect of time within a given treatment) were treated 
as planned comparisons and LSD comparison was used to determine significance of 
changes from min 10 to 60. The 60 minute values for each measurement were 
separately analyzed using a one-way ANOVA. If a significant main effect was found, 
Tukey’s HSD was used to determine significant differences between means. The 60 
minute comparison was chosen as this time point yielded the greatest difference 
between means for many of the measured variables (primarily Tcore, HR, and SV). The 
Sidak correction for multiple comparisons was used to determine significant differences 
between all other comparisons. If the sphericity assumption was violated the 
Greenhouse-Geisser correction was employed to ensure significant differences for the 
main effect. If no difference was observed between placebo and βB trials for a given 
temperature the trials were combined to determine the independent effect of 
temperature in normothermic (Normo) and hyperthermic (Hyper) conditions. Similarly, 
if no difference was identified between normothermia and hyperthermia within a given 
treatment the trials were combined to determine the independent effect of Placebo vs. 
Beta Blockade treatments. A paired samples t-test was used to determine significant 
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differences between means of combined groups. In order to determine the onset of βB 
a paired samples t-test was used to determine the first significant difference in HR for 
















Respiratory responses: The one hour bout of exercise was performed at 147 ± 
18.5 watts which elicited ~ 57% of VO2max. VO2 was similar between all trials and 
increased slightly from min 10 to 60 (p < 0.01) (Table 3.1).  
Body temperature regulation; Tcore and Tskin: The technique employed to 
induce hyperthermia (combination of cycling apparel and space heaters) was successful 
at increasing both Tcore and Tskin during exercise (Figure 3.1 and Table 3.1). The 
earliest significant difference for Tcore between Normo and Hyper trials occurred at 
minute 30 (Normo; 37.71 ± 0.32 vs. Hyper; 37.89 ± 0.41ºC, p < 0.01). During exercise, 
Tskin was well maintained between 30.3 and 31.5ºC during Normo trials and between 
35.1 and 36.0ºC during Hyper trials (Table 3.1). At minute 60, hyperthermia elevated 
Tcore and Tskin by 0.78ºC (p < 0.01) and 4.3ºC (p < 0.01), respectively. There were no 
differences for Tcore or Tskin between NormoPL and NormoβB or between the HyperPL 
and HyperβB trials (Figure 3.1 and Table 3.1).  
Cardiovascular responses: The HR response under each condition is presented in 
Figure 3.2. During NormoPL, HR increased 11% from minute 10 to 60 (138.9 ± 13.0 to 
154.6 ± 11.0 bpm, p < 0.01). HyperPL nearly doubled the increase in HR (i.e.; 21% 
increase) during this same time period (149.2 ± 11.4 to 180.1 ± 9.2 bpm, p < 0.01). 
NormoβB prevented the normal increase in HR (135.6±11.5 to 135.3 ± 12.2 bpm, p = 
0.89). HR increased 7% during HyperΒB (144.1 ±13.7 to 153.8 ± 13.3 bpm, p < 0.01) from 
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minute 10 to 60, however the last significant increase in HR during HyperβB occurred 
from minute 15 to 20 (p < 0.01) (i.e.; no significant increase in HR during HyperβB from 
minute 20 to 60). HR was not different at any time point when comparing NormoPL and 
HyperβB (Figure 3.1). Therefore, the βB treatment was successful at controlling HR 
despite a significant increase in Tcore and Tskin, a critical condition allowing us to 
directly test our hypothesis. Using the criteria as outlined in the methods section, the 
onset of βB occurred at minute 15 during NormoβB (141.7 vs. 136.2, p < 0.01) and 
minute 10 during HyperβB (149.2 vs. 144.1, p = 0.03). 
The manipulation of core and skin temperature coupled with or without the βB 
treatment yielded a wide range in HR (Figure 3.4a). HR at minute 60 was 12% lower 
during NormoβB compared to NormoPL (135.3 ± 12.2 vs. 154.6 ± 11.0 bpm, p < 0.01) 
which coincided with a 13% elevation in SV (139.7 ± 21.5 vs. 123.1 ± 14.5 ml/beat, p < 
0.01)(Figure 3.4b). HyperβB lowered HR by 17% compared to HyperPL (180.1 ± 9.2 vs. 
153.8 ±13.3 bpm, p < 0.01) which was associated with a 16% increase in SV (132.1 ± 21.4 
vs. 110.8 ± 4.3ml/beat, p < 0.01). SV declined over time during both NormoPL (134.9 ± 
16.6 to 123.1 ± 14.5 ml/beat, p < 0.01) and HyperPL (128.4 ± 14.4 to 110.8 ± 14.3 
ml/beat, p < 0.01) (Figure 3.3). HR at minute 60 was nearly identical between NormoPL 
and HyperβB despite significantly different Tcore and Tskin. Contrary to our original 
hypothesis that hyperthermia, independent of HR, would reduce SV, hyperthermia 
increased SV as evidenced by the 6 to 7% higher SV when comparing HyperβB and 
NormoPL at minute 40, 50, and 60 (treatment x time interaction; F = 3.234, p <0.03) 
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(Figure 3.5).  The elevation in SV during HyperβB is most likely due to the 6% increase in 
CO (p < 0.01) (Figure 3.4c) as a result of increased cutaneous blood flow during 
hyperthermic conditions (Table 3.1). Based on these findings, the increase in HR appears 
responsible for the reduction in SV observed under both normothermic and 
hyperthermic conditions (Figure 3.5).    
Blood Pressure and Total Peripheral Resistance:  Hyperthermia, under both PLA 
and βB, lowered MAP and DBP during exercise (Table 3.1 and Figure 3.4d). At minute 60, 
MAP and DBP were 7% (p < 0.01) and 18% (p < 0.01) lower during Hyper than Normo 
trials, respectively (Figure 3.4d). Unlike MAP and DBP, βB, independent of temperature, 
reduced SBP during the final 20 minutes of exercise. At minute 60, βB reduced SBP by 
5% (p < 0.01).  Due to the reduction in MAP, hyperthermia reduced TPR throughout 
exercise compared to normothermia (p < 0.01). 
FBF and CBF: FBF and CBF were not different between the two normothermia 
trials or between the two hyperthermia trials. Hyperthermia alone increased FBF and 
CBF at minute 60 FBF by 40% (p < 0.01) and 37% (p < 0.01), respectively (Table 3.1). Both 
FBF and CBF did not increase significantly after minute 15.  
Bodyweight changes, fluid intake, and sweat volume: Fluid replacement 
maintained bodyweight (BW) between + 0.1kg and - 0.2kg of pre-exercise BW (Table 
3.2). The change in BW from pre to post exercise was significant for NormoβB (p = 0.04), 
HyperPL (p < 0.05), and HyperβB (p = 0.01); however, such minor changes in BW are 
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assumed to not be physiologically important. Moreover, there were no differences in 
pre or post exercise BW between any of the treatments. Hyperthermia, on average, 
increased total sweat volume by 0.58 L (p < 0.01). In order to compensate for this 
increased sweat volume subjects ingested approximately 0.35 L more fluid during the 
hyperthermia trials (Table 3.2). 
Blood volume and plasma volume: BV and PV were reduced during exercise 
compared to rest for all trials. The reductions in both BV and PV were maintained 
throughout exercise and there were no differences between trials indicating that the 
observed differences in SV were not due to differences in BV and PV. At min 60 BV and 
PV were reduced by 5.7% (range: 4.2 to 6.7%) and 8.4% (range: 6.5 to 10.6%), 
respectively (Table 3.3).   
Perceived exertion: There were no significant differences in RPE between 
NormoPL and NormoβB or between HyperPL and HyperβB. The first indication that the 
hyperthermia trials were perceived as being more difficult occurred at minute 30, 
coinciding with the first significant difference in Tcore between the Hyper and Normo 
trials. At min 60 RPE was 1.7 points higher during Hyper than Normo (14.1 ± 1.2 vs. 15.8 





We sought to determine whether hyperthermia, independent of elevations in 
HR, would reduce SV. Contrary to our original hypothesis, whole body hyperthermia did 
not lower SV when the increase in HR was prevented (i.e.; NormoPL vs. HyperΒB). 
Hyperthermia had no independent effect on reducing SV. However, under normal 
conditions when HR is allowed to increase SV is reduced (NormoPL and HyperPL).  As a 
result of increased peripheral blood flow (CBF and FBF) CO was slightly elevated during 
hyperthermia. With nearly identical heart rates between these two conditions, 
hyperthermia elevated SV by 6 to 7% during HyperβB when compared to NormoPL 
(significant treatment x time interaction, p < 0.03). Based upon the findings of this study 
it appears that there is a wide range in which HR can influence SV and that the reduction 
in SV during both normothermia and hyperthermia is due to the elevation in HR. 
The finding that hyperthermia, independent of the increase in HR, did not lower 
SV during moderate intensity exercise was surprising. The hypothesis for this 
investigation was based on findings of reduced cardiac function during intense or 
prolonged exercise in the heat (Gonzalez-Alonso et al., 1995; Gonzalez-Alonso et al., 
1997; Gonzalez-Alonso et al., 1998; Gonzalez-Alonso et al., 1999a; Gonzalez-Alonso et 
al., 1999b; Gonzalez-Alonso et al., 2000; Gonzalez-Alonso & Calbet, 2003; Gonzalez-
Alonso et al., 2004; Mortensen et al., 2005; Gonzalez-Alonso et al., 2008). 
Hyperthermia, independent of dehydration, reduced SV by 11 ml/beat; however, 
hyperthermia was associated with an 8 bpm higher HR (Gonzalez-Alonso et al., 1997). In 
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a follow-up study (Gonzalez-Alonso et al., 1999a) supine exercise restored two thirds of 
the reduction in SV and prevented one third of the increase in HR. Since SV was still 
reduced it appeared that a factor associated with hyperthermia and not dehydration 
was associated with the reduction in SV. Based on the findings of these studies, 
hyperthermia appears to be a critical factor affecting cardiac function during prolonged 
exercise. An important difference between the present study and those previously 
discussed by Gonzalez-Alonso et al. is that the degree of hyperthermia was substantially 
less in the current study (38.9ºC vs. 39.5 to 40ºC). The higher core temperature may be 
critical to induce a reduction in SV during prolonged exercise. However, such a high core 
temperature is difficult to attain at a moderate exercise intensities without dehydration 
or without an uncompensable heat stress.  
Similarly, heat stress during maximal exercise results in an acceleration of the 
decline in CO and MAP that leads to a reduction in muscle blood flow, O2 delivery, and 
O2 uptake (Gonzalez-Alonso et al., 1999b; Gonzalez-Alonso & Calbet, 2003; Gonzalez-
Alonso et al., 2004). In fact, figure 5 of Gonzalez-Alonso et al. (Gonzalez-Alonso & 
Calbet, 2003) shows a leftward shift in SV when comparing heat stress to normal 
conditions indicative of reduced cardiac function during exercise. Similarly, maximal 
values of CO, SV, systemic O2 delivery and VO2 were attained within 5 minutes of 
exercise at VO2max and were reduced prior to exhaustion which coincided with a high 
core temperature (~ 39.5º C) (Mortensen et al., 2005). Based upon these findings and 
the strong association between elevated Tcore and reduced cardiac function we 
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hypothesized that hyperthermia, independent of increases in HR, would lower SV. 
However, the cardiovascular adjustments to heat stress during moderate intensity 
exercise, as performed in this study, appear to be more similar to passive heat stress at 
rest than during maximal exercise. During maximal exercise, cardiac function is maximal 
(i.e.; VO2, HR, CO are all at maximum) and any increase in the demand for the limited 
CO will lead to an accelerated rate of fatigue (Gonzalez-Alonso et al., 1999b; Gonzalez-
Alonso et al., 2004; Gonzalez-Alonso et al., 2008).  
Passive heat stress at rest can induce significant cardiovascular strain by 
increasing HR well above 100 bpm and can increase CO up to 13 l/min (Crandall, 2008; 
Crandall et al., 2008). An elevation of 1ºC at rest was found to increase ejection fraction 
by lowering ESV while EDV was maintained (Crandall, 2008; Crandall et al., 2008). This 
finding, along with prior reports of sustained or elevated stroke volume during heat 
stress (Rowell et al., 1969; Rowell, 1986; Johnson & DW, 1996; Wilson et al., 2007), 
coupled with reduction in cardiac filling pressure (Rowell et al., 1969; Minson et al., 
1998; Crandall et al., 1999; Peters et al., 2000; Wilson et al., 2007), indicate that heat 
stress increases cardiac contractility. Furthermore, Crandall et al. (Crandall et al., 2008) 
found that despite a reduction in central venous and left ventricular filling pressure 
during passive heat stress, left ventricular EDV was unchanged by heat stress and that 
the heat stress may improve diastolic function resulting in greater diastolic filling for a 
given filling pressure. This improved diastolic function during heat stress may be related 
to a shift in the operating point to a steeper portion of the Frank-Starling curve where 
115
small changes in pulmonary capillary wedge pressure (estimated left ventricular filling 
pressure) result in large changes in SV (Wilson et al., 2009).  Although invasive measures 
of cardiac function were not made during the present study, this is the first time that 
heat stress in combination with moderate intensity exercise has been shown to 
maintain and increase SV for a given HR under hyperthermic conditions (i.e.; HyperβB 
vs. NormoPL comparison).  
Previous work from our laboratory (Fritzsche et al., 1999) showed that during 
prolonged exercise the reduction in SV corresponds to the increase in HR and is 
temporally unrelated to an increase in cutaneous blood flow. The findings of the current 
study confirm these earlier results and for the first time, provide further evidence that 
HR is the primary factor determining SV even under conditions of hyperthermia. This 
finding is in direct opposition to the hypothesis put forth by Rowell that cardiovascular 
drift is the consequence of a progressive increase in cutaneous blood flow (Rowell, 
1974, 1986). The classic thinking regarding CV drift (Rowell, 1986) is that a rise in 
cutaneous blood flow leads to an increase in skin venous volume, which reduces 
ventricular filling pressure, end diastolic volume, and SV. However, even under the 
hyperthermic conditions present in the current study in which FBF and CBF were 
elevated by 40%, blocking the normal increase in HR prevented the drop in SV. 
Therefore, an alternative hypothesis that the decline in SV during prolonged exercise is 
caused by a reduction in ventricular filling time leading to a reduction in end diastolic 
volume as a result of the increased HR (Ross et al., 1965; Bevegard et al., 1967; Sheriff et 
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al., 1993) appears to be appropriate under both normothermic and hyperthermic 
conditions.  
The mechanism responsible for the reduction in SV during prolonged exercise 
appears to be associated with a reduction in diastolic filling time which leads to a 
decrease in EDV and SV. As with the previous study from our laboratory (Fritzsche et al., 
1999), it appears unlikely that an unknown mechanism related to the presence of the βB 
prevented the decline in SV. Furthermore, some variables that could have been causally 
related to the decline in SV (blood volume, CBF, FBF, Tskin, and Tcore) were not 
different between NormoPL and NormoβB or between HyperPL and HyperβB.  CBF, FBF, 
Tcore, and Tskin were all higher during hyperthermic conditions and these increases are 
most likely responsible for the greater increase in HR reduction in SV during HyperPL 
when compared to NormoPL. However, these increases in peripheral blood flow are not 
temporally associated with the drift in HR and reduction in SV as neither CBF nor FBF 
increased from min 15 to 60 of exercise.  Under the hyperthermic conditions employed 
in the current study the cardiovascular system was able to respond appropriately to the 
increase in thermoregulatory demand by increasing skin blood flow and CO. A similar 
increase in CO (1 to 3 l/min) has been reported during low intensity cycling in the heat 
(Savard et al., 1988; Nielsen et al., 1990; Nielsen et al., 1993). However, if such 
conditions are prolonged (> 90 minutes) or accompanied by significant dehydration, the 
cardiovascular system may not be able to meet the demands of the thermoregulatory 
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system as CO and MAP are reduced and progressive increases in core temperature will 
lead to fatigue (Gonzalez-Alonso et al., 1999b).  
The reason for the increase in HR during the 10 to 60 min period of prolonged 
exercise is not entirely clear. Based on the results of this study and Fritzsche et al. 
(Fritzsche et al., 1999) the progressive increase in HR during both normothermic and 
hyperthermic conditions is not temporally related to progressive increases in CBF, FBF, 
or Tskin as these variables did not change from min 10 or 15 to 60 of exercise. Typically 
during prolonged exercise when the HR increase is prevented by reducing the 
environmental stress, reducing the exercise intensity (Shaffrath & Adams, 1984), or by 
having well trained, euhydrated, heat acclimated athletes (Gonzalez-Alonso et al., 1995; 
Gonzalez-Alonso et al., 1997) perform the exercise bout the increases in perceived 
exertion and core temperature are also prevented. However, due to the 
pharmacological intervention in the present study, increases in RPE and Tcore were 
disassociated from HR during the βB trials. An alternate explanation for the increase in 
HR as put forth by Fritzsche et al. (Fritzsche et al., 1999) is that a progressive increase in 
motor unit recruitment coupled with a minor increase in core temperature may account 
for the increase in HR. The current findings from the hyperthermia and the 
normothermia trials lend support for the role of the progressive increase in Tcore 
leading to the increase in HR. During normothermia, a 0.9ºC increase in Tcore was 
associated with a 16 bpm increase in HR and during hyperthermia a 1.7ºC increase in 
Tcore was associated with a 30 bpm increase in HR. Furthermore, VO2 increased 6.5% 
118
over the duration of the exercise bout (present study and Fritzsche et al., 1999) which 
may be related to a progressive increase in motor unit recruitment.  
Overall, hyperthermia independent of an increase in HR was not associated with 
a reduction in SV. Due to the elevation in CO associated with an increase in skin blood 
flow during hyperthermia, SV was slightly elevated when the increase in HR was 
prevented (HyperβB vs. NormoPL). The increase in HR that occurs during normal 
exercise appears to be the primary factor responsible for the decrease in SV under both 
normothermic and hyperthermic conditions. The progressive increase in HR, although 
not entirely understood, appears to be associated with the progressive increase in core 
temperature as other factors such as cutaneous blood flow and skin temperature are 
not temporally related to the increase in HR during exercise under both normothermic 
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Figure 3.1: Values are mean ± SE of 11 subjects. * Indicates significant difference 






Figure 3.2: Values are mean ± SE for 11 subjects. * Indicates significant difference 
between NormoPL and NormoβB, † indicates significant difference between HyperPL 
and HyperβB, # indicates significant increase from previous value for HyperβB, †† 
indicates significant increase from previous value for NormoPL. Both HyperPL and 
NormoPL exhibited a continual significant increase in HR, however for the purpose of 
clarity this is not included on the above graph. ‡ Indicates significant increase from min 




Figure 3.3: Values are mean ± SE for 11 subjects. * Indicates significant difference 
between NormoPL and NormoβB, † indicates significant difference between HyperPL 













Figure 3.4A-E: Values are mean ± SE of 11 subjects. All graphs depict values at min 60 of 
exercise ; A) heart rate, B) stroke volume, C) cardiac output, D) mean arterial blood 
pressure, and E) total peripheral resistance. * Indicates significant difference between 
NormoPL and NormoβB, † indicates significant difference between HyperPL and 
HyperβB, ‡ indicates significant difference between pooled data from Normo and Hyper 














Figure 3.5: Values are mean ± SD of 11 subjects. Normothermia conditions are 
represented by the solid line and filled circles (•). Hyperthermia conditions are 
represented by the dotted line and open circles (o). Hyperthermia resulted in a 
rightward shift of the SV vs. HR curve. Significant treatment by time interaction for SV 





NormoPL 0.364 ± 0.099 2.120 ± 0.298 2.186 ± 0.280 2.198 ± 0.296 2.254 ± 0.321 2.254 ± 0.318 2.272 ± 0.323 2.286 ± 0.312 2.289 ± 0.319†
NormoBB 0.365 ± 0.149 2.102 ± 0.259 2.123 ± 0.271 2.153 ± 0.294 2.207 ± 0.280 2.230 ± 0.335 2.252 ± 0.316 2.279 ± 0.312 2.242 ± 0.342†
HyperPL 0.350 ± 0.170 2.069 ± 0.283 2.134 ± 0.322 2.145 ± 0.318 2.241 ± 0.327 2.255 ± 0.336 2.257 ± 0.387 2.292 ± 0.358 2.302 ± 0.378†
HyperBB 0.318 ± 0.114 2.040 ± 0.280 2.080 ± 0.290 2.126 ± 0.291 2.197 ± 0.324 2.199 ± 0.354 2.211 ± 0.314 2.243 ± 0.331 2.257 ± 0.340†
CO, l/min
NormoPL 7.0 ± 1.1 18.1 ± 2.2 18.6 ± 1.9 18.6 ± 2.1 18.9 ± 2.3 19.2 ± 2.2 18.9 ± 2.2 19.3 ± 2.1 19.0 ± 2.4
NormoBB 6.9 ± 1.1 18.1 ± 1.7 18.1 ± 1.9 18.2 ± 1.7 18.4 ± 2.1 19.1 ± 2.6 18.8 ± 2.4 18.8 ± 2.3 18.8 ± 2.9
NORMO 7.0 ± 1.1 18.1 ± 1.9 18.4 ± 1.9 18.4 ± 1.9 18.7 ± 2.1 19.1 ± 2.4 18.9 ± 2.2 19.1 ± 2.2 18.9 ± 2.6
HyperPL 7.1 ± 0.9 19.0 ± 2.3 19.1 ± 2.0 19.6 ± 1.8 19.6 ± 1.9 19.9 ± 2.2 20.4 ± 2.4 20.4 ± 2.5 19.9 ± 2.4
HyperBB 7.3 ± 1.0 18.8 ± 2.7 19.0 ± 2.6 20.0 ± 2.4 19.6 ± 2.5 20.1 ± 2.6 19.9 ± 2.2 20.5 ± 2.8 20.3 ± 2.8
HYPER 7.2 ± 0.9 18.9 ± 2.4* 19.1 ± 2.3*  19.8 ± 2.1* 19.6 ± 2.2* 20.0 ± 2.4* 20.2 ± 2.2* 20.4 ± 2.6* 20.1 ± 2.5*†
SBP, mmHg
NormoPL 126.7 ± 8.1 168.9 ± 9.3 179.9 ± 15.3 184.0 ± 13.9 182.7 ± 14.9 182.5 ± 14.7 183.1 ± 16.3 183.0 ± 12.2 181.5 ± 15.6
NormoBB 127.5 ± 11.9 170.5 ± 13.6 181.3 ± 21.7 184.2 ± 20.1 182.0 ± 18.1 176.9 ± 18.8 172.5 ± 17.6 172.4 ± 14.8 169.2 ± 14.0
HyperPL 128.9 ± 9.5 170.8 ± 14.4 179.5 ± 17.4 182.9 ± 19.8 184.6 ± 14.9 184.6 ± 16.5 185.3 ± 20.0 179.6 ± 12.9 180.3 ± 14.0
HyperBB 127.6 ± 9.2 167.3 ± 10.7 177.6 ± 17.7 177.4 ± 14.9 181.5 ± 16.4 179.9 ± 20.7 176.0 ± 16.8 175.3 ± 16.7 173.3 ± 15.6
PLACEBO 127.8 ± 8.8 169.9 ± 11.9 179.7 ± 16.4 183.4 ± 16.8 183.7 ± 14.9 183.5 ± 15.6 184.2 ± 18.1 181.3 ± 12.6 180.9 ± 14.8
BB 127.5 ± 10.5 168.9 ± 12.1 179.5 ± 19.7 180.8 ± 17.5 181.8 ± 17.3 178.4 ± 19.7* 174.2 ± 17.2* 173.8 ± 15.7* 171.2 ± 14.8*†
DBP, mmHg
NormoPL 77.2 ± 10.4 77.5 ± 10.1 73.9 ± 10.1 68.0 ± 5.4 69.6 ± 7.6 66.8 ± 10.8 66.7 ± 8.7 69.2 ± 7.4 62.9 ± 7.6
NormoBB 81.9 ± 6.8 80.6 ± 9.7 79.8 ± 10.7 77.8 ± 10.8 73.0 ± 10.1 72.1 ± 13.0 69.9 ± 13.1 69.9 ± 11.9 67.0 ± 14.2
NORMO 79.5 ± 8.6 79.0 ± 9.9 76.8 ± 10.4 72.9 ± 8.1 71.3 ± 8.9 69.5 ± 11.9 68.3 ± 10.9 69.5 ± 9.7 65.0 ± 10.9*†
HyperPL 77.9 ± 3.8 70.7 ± 9.3 67.2 ± 11.8 62.2 ± 11.3 64.0 ± 10.8 60.0 ± 10.5 53.3 ± 8.5 54.0 ± 6.2 53.2 ± 6.7
HyperBB 77.4 ± 6.6 69.0 ± 9.7 65.8 ± 9.2 65.1 ± 8.0 63.7 ± 9.1 60.2 ± 13.7 59.0 ± 14.2 55.5 ± 10.3 53.8 ± 10.5
HYPER 77.7 ± 5.2 69.9 ± 9.5* 66.5 ± 10.5* 63.6 ± 9.7* 63.9 ± 10.0* 60.1 ± 12.1* 56.1 ± 11.3*  54.7 ± 8.3* 53.5 ± 8.6*†
MAP, mmHg
NormoPL 93.7 ± 8.5 107.9 ± 7.8 109.2 ± 5.4 107.0 ± 4.4 107.3 ± 6.0 105.4 ± 9.1 105.5 ± 5.6 107.1 ± 5.1 102.4 ± 6.9
NormoBB 96.0 ± 6.8 110.6 ± 7.5 113.2 ± 9.7 112.5 ± 10.0 109.6 ± 9.3 107.0 ± 10.7 104.2 ± 10.9 104.6 ± 8.0 101.3 ± 11.1
NORMO 94.9 ± 7.7 109.3 ± 7.7 111.2 ± 7.6 109.7 ± 7.2 108.4 ± 7.7 106.2 ± 9.9 104.8 ± 8.3 105.9 ± 6.6 101.9 ± 9.0†
HyperPL 94.9 ± 4.1 104.1 ± 5.3 104.6 ± 8.9 102.4 ± 7.8 104.2 ± 6.7 101.5 ± 8.1 97.3 ± 6.8 95.9 ± 5.1 95.6 ± 4.4
HyperBB 94.1 ± 6.4 101.8 ± 7.6 103.1 ± 7.6 102.5 ± 5.6 102.9 ± 6.4 100.1 ± 9.0 98.0 ± 7.0 95.4 ± 6.0 93.6 ± 7.7
HYPER 94.5 ± 5.3 102.9 ± 6.5* 103.9 ± 8.2* 102.5 ± 6.7* 103.6 ± 6.6* 100.8 ± 8.5* 97.6 ± 6.9* 95.6 ± 5.6* 94.6 ± 6.1*†
Table 3.1: Exercise responses during 1 hour exercise bout under normothermia + PL (NormoPL), normothermia + BB (NormoBB), hyperthermia + PL (HyperPL), 
and hyperthermia + BB (HyperBB) conditions




NormoPL 13.58 ± 2.02 6.07 ± 0.82 5.96 ± 0.88 5.70 ± 0.74 5.74 ± 0.74 5.50 ± 0.85 5.48 ± 0.66 5.61 ± 0.58 5.34 ± 0.73
NormoBB 14.22 ± 2.03 6.10 ± 0.69 6.18 ± 0.87 6.10 ± 0.64 5.96 ± 0.70 5.64 ± 0.64 5.50 ± 0.78 5.58 ± 0.74 5.41 ± 0.75
NORMO 13.90 ± 2.03 6.09 ± 0.76 6.07 ± 0.88 5.90 ± 0.69 5.85 ± 0.72 5.57 ± 0.74 5.49 ± 0.72 5.60 ± 0.66 5.37 ± 0.74†
HyperPL 13.58 ± 1.44 5.60 ± 0.68 5.55 ± 0.60 5.27 ± 0.51 5.33 ± 0.63 5.08 ± 0.50 4.87 ± 0.58 4.85 ± 0.62 4.83 ± 0.63
HyperBB 13.11 ± 1.61 5.46 ± 0.97 5.47 ± 0.80 5.18 ± 0.72 5.37 ± 0.90 4.98 ± 0.82 4.96 ± 0.77 4.73 ± 0.64 4.64 ± 0.69
HYPER 13.34 ± 1.52 5.53 ± 0.82* 5.51 ± 0.70* 5.22 ± 0.61* 5.35 ± 0.76* 5.03 ± 0.66* 4.91 ± 0.68* 4.79 ± 0.63* 4.74 ± 0.66*†
Tskin, ºC
NormoPL 30.80 ± 0.68 30.45 ± 0.67 30.85 ± 0.77 31.49 ± 0.52 31.52 ± 0.47 31.61 ± 0.49 31.57 ± 0.56 31.31 ± 0.69 31.47 ± 0.71
NormoBB 30.60 ± 0.46 30.27 ± 0.45 30.65 ± 0.53 31.25 ± 0.35 31.24 ± 0.24 31.37 ± 0.26 31.28 ± 0.42 31.10 ± 0.46 31.32 ± 0.60
NORMO 30.70 ± 0.58 30.36 ± 0.56 30.75 ± 0.65 31.37 ± 0.45 31.38 ± 0.39 31.49 ± 0.40 31.43 ± 0.51 31.21 ± 0.58 31.40 ± 0.65
HyperPL 34.83 ± 0.69 35.13 ± 0.84 35.68 ± 0.93 35.70 ± 0.75 35.80 ± 0.55 35.82 ± 0.60 35.99 ± 0.68 35.91 ± 0.74 35.91 ± 0.71
HyperBB 35.02 ± 0.91 35.14 ± 1.01 35.60 ± 1.02 35.59 ± 0.80 35.61 ± 0.74 35.55 ± 0.78 35.63 ± 0.87 35.43 ± 0.80 35.51 ± 0.78
HYPER 34.93 ± 0.79* 35.14 ± 0.91* 35.64 ± 0.95* 35.64 ± 0.76* 35.70 ± 0.64* 35.68 ± 0.70* 35.81 ± 0.79* 35.67 ± 0.79* 35.71 ± 0.75*
FBF, ml/100ml/min
NormoPL 1.70 ± 0.75 8.06 ± 3.27 9.31 ± 3.48 9.65 ± 3.87
NormoBB 1.92 ± 0.94 9.13 ± 3.20 10.33 ± 2.74 11.68 ± 4.26
NORMO 1.81 ± 0.84 8.59 ± 3.20 9.82 ± 3.10 10.67 ± 4.10
HyperPL 2.06 ± 1.04 14.33 ± 4.39 16.76 ± 5.19 15.39 ± 4.67
HyperBB 2.20 ± 1.19 14.48 ± 4.46 15.75 ± 3.91 14.48 ± 4.45
HYPER 2.13 ± 1.09 14.40 ± 4.32* 16.26 ± 4.52* 14.94 ± 4.48*
CBF, arbitray units
NormoPL 26.2 ± 7.9 41.4 ± 14.4 84.1 ± 43.5 103.4 ± 31.8 101.0 ± 34.0 112.9 ± 46.7 118.1 ± 46.9 115.4 ± 45.1 115.8 ± 41.1
NormoBB 24.7 ± 6.4 37.6 ± 15.2 89.0 ± 43.4 100.4 ± 39.0 104.5 ± 39.8 104.7 ± 35.0 107.1 ± 34.3 108.8 ± 31.5 106.5 ± 29.0
NORMO 25.4 ± 7.0 39.5 ± 14.6 86.6 ± 42.4 101.9 ± 34.7 102.7 ± 36.1 108.8 ± 40.4 112.6 ± 40.4 112.1 ± 38.0 111.1 ± 35.0 †
HyperPL 34.6 ± 12.0 90.9 ± 56.2 147.4 ± 73.4 147.7 ± 67.2 151.3 ± 55.3 159.6 ± 72.1 160.4 ± 67.3 142.2 ± 43.7 145.0 ± 43.6
HyperBB 56.5 ± 83.5 109.3 ± 97.8 145.8 ± 80.5 145.5 ± 68.1 163.2 ± 71.8 139.4 ± 71.3 156.0 ± 56.2 151.0 ± 45.4 158.8 ± 45.6
HYPER 45.6 ± 59.1 100.1 ± 78.2* 146.6 ± 75.0* 146.6 ± 65.8* 157.3 ± 62.7* 149.5 ± 70.5* 158.2 ± 60.4* 146.6 ± 43.6* 151.9 ± 44.0*
RPE
NormoPL 11.6 ± 1.3 12.1 ± 1.1 12.5 ± 0.8 12.5 ± 0.8 12.9 ± 0.8 13.0 ± 0.8 13.3 ± 1.1 13.8 ± 1.0
NormoBB 12.0 ± 1.4 12.2 ± 1.2 12.5 ± 0.8 13.1 ± 0.9 13.0 ± 0.8 13.5 ± 1.1 13.9 ± 0.8 14.4 ± 1.3
NORMO 11.8 ± 1.3 12.1 ± 1.1 12.5 ± 0.8 12.8 ± 0.9 12.9 ± 0.8 13.2 ± 1.0 13.6 ± 1.0 14.1 ± 1.2 †
HyperPL 12.0 ± 1.2 12.4 ± 1.0 12.8 ± 1.1 12.9 ± 0.8 13.8 ± 1.0 14.5 ± 1.1 15.1 ± 1.4 15.6 ± 1.7
HyperBB 12.3 ± 1.3 12.5 ± 1.4 13.0 ± 1.0 13.2 ± 1.3 13.9 ± 1.1 14.7 ± 1.1 15.3 ± 1.3 16.0 ± 1.7









Rest 5 10 15 20 30 40 50 60
130
Pre Bodyweight (kg) 77.9 ± 11.5 77.7 ± 11.6 77.8 ± 11.9 77.5 ± 11.5
Post Bodyweight (kg) 77.9 ± 11.5 77.8 ± 11.6* 77.6 ± 11.8* 77.3 ± 11.4*
% Change in BW (%) ‐0.02 ± 0.26 0.13 ± 0.19 ‐0.21 ± 0.25 ‐0.26 ± 0.25
Fluid intake (l) 1.272 ± 0.405 1.272 ± 0.405 1.624 ± 0.346† 1.624 ± 0.346†
Sweat Volume (l) 1.286 ± 0.441 1.172 ± 0.376 1.787 ± 0.553† 1.824 ± 0.529†
Table 3.2: Bodyweight changes pre to post exercise, fluid intake, and sweat volume






NormoPL ‐5.4 ± 2.4 ‐5.1 ± 2.8 ‐5.8 ± 3.6 ‐5.3 ± 3.0 ‐4.2 ± 3.9
NormoBB ‐5.4 ± 4.1 ‐6.6 ± 3.9 ‐7.3 ± 3.7 ‐7.0 ± 3.6 ‐6.1 ± 2.7
HyperPL ‐7.1 ± 2.7 ‐6.3 ± 3.7 ‐5.8 ± 3.8 ‐6.4 ± 3.6 ‐5.7 ± 4.3
HyperBB ‐6.4 ± 2.2 ‐6.7 ± 2.3 ‐7.2 ± 2.2 ‐6.5 ± 2.2 ‐6.8 ± 3.0
∆ PV, %
NormoPL ‐9.2 ± 4.1 ‐8.8 ± 4.5 ‐8.7 ± 6.0 ‐8.2 ± 5.0 ‐6.5 ± 6.9
NormoBB ‐8.9 ± 5.8 ‐10.3 ± 3.9 ‐11.0 ± 4.0 ‐10.1 ± 4.8 ‐8.1 ± 3.2
HyperPL ‐12.3 ± 4.4 ‐10.2 ± 5.6 ‐9.5 ± 5.6 ‐10.1 ± 6.3 ‐8.6 ± 5.9
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CHAPTER VII: REVIEW OF RELEVANT LITERATURE 
1 – Cardiovascular Drift during Prolonged Exercise 
 Cardiovascular (CV) drift is characterized by the progressive increase in HR and 
decrease in SV and MAP, while Q remains relatively constant. The underlying cause of 
the CV drift is controversial. One hypothesis is that the peripheral displacement of blood 
to increase cutaneous blood flow causes a progressive fall in central venous pressure, SV 
and MAP (Rowell et al., 1969a; Rowell et al., 1969b; ROWELL et al., 1969; Rowell, 1986, 
1993).  The alternate hypothesis is that the progressive increase in HR caused by 
hyperthermia and/or increased sympathetic nervous system activity decreases 
ventricular filling time and end diastolic volume (Gonzalez-Alonso et al., 2000). 
1a: Classic CV Drift 
 The original hypothesis for the peripheral displacement of blood to cause CV 
drift was developed based on experimental evidence during exercise in extreme heat of 
43.3 ºC and with minimal air movement or evaporative cooling of the skin. Under such 
conditions skin temperature may have been elevated to the point where venous pooling 
in the skin may have occurred as skin temperature under these conditions may be 
greater than 38 ºC (ROWELL et al., 1969; Rowell, 1986) (skin temperature is assumed as 
it was not directly measured in the original investigation;(Rowell et al., 1966). The 
alternate hypothesis was developed under thermal conditions similar to what may be 
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encountered during actual exercise in the heat with skin allowed to cool to 31-34°C by 
the evaporation of sweat, and therefore may be more appropriate for application to 
typical exercise performed without protective garments (e.g.; fire fighting suits,  
hazardous material garments, football uniforms and pads, etc…)  
1b: Environment, Exercise Intensity, Dehydration 
 The foundation for the alternate hypothesis comes from the work of Coyle and 
colleagues (González-Alonso et al., ; Gonzalez-Alonso et al., 1997; Fritzsche et al., 1999; 
González-Alonso et al., 1999; Gonzalez-Alonso et al., 2000). During two hours of exercise 
that caused dehydration and hyperthermia, declines in SV and CO were confirmed 
(Montain & Coyle, 1992a). During similar exercise bouts skin blood flow was found to be 
severely compromised due to cutaneous vasoconstriction as a result of a catecholamine 
response (Mora-Rodriguez et al., 1996) that appears to be triggered by declining arterial 
blood pressure (Gonzalez-Alonso et al., 1999; Coyle & Gonzalez-Alonso, 2001).  The 
failing cardiovascular system was attempting to attenuate reductions in blood pressure 
through peripheral vasoconstriction (i.e.; increased TPR). Skin blood flow was 
particularly reduced and core temperature increased dramatically as the body 
attempted to balance the immediate need to maintain arterial blood pressure versus 
the need for heat dissipation, that can't be forestalled for more than 5-15 min without 
severe hyperthermia (Montain & Coyle, 1992b; Gonzalez-Alonso et al., 1995; Coyle & 
Gonzalez-Alonso, 2001).  A main outcome of these studies was to counter the prevailing 
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thinking that SV is reduced due to increased skin blood flow and pooling of blood in 
veins and thus reduced venous return (Coyle & Gonzalez-Alonso, 2001). This initial work 
regarding CV drift during prolonged exercise led to the question of what causes the 10 
to 30% reductions in SV and CO during the 15 to 120 minute period of exercise resulting 
in hyperthermia that is performed in the upright or supine position. This remains only 
partially answered; however, recent work by Dawson et al. (Dawson et al., 2005) 
provides echocardiographic evidence that reduced diastolic function may lead to 
cardiovascular drift during prolonged exercise.  
 The works of Coyle and colleagues in the late 1990's were designed to measure 
SV and cardiovascular drift in athletes after two hours of exercise in a hot environment 
subsequent to reversing extra-myocardial factors (e.g.; body position and blood volume) 
that might be responsible for part of the large reduction in SV observed during upright 
exercise (Coyle & Gonzalez-Alonso, 2001). Indeed, dehydration and reductions in blood 
volume accounted for part of the reduction in SV (Montain & Coyle, 1992a; Gonzalez-
Alonso et al., 1997). Body position during cycling (upright vs. supine) influences venous 
return due to gravity as measured by left ventricular end-diastolic volume and SV 
(Martin et al., 1986).  Positioning the heart below the legs with supine exercise reversed 
approximately one-half of the decline in SV observed with the cardiovascular drift and 
hyperthermia of prolonged exercise  (Gonzalez-Alonso et al., 1999). Furthermore, heart 
rate elevation  during exercise  at a given  power output appears to reduce SV (Fritzsche 
et al., 1999; Gonzalez-Alonso et al., 1999), possibly by reducing ventricular filling time. 
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No attempts were made to manipulate myocardial afterload because under conditions 
of cardiovascular failure, afterload (systolic blood pressure) was not increased as 
reflected by arterial pressure and rough indices of ventricular wall stress (Coyle, 1998; 
Gonzalez-Alonso et al., 1999). The reductions in systolic blood pressure with 
cardiovascular failure during exercise and thus reduced afterload should attenuate 
reductions in SV. This suggests that reduce cardiac function (cardiac fatigue) might be 
underestimated as it appears to be naturally compensated by reduced afterload. 
 These studies were of utmost importance because they systematically identified 
the contribution of extra-myocardial factors (i.e.; blood volume, body position; 
ventricular filling time, arterial pressure) that must be controlled during exercise in 
order for SV to be limited by heart function per se. Based upon the results of the 
aforementioned studies it became apparent that hyperthermia alone caused marked 
reductions in SV (Gonzalez-Alonso et al., 1997; Gonzalez-Alonso et al., 2000). It could 
not be determined if this was due to myocardial or extra-myocardial factors as cardiac 
images were not obtained.  However, three important points became clear. First, the 
reductions in SV after 2 h of exercise could be entirely reversed by expanding blood 
volume to normal euhydrated levels as long as hyperthermia was prevented (Gonzalez-
Alonso et al., 1999, 2000; Coyle & Gonzalez-Alonso, 2001).  This indicated that if 
reductions in SV were due to cardiac fatigue then the fatigue was not chronic and it 
could be reversed in a matter of minutes. This indicates that the cause of cardiovascular 
failure was acute and implies it was not due to substrate depletion of myocytes or 
136
protein denaturing. Second, it became clear that countermeasures against 
cardiovascular failure, involving cooling and blood volume expansion, can allow a person 
to resume intense exercise  in a matter of minutes after experiencing acute 
cardiovascular fatigue (Gonzalez-Alonso et al., 1999). Third, hyperthermia always 
elicited reductions in SV and some degree of cardiovascular fatigue even when blood 
volume was increased (21) or exercise was performed in the supine position (Gonzalez-
Alonso et al., 1999). 
1c. Effect of Body Position 
 Body position plays an important role in the attempt to determine the 
underlying cause of reduced cardiac function during exercise. Gonzalez-Alonso et al. 
(González-Alonso et al.) had subjects exercise at 62% of VO2max in the heat (35°C) while 
either euhydrated or dehydrated by 5% and in both the supine and upright positions. 
Dehydration elicited similar hyperthermia independent of exercise position (+ 0.8°C). 
Supine exercise attenuated the increase in HR (7 vs. 9%), the reduction in SV (13 vs. 
21%), and the reduction in CO (8 vs. 14%). During supine exercise with dehydration skin 
temperature was 1°C higher during supine exercise compared to the upright trial. This 
increase in skin temperature during supine exercise is most likely to the fact that the 
skin of the back is not exposed to fan cooling. The reductions in MAP and cutaneous 
vascular conductance and the increase in NE observed with dehydration and 
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hyperthermia during upright exercise were totally absent during supine exercise. 
Despite this finding SV was still reduced even in the supine positions.  
1d. Role of Plasma Volume on Cardiovascular Drift 
One of the most rapid physiological adaptations to exercise training is an 
increase in blood volume. Similarly, during detraining the expanded blood volume of 
athletes is one of these first adaptations that is lost (Coyle et al., 1984; Coyle et al., 
1986). When PV expansion is induced by only 3 to 4 days of training (Green et al., 1990) 
or with training and acclimatization (Mitchell et al., 1976; Senay et al., 1976; Wyndham 
et al., 1976) little effect on the CV or thermoregulatory changes is observed beyond the 
early adjustment period to exercise. It is only when the training period is extended that 
the CV and thermoregulatory events appear to be modified with exercise time (Mitchell 
et al., 1976; Wyndham et al., 1976; Convertino, 1991).  Too large of an increase in PV 
may increase blood flow to working muscle due to hemodilution and reduction in 
arterial O2 delivery (Kanstrup & Ekblom, 1982; Convertino, 1991).  
A series of studies (Mitchell et al., 1976; Senay et al., 1976; Wyndham et al., 
1976) examined the effects of acclimatization in a hot and humid environment found 
that cardiovascular adjustments follow a predictable time course with four distinct 
phases. Exercise on day 1 was characterized by a fall in SV and a high HR. During days 2 
to 3 SV increased and HR decreased with little change in CO. After 4 to 8 days CO 
increased due to an increased SV and not until days 6 to 8 did Trec and Tskin return 
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toward control levels. It is important to note that events occurring during the first 4 days 
had little effect on body temperature. Green et al. (Green et al., 1990) showed similar 
results in that that 3 days of training for 2 hours per day at 65% of VO2max resulted in a 
20% increase in plasma volume and a 12% increase in blood volume (BV). These 
increases in PV and BV corresponded to an increase in SV of 22ml/beat and a reduction 
in HR. Despite these large changes in CV function there appeared to be no benefit on 
thermoregulatory behavior.  After the first few days of exercise that hypervolemia that 
accompanies the acclimatization may provide advantages of greater body fluid for heat 
dissipation and thermoregulatory stability. Furthermore, the increase in vascular volume 
increases filling pressure which can lead to increased SV and reduced HR (Convertino, 
1991). 
1e. Effect of Cardiovascular Drift on Maximal Exercise Capacity 
 Cardiovascular drift has recently been shown to reduce VO2max. Wingo et al. 
(Wingo et al., 2005; Wingo & Cureton, 2006a, b) showed VO2 max was reduced (19%) in 
proportion to the amount of CV drift (12% increase in HR and 16% in SV) that occurred 
from 15 to 45 minutes of exercise under hot environmental conditions without fan 
cooling. The cause of the decrease in VO2max is not entirely clear as SV was unable to 
be measured during the incremental exercise VO2max test. Cardiac function appears to 
be maximal as HR was similar at fatigue under. Interestingly, core temperature at 45 
minutes of exercise was elevated by 1º C when compared to 15 minutes of exercise, 
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which is same elevation of core temperature induced by preheating in the study by 
Gonzalez-Alonzo et al. (Gonzalez-Alonso & Calbet, 2003b). Based upon the assumption 
that local muscle fatigue during the 30 minute exercise at a moderate intensity (60%) 
did not cause the reduced VO2max and the findings that skin temp was the same these 
studies effectively isolated the effect of elevated core temperature on VO2max.  
 Overall, under conditions eliciting hyperthermia, cardiac drift occurs as 
evidenced by an elevated HR and reduced SV during constant workload cycling. 
Environmental changes such as increases in ambient temperature and relative humidity 
will influence the degree of cardiovascular drift as cardiac output is elevated and 
cutaneous blood flow is increased. Stroke volume is reduced even under conditions that 
maximize venous return (supine exercise) indicating that cardiac function is lessened. 
The underlying reason for this reduction in cardiac function may be due to altered 
contractility of the myocardium or reduced ventricular filling and performance. 
 
2-  Cardiovascular Function with B-blockade 
2a. High-dose ΒB (acute vs. chronic) 
B-adrenergic blocking agents are used in the treatment of cardiovascular 
diseases including angina pectoris and hypertension. Individuals with symptoms or risk 
factors of cardiovascular disease are routinely prescribed exercise in combination with 
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ΒB. B-blockers act to block the sympathetic effect of hormones, primarily epinephrine. 
Therefore, the cardiovascular response to exercise with ΒB will be altered when 
compared to normal exercise conditions. Cardiovascular compensation with ΒB include 
the following; decrease in HR (~25%), increase SV, increase in a-vO2diff. ΒB decreases 
HRmax and increases SVmax while CO is generally maintained. When VO2max is < 45 – 
50 (ml/kg/min) ΒB does not appear to reduce VO2max (Anderson et al., 1985; Tesch, 
1985; Wilmore et al., 1985; Joyner et al., 1986; Jilka et al., 1988; Kalis et al., 1988; Mier 
et al., 1997a). When VO2max is higher > 50 (ml/kg/min) ΒB appears to reduce VO2max 
by about 10%. There is a limit to the compensation by SV and avO2diff.  In addition to 
the cardiovascular effect of ΒB, ΒB also effects Thermoregulation. Individuals on ΒB 
exhibit a lower FBF for any given Tcore. ΒB also enhances sweat loss and a lower Tskin 
(Gordon et al., 1985; Freund et al., 1987). The reduction in FBF at any given Tcore was 
concomitant to lower blood pressure, suggesting that baroreflexes provide significant 
input to control of skin blood flow. 
2b. Minimal dosage to alter SV and HR response to exercise 
 Large doses of ΒB have substantial impact on CV function and exercise capacity. 
However, a few investigators have used low doses of ΒB to alter the normal response to 
exercise in order to control cardiovascular responses to exercise. Pawelczyk et al. 
(Pawelczyk et al., 1992) gave subjects 0.2mg/kg metoprolol and effectively reduced 
cardiac output (19%) and leg blood flow (11%) to the active muscle. This study was 
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designed to determine whether or not leg vasoconstriction occurs when cardiac output 
is reduced. The authors concluded that neurogenic vasoconstriction evidenced by an 
increase in NE spillover under ΒB can offset metabolic vasodilation during intense 
exercise when cardiac output is compromised. Fritzsche et al. (Fritzsche et al., 1999) 
gave subjects 0.1mg/kg atenolol immediately prior to exercise in order to alter the CV 
response to prolonged exercise. Under normal conditions (ie; no ΒB) CV drift occurred 
as HR increased and SV decreased.  ΒB was able to completely block the normal increase 
in HR after the initial 15 minutes of exercise. The attenuation of the increase in HR and 
decrease in SV abolished the CV drift observed under control conditions. CV drift was 
not correlated to forearm blood flow as FBF was the same in both conditions. Based on 
the findings of this study it is evident that under conditions where skin temp is relatively 
low (31.5 C) and core temp is low (37.8 C) CV drift occurs because of the progressive 
increase in HR. It has been proposed that this increase in HR reduced diastolic filling 
time and EDV leading to a reduction in SV.   
 
3 - Core temperature and fatigue 
3a. Critical Core Temperature and Fatigue 
 Evidence that Q and skeletal muscle blood flow is the limiting factor in 
maintaining exercise at VO2max comes from the invasive investigations of Gonzalez-
Alonso and colleagues (Gonzalez-Alonso et al., 2001; Gonzalez-Alonso & Calbet, 2003b; 
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Gonzalez-Alonso et al., 2004; Mortensen et al., 2005). Subjects performed exercise at 
workloads eliciting VO2max under normal and hyperthermic (elevation of core 
temperature by 1º C) conditions in order to determine the central cardiovascular 
responses to the fatigue process. The main finding of this study was that the pattern of 
fatigue was similar in both the normal and hyperthermic conditions with the heat stress 
decreasing VO2max and accelerating the decrease in Q, and MAP, that lead to the 
decrease in locomotor blood flow, O2 delivery and O2 uptake. This decline in skeletal 
muscle VO2 was solely attributed to the decrease in systemic and skeletal muscle O2 
delivery as the arterial O2 content, leg O2 extraction, and leg vascular conductance 
were unaltered. Heat stress increased Q (~1.5 l/min) and decreased leg blood flow (0.7 – 
2.7 l/min); however, VO2 at the leg was similar as CaO2, a-vO2diff, and O2 extraction 
were increased. Similar adjustments to decreasing O2 delivery have been determined 
under conditions of anemia and hypoxia. These findings also argue against a diffusion 
limitation to maintaining exercise at VO2max as leg a-vO2diff and O2 extraction 
increased progressively until the end of exercise.  
 These findings show that cardiac fatigue is occurring during high intensity 
exercise and in a manner remarkably similar to the prolonged exercise bouts in the heat 
that cause cardiovascular drift (references from above). The decline in Q, leg blood flow, 
and MAP occurred before maximal HR was achieved indicating that maximal CV function 
can be attained below max HR. The inability to maintain SV appears to be the main 
reason for the decline in cardiac function. The decline in SV coincided with the decrease 
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in MAP, a core temperature of greater than 39 C, and an almost maximal HR. The 
lowered MAP rules out the influence of altered afterload contributing the reduced SV. 
Therefore, preload and myocardial contractility appear to be responsible for the 
decreased SV although no direct evidence is available.  
 The central limitation to aerobic power and capacity has been further advanced 
by the work of Mortenson et al. (Mortensen et al., 2005). Systemic hemodynamics, O2 
transport and O2 uptake were measured during incremental exercise to exhaustion, 
constant load cycling to exhaustion, and one leg knee extension to exhaustion. During 
incremental cycling to exhaustion systemic and locomotor O2 delivery did not increase 
linearly from rest to VO2max but plateaued at approximately 80% of VO2max. Similarly, 
vasoconstriction as evidenced by the plateau and non-significant decline in leg vascular 
conductance at 80% of VO2max. Oxygen extraction at the working muscle continued to 
increase despite a concomitant plateau in O2 delivery. Under constant load cycling at a 
workload eliciting VO2max, O2 delivery and VO2 declined 3% prior to exhaustion. 
During the final portion of the exercise bout, just prior to exhaustion CO declined 
approximately 7%. The reduction in the O2 delivery in both cycling exercise was 
associated with the fall in SV when core temperature was highest (39.5º to 39.9º C).  In 
contrast, during one leg knee extension under conditions where leg blood flow 
(l/kg/min) was 3 to 4 fold higher than cycling and oxygen delivery was not limited, leg 
blood flow and VO2 increased linearly until exhaustion.   
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The underlying mechanism regulating the critical core temperature and fatigue 
may be related to dopamine and noradrenaline levels in the hypothalamus (Hasegawa 
et al., 2008). In order to understand this mechanism Watson et al. (Watson et al., 2005) 
had subjects perform 4 trials consisting of 60 minutes of exercise at 55% Wmax followed 
by a time trial under placebo or bupropion treatments. Buproprion, a dopamine and 
noradrenaline reuptake inhibitor, may act on central DA and NA neurotransmission to 
maintain motivation and arousal, enabling subjects to sustain a higher power output 
despite approaching the critical core temperature (Watson et al., 2005; Hasegawa et al., 
2008). During the time trial in the heat Tcore was 0.3°C higher and HR 5 bpm higher 
under bupropion. The authors conclude that the drug may dampen or override 
inhibitory signals arising from the CNS to cease exercise due to hyperthermia and enable 
an individual to continue to maintain a high power output.  
3b. Evidence against a Critical Core Temperature  
The tight relationship between core temperature and fatigue has drawn criticism 
from numerous researchers. Two alternative hypotheses argue against a critical core 
temperature as the cause of fatigue. One of these hypothesis states that the ability to 
tolerate high core temperatures is likely dependent upon the athlete’s skin 
temperature, as warmer skin (warmer environment) creates greater circulatory strain 
and lowers core temperature tolerance (Kenefick et al., 2007). This theory is 
physiologically viable as many thermoregulatory responses depend on both core and 
145
skin temperature: at any given skin temperature, each thermoregulatory response is 
proportional to esophageal temp, and increasing the skin temp lowers the threshold 
level of esophageal temp and increases the response at any given core temp ((Michael N 
Sawka, 1988)Sawka and Wenger). However, research relating this core to skin temp 
gradient to actual exercise performance is limited. The other argument states that the 
rate of heat production may be more important than the actual core temperature in the 
development of fatigue (Noakes, 2000; Noakes et al., 2001; Noakes et al., 2004; Noakes 
& St Clair Gibson, 2004; Tucker et al., 2004; Tucker et al., 2006). This hypothesis is based 
on the anticipatory regulation of exercise intensity or duration based on the initial rate 
of heat storage thus allowing the individual to avoid catastrophe.  
3c. Rate of Heat Production as a Critical Factor 
The rate of heat storage and the skin to core temp gradient was addressed by 
Gonzalez-Alonso et al. (González-Alonso et al., 1999).  The rate of heat storage was 
altered by having subjects exercise with and without a jacket. Rate of heat storage was 
either 0.05 or 0.10 °C/min. Despite the difference in rate of heat production and the 
higher Tskin (38.4 vs 35.6°C) exhaustion occurred at the same core temperature. While 
the rate of heat production was drastically different skin temp may consider high under 
both conditions (> 35 C). Based on research by Cureton (Arngrimsson et al., 2003; Wingo 
et al., 2005; Wingo & Cureton, 2006a, b) and colleagues skin temperature may have to 
be above 33 to 34°C in order to affect cardiac function during exercise, therefore the 
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skin temps of Gonzalez-Alonso (González-Alonso et al., 1999) may not have different 
physiological effects. Similarly, well trained individuals with high aerobic fitness appear 
to be able to tolerate hyperthermia and perform longer in uncompensable hot 
environments better than untrained and moderately trained (Cheung & McLellan, 
1998). Therefore, the relationship between core temp and fatigue may not be applicable 
to all subjects.  
3d. Hyperthermia and the Myocardium 
In all cases, prolonged exercise in the heat as well as during high intensity 
exercise at VO2max, cardiovascular failure occurred when core temperature 
approached 40º C.  This was the case when intense exercise (95% VO2max) was 
maintained for 7-8 min under control or when the participants began with elevated core 
temperature and fatigued after 5 min (Gonzalez-Alonso & Calbet, 2003a), or when the 
intensity is lower (65% VO2max) and elicits hyperthermia after 120 min when significant 
dehydration is experienced (Coyle & Gonzalez-Alonso, 2001). It has been well 
established in isolated heart and myocytes that elevated temperature markedly reduces 
contractile function (Ranatunga, 1994; Saeki et al., 2000; Janssen et al., 2002; 
Hiranandani et al., 2006).  Saeki et al. (Saeki et al., 2000) showed that hyperthermia 
causes a negative inotropism (decrease in force development) and an increase in the 
oxygen cost of contractility by approximately 1.5 fold. The depressed left ventricle 
contractility during hyperthermia appears to be largely due to a decrease in calcium 
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responsiveness to the contractile protein. Janssen et al. (Janssen et al., 2002) 
demonstrated that under hyperthermic (42º C) conditions force development of the 
isolated myocyte is reduced by 67% when compared to normothermia (37º C). Despite 
this substantial reduction in developed force, relaxation rate is accelerated and may 
partially offset the reduction in force development at high stimulation frequencies. 
Therefore, it is quite possible that hyperthermia of the blood and heart is the primary 
factor that causes reductions in SV, BP, CO and reduced oxygen delivery to the leg 
muscles.  It seems that hyperthermia might simply reduce myocardial contractile 
function.  
 
4 - Cardiovascular responses to various skin temperatures. 
 Skin and muscle blood flow are first and foremost determined by cardiac output. 
Therefore it is critical to understand how rapidly changing one of these variables (skin 
blood flow or muscle blood flow) influences CO. Despite this logic only a few studies 
have manipulated skin and core temperature independently of one another in order to 
determine the control and regulation of CO. The rationale for such a protocol originates 
from pilot work in our lab. During exercise when heat stress is removed and evaporative 
cooling is allowed to function Tskin drops from 36 to 27 C in a matter of 2 to 3 minutes. 
During this same time period Tcore remains elevated as the rate of metabolic heat 
production is maintained. Therefore, using such a design conditions of [high core & low 
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skin temp], [low core & high core] can be compared to [high core & high skin] and [low 
core & low skin] paradigms. Rowell et al. (ROWELL et al., 1969) had subjects exercise at 
low (26% of VO2max) and moderate workrates (64% of VO2max) while wearing a suit 
perfused with different water temperatures. Water temperature of the suit was 32 C for 
the first 30 minutes, 40 C during the 30 to 60 minute period, 10 C during the 60 to 90 
minute period and then 50 C during the final stage of exercise. Upon switching from 32 
to 40°C water during the moderate intensity trials Tskin increased from 32 C to 38.7 C. 
During this time CO increased 19% and SV was reduced by 14%.  Interestingly the 
decrease in HR upon cooling appears to directly relate to the reduction in blood 
temperature and presumably skin temperature (although not reported). SV on the other 
hand remains partially reduced during the first 10 minutes of the transition period as 
core temperature remains elevated. Increases in CO during heating were related to skin 
temperature and not to VO2 or body temperature. Due to the fact that this study was 
not specifically designed to isolate skin and core temperature it is difficult to draw 
conclusions based on this topic from these results.     
 As alluded to in the previous section evaporative cooling plays a large part in skin 
and core temperature. Exercise with a water perfused suit removes any evaporation 
that may occur during normal exercise for portions of the body covered by the suit and 
not exposed to moving air. Shaffrath and Adams (Shaffrath & Adams, 1984) investigated 
the effect of airflow and work load on CV drift and skin blood flow. Moderately trained 
individuals (58 mlO2/kg/min) exercised for 70 minutes under relatively cool conditions 
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(24.2°C and 40%RH) at 40 and 60% of VO2max with fan speeds of 4.3 or 0.2m/sec. 
Under conditions of low airflow during the 60% VO2max trial HR increased 21.6 bpm, 
SkBF increased 14%/min, SV decreased 16.4 ml and MAP decreased 11.3 mmHg. Skin 
temp at 60% of VO2 max under fan cooling was 28.5° C while without fan is ~32°C (∆ 
~3.5 °C), Trec was only ~ 0.3° C different between the conditions, Therefore it is likely 
that the lower Tskin results in lower FBF and therefore no CV drift. In one subject 
(triplicate data) turning the fan on at minute 70 reversed a portion of the CV drift as 
evidenced by the 10 bpm reduction in HR from minute 70 to 75.  
 
5 – Stroke Volume Response to Graded and Constant Load Exercise 
5a. Stroke Volume Plateau / Decline during Incremental and Constant Load Exercise 
 Evidence that Q and skeletal muscle blood flow is the limiting factor in 
maintaining exercise at VO2max comes from the invasive investigations of Gonzalez-
Alonso and colleagues (Gonzalez-Alonso et al., 2001; Gonzalez-Alonso & Calbet, 2003b; 
Gonzalez-Alonso et al., 2004; Mortensen et al., 2005). Subjects performed exercise at 
workloads eliciting VO2max under normal and hyperthermic (elevation of core 
temperature by 1º C) conditions in order to determine the central cardiovascular 
responses to the fatigue process. The main finding of this study was that the pattern of 
fatigue was similar in both the normal and hyperthermic conditions with the heat stress 
decreasing VO2max and accelerating the decrease in Q, and MAP, that lead to the 
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decrease in locomotor blood flow, O2 delivery and O2 uptake. This decline in skeletal 
muscle VO2 was solely attributed to the decrease in systemic and skeletal muscle O2 
delivery as the arterial O2 content, leg O2 extraction, and leg vascular conductance 
were unaltered. Heat stress increased Q (~1.5 l/min) and decreased leg blood flow (0.7 – 
2.7 l/min); however, VO2 at the leg was similar as CaO2, a-vO2diff, and O2 extraction 
were increased. Similar adjustments to decreasing O2 delivery have been determined 
under conditions of anemia and hypoxia. These findings also argue against a diffusion 
limitation to maintaining exercise at VO2max as leg a-vO2diff and O2 extraction 
increased progressively until the end of exercise.  
 These findings show that cardiac fatigue is occurring during high intensity 
exercise and in a manner remarkably similar to the prolonged exercise bouts in the heat 
that cause cardiovascular drift (references from above). The decline in Q, leg blood flow, 
and MAP occurred before maximal HR was achieved indicating that maximal CV function 
can be attained below max HR. The inability to maintain SV appears to be the main 
reason for the decline in cardiac function. The decline in SV coincided with the decrease 
in MAP, a core temperature of greater than 39 C, and an almost maximal HR. The 
lowered MAP rules out the influence of altered afterload contributing the reduced SV. 
Therefore, preload and myocardial contractility appear to be responsible for the 
decreased SV although no direct evidence is available.  
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 The central limitation to aerobic power and capacity has been further advanced 
by the work of Mortenson et al. (Mortensen et al., 2005). Systemic hemodynamics, O2 
transport and O2 uptake were measured during incremental exercise to exhaustion, 
constant load cycling to exhaustion, and one leg knee extension to exhaustion. During 
incremental cycling to exhaustion systemic and locomotor O2 delivery did not increase 
linearly from rest to VO2max but plateaued at approximately 80% of VO2max. Similarly, 
vasoconstriction as evidenced by the plateau and non-significant decline in leg vascular 
conductance at 80% of VO2max. Oxygen extraction at the working muscle continued to 
increase despite a concomitant plateau in O2 delivery. Under constant load cycling at a 
workload eliciting VO2max, O2 delivery and VO2 declined 3% prior to exhaustion. 
During the final portion of the exercise bout, just prior to exhaustion CO declined 
approximately 7%. The reduction in the O2 delivery in both cycling exercise was 
associated with the fall in SV when core temperature was highest (39.5º to 39.9º C).  In 
contrast, during one leg knee extension under conditions where leg blood flow 
(l/kg/min) was 3 to 4 fold higher than cycling and oxygen delivery was not limited, leg 
blood flow and VO2 increased linearly until exhaustion.   
 In all cases, prolonged exercise in the heat as well as during high intensity 
exercise at VO2max, cardiovascular failure occurred when core temperature 
approached 40º C.  This was the case when intense exercise (95% VO2max) was 
maintained for 7-8 min under control or when the participants began with elevated core 
temperature and fatigued after 5 min (Gonzalez-Alonso & Calbet, 2003a), or when the 
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intensity is lower (65% VO2max) and elicits hyperthermia after 120 min when significant 
dehydration is experienced (Coyle & Gonzalez-Alonso, 2001). It has been well 
established in isolated heart and myocytes that elevated temperature markedly reduces 
contractile function (Ranatunga, 1994; Saeki et al., 2000; Janssen et al., 2002; 
Hiranandani et al., 2006).  Saeki et al. (Saeki et al., 2000) showed that hyperthermia 
causes a negative inotropism (decrease in force development) and an increase in the 
oxygen cost of contractility by approximately 1.5 fold. The depressed left ventricle 
contractility during hyperthermia appears to be largely due to a decrease in calcium 
responsiveness to the contractile protein. Janssen et al. (Janssen et al., 2002) 
demonstrated that under hyperthermic (42º C) conditions force development of the 
isolated myocyte is reduced by 67% when compared to normothermia (37º C). Despite 
this substantial reduction in developed force, relaxation rate is accelerated and may 
partially offset the reduction in force development at high stimulation frequencies. 
Therefore, it is quite possible that hyperthermia of the blood and heart is the primary 
factor that causes reductions in SV, BP, CO and reduced oxygen delivery to the leg 
muscles.  It seems that hyperthermia might simply reduce myocardial contractile 
function. 
 Recently Calbet et al. (Calbet et al., 2007) examined the CO and leg and arm 
blood flow response during incremental exercise to exhaustion. Invasive techniques 
were employed to directly measure CO and SV. Similar to Mortenson et al. (Mortensen 
et al., 2005) CO increased curvilinearly up to 84% of Wmax, CO only increased 1.2 L/min 
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from 84 to 100% of Wmax. However, unlike Mortenson et al. SV stabilized at 
approximately 50% of Wmax and did not decline prior to exhaustion. The authors 
recognized this discrepancy and believe the lower MAP and difference in the exercise 
protocols between the two investigations may account for the different SV response. 
Beck et al. (Beck et al., 2006) showed that a subset of subjects exhibited a negative 
curvature for both HR and SV during progressive exercise to exhaustion and that this 
negative curvature may indicate a Q limitation to VO2max. Similarly, Stringer et al. 
(Stringer et al., 2005) determined that a curvilinear fit was more appropriate than a 
linear fit in describing the VO2 to Q relationship. Fundamental aspects of human 
physiology such as the CO and VO2 relationship as well as the HR and workload 
relationships may need to be re-examined as more data is collected in subjects 
exercising at high intensities. Generally data describing these fundamental relationships 
are made at low and moderate exercise intensities thus yielding apparent linear 
relationships; however, most competitive events are won or lost at exercise intensities 
above 80% of VO2max with the exception of ultra-endurance events.  
5b. Stroke Volume does not Decline During Exercise 
 Warburton and Gledhill (Gonzalez-Alonso et al., 2007) argue in a recent point-
counterpoint in the Journal of Applied Physiology that “only the least fit exhibit a 
decrease in SV at higher intensities; a pattern that is consistent with reduced myocardial 
compliance and marked pericardial constraint.” It is their assertion that endurance 
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exercise training causes specific adaptations to the cardiovascular system that 
attenuates the reduction in SV observed in untrained individuals. These training related 
adaptations include; increased myocardial compliance, reduced diastolic ventricular 
interaction, increased LV internal cavity, increase early filling (E/A ratio), increased 
transmitral pressure gradient and flow velocity, hypervolemia, increased rate of LV 
pressure decline, increased rate of calcium uptake in SR. Despite the scientific evidence 
provided by these authors the method in which maximal exercise was performed may 
give rise to spurious cardiovascular responses. Gledhill et al. (Gledhill et al., 1994), the 
first investigation from this group, showed that endurance athletes posses a continual 
increase in SV up to maximum and that this response is primarily due to enhanced 
diastolic function. However, methodological considerations must be examined. First, 
each stage of the progressive exercise test consisted of four minutes. VO2 was 
determined during the end of the second minute (90 to 120 sec) while CO was 
performed in triplicate via acetylene rebreathing during the final two minutes (120 to 
240 sec) of each stage. Under ideal conditions VO2 and CO measurements would be 
made at the same time. VO2 may continue to drift during high intensity exercise thereby 
altering the VO2 vs. CO relationship. VO2 and CO were determined during the 
progressive test. As recently reviewed by Rowland (2008) the non-conventional 
supramaximal testing protocol of Gledhill and colleagues appears to alter the SV to HR 
relationship established during the standard progressive test to exhaustion. After 
subjects completed the standard progressive test to exhaustion they were given one 
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minute to rest before pedaling again at a supramaximal workload. It was during this 
supramaximal stage that CO, HR, and VO2 were defined as maximum. After investigating 
this data it is clear that this final supramaximal stage interrupts the apparent plateau 
established by the progressive test.  Warburton et al. (Warburton et al., 2002) 
demonstrated a similar SV response in well trained endurance athletes and concluded 
that enhanced diastolic function manifested by progressive increases in diastolic filling 
rate and EDV allow endurance trained athletes to increasingly use the Frank-Starling 
mechanism throughout incremental to maximal exercise. These authors conclude that 
chronic volume overload placed on the myocardium by athletes who repeatedly 
exercise at large SV and CO may lead to morphological and functional adaptations 
allowing for the progressive utilization of the Frank-Starling mechanism.  
 
5c. Effect of Exercise Training on the Stroke Volume Response to Exercise 
 Longitudinal exercise training studies provide insight regarding the malleability 
of the SV response in a given individual. Spina et al. (Spina et al., 1992) determined that 
exercise training prevented the decline in SV during exercise in young healthy adults. 
Prior to training SV at VO2max was 9% lower than during exercise at 50% of VO2max 
indicating a clear reduction in SV from submaximal to maximal exercise. Following 
training CO increased 12%, SV increased 16% and HR was reduced at the same exercise 
intensity. Furthermore, SV was only 2% lower at VO2max than 50% VO2max following 
156
training. This minor reduction in SV was not significantly and most likely within the error 
of the acetylene rebreathing technique.  The mechanism responsible for the attenuation 
of the SV response is not entirely clear but appears to involve increased blood volume 
which augments left ventricular filling, and or altered diastolic properties of the 
myocardium.   
Short term endurance training of 6 to 10 days also effects the SV response to 
exercise. Goodman et al. (Goodman et al., 2005) exercise subjects for 2 hours at 65% of 
VO2max for 6 consecutive days. Training increased PV 11.4%, increased VO2max from 
45.9 to 49 ml/kg/min, and decreased HRmax by 9 bpm (197 – 188 bpm). Following the 
training regimen SV was 10.4, 10.2, and 7% higher at 53, 68, 83% of VO2max and was 
accompanied by substantial bradycardia at each workload. EDV increased significantly 
and increases in SV were secondary to a Frank-Starling effect with minor changes in 
contractile performance. Mier at el. (Mier et al., 1997b) demonstrated the LV contractile 
performance, assessed by relating fraction shortening to estimated end systolic wall 
stress, was improved by 10 days of endurance training. 
 There is currently much debate regarding whether or not SV declines during 
maximal exercise (Gonzalez-Alonso et al., 2007). The argument is centered on the SV 
response to incremental exercise, however of greater relevance to this review is the SV 
response during constant load maximal exercise. Numerous factors such as body 
position during exercise (supine vs. upright), instrumentation for the determination of 
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SV (inert gas rebreathing, direct fick, thermodilution, echocardiography, etc…), subject 
training status (highly trained, trained, untrained), and the timing of the measurements 
during exercise may account for the differences observed in the literature. Critical to the 
purpose of this review is the determination of whether or not SV declines during 
constant load cycling at VO2max. This protocol (constant load cycling at VO2max) allows 
for the assessment of the capacity of the cardiovascular system to sustain systemic and 
locomotor blood flow (Gonzalez-Alonso & Calbet, 2003b; Gonzalez-Alonso et al., 2004; 
Mortensen et al., 2005; Gonzalez-Alonso et al., 2007). It is therefore paramount that 
physiological measurements (VO2, SV, CO, HR, BP) be made prior to the development of 
fatigue and just prior to exhaustion. To date, only a few studies have made such 
measurements (Gonzalez-Alonso & Calbet, 2003b; Gonzalez-Alonso et al., 2004; 
Mortensen et al., 2005) and have showed reductions in SV and Q prior to exhaustion. 
The cause of this decline in SV may be due to reduced preload and/or reduced left 














Indirect Calorimetry (Study 1): Subjects breathed through a two-way valve connected to 
a pneumotachometer (Hans Rudolph, Kansas City, MO) to measure inspiratory air 
volume (VI; l/min). Expired air was sampled continuously from a mixing chamber and 
analyzed for O2 (FeO2; Ametek CD-3A) and CO2 concentrations (FeCO2; Beckman LB-2). 
Both analyzers and the pneumotachometer were interfaced to a laboratory computer 
(Dell) with an A/D board (Physiodyne). The gas analyzers were calibrated before every 
measurement period using gases of a known concentration (15% O2, 5% CO2). Oxygen 
consumption (VO2; L/min) was calculated as: VO2 = (VI x 0.2093) - (VE x FeO2) where VE 
= expired air volume (L/min). Carbon dioxide consumption (VCO2; L/min) was calculated 
as: VCO2 = (VE x FeCO2) - (VI x 0.0003). The VE and VI values used in the above 
equations were standardized to STPD (L/min). VE was calculated using the Haldane 
transformation as: VE = VI x [(1 - FeO2 - FeCO2)/0.7903]. Respiratory exchange ratio 
(RER) (non-protein) was calculated as: RER = VCO2/VO2. 
 
Gross efficiency (Study 1): Gross efficiency (GE) was calculated as the ratio of work 
accomplished per minute (i.e.; watts converted to kcal/min) to energy expended per 
minute (kcal/min). Energy expenditure per min (i.e.; kcal/min) was calculated from VO2 
and RER using the table of Lusk (Lusk, 1924). VO2 used in the calculation of GE was the 




Body Temperature Calculations: Core temperature (Tcore) was measured using a rectal 
temperature probe (model 401, Yellow Springs Instrument) inserted 12 cm past the anal 
sphincter. A subset of subjects in study 2 performed esophageal core temperature 
measurements (Teso) in combination with the rectal temperature measurement. The 
esophageal probe (model 4491, Yellow Springs Instruments) was inserted through the 
nasal passage and swallowed to depth of one-fourth of the subject’s standing height 
(Mekjavic 1990). Skin Temperature (Tskin) was measured using skin thermistors (model 
409A, Yellow Springs Instrument) at six sites; back, chest, bicep, forearm, thigh and calf 
and mean Tskin was calculated based on a modified equation of Hardy and Dubios 
(Hardy et al., 1938).  
 
Tskin = 0.173 (Forearm + Bicep)/2)) + (0.160 x gastroc) + (0.235 x thigh) + 0.432(back + 
chest)/2)) 
 
Body temperature (Tbody) was calculated using the equation of Baum et al. (1976)  
 
Tbody = (0.87 x Tcore) + (0.13 x Tskin).   
 
All temperature data for study 1 was collected continuously (1 Hz) on a personal 
computer using Tracer-Daq (Measurement Computing) software interfaced with an 
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analog to digital data acquisition board (USB Temp, Measurement Computing). For 
studies 2 and 3 all temperature was collected continuously (1 Hz) on a personal 





















Impedance Cardiography (Study 1): The methodology for the physioflow impedance 
cardiograph has been previously published by Charloux et al. (Charloux et al., 2000).  
The methodology employed in the current study was not different than the previously 
described methodology, therefore the following descriptions is taken directly from 
Charloux et al. (Charloux et al., 2000).  
“Cardiac output measurement by the Physioflow device is based on the following 
formula; 
Qc = fc x SVi x BSA 
where Qc is cardiac output (l/min), fc is the heart rate (bpm, based on the RR interval 
measurement, determined on the ECG first derivative, dECG/dt, which provides more 
stable signal than the ECG signal itself, BSA (m²) is the body surface calculated according 
the Hancock formula (BSA – 0.024265 x BM0.05378 x H0.3964, where BM is body mass in kg 
and H is height in cm), and SVi is the SV index (ml/min²; i.e. the SV divided by the BSA). 
With the Physioflow device, a first evaluation of the SVi, called SVical, is 
computed during a calibration procedure based on 24 consecutive heart beats recorded 
in the resting condition. This evaluation retains the largest impedance variation during 
systole (Zmax – Zmin), and the largest rate of variation of the impedance signal 
(dZ/dtmax, called the contractility index, CTI). The SVi calculation also depends on the 
ventricular ejection time (t). The ventricular ejection time is usually measured using 
echocardiography or phonocardiography, but impedance cardiography can provide a 
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very precise estimation of this variable (Stern et al., 1985; Mehlsen et al., 1990). The 
designers of the Physioflow have chosen to use a related, but slightly different 
parameter, called the thoracic flow inversion time (TFIT, in ms). The TFIT is measured on 
the first mathematical derivative of the impedance signal. The TFIT is the time interval 
between the first zero value beginning of the cardiac cycle (beginning of the ECG’s QRS) 
and the first nadir after the peak of the ejection velocity (dZ/dtmax). Afterwards, the 
TFIT is weighted [W(TFIT)] using a specific algorithm [alg(TRIT, fc, PP)] which in addition 
to the signal waveform, comprises two factors, the pulse pressure (PP, systolic arterial 
pressure – diastolic arterial pulse pressure) and fc. The impedance signal morphology is 
indeed affected by several phenomena that occur in the aorta. Aortic compliance 
contributes to the signal waveform; Chemla et al. (Chemla et al., 1998) have 
demonstrated the existence of a linear relationship between aortic compliance and the 
SV/PP ration. In the [alg(TFIT, fc, PP)], the PP, calculated from sphygmomanometer 
measurement, is introduced at the end of the Physioflow calibration phase. Similarly, 
certain oscillatory and resonance phenomena in relationship with fc influence the signal 
morphology. Murgo et al. (Murgo et al., 1980) described a relationship between 
pressure waveform and aortic impedance or fc, fc is second factor entering into the 
algorithm.           
 As a result of the above concepts, SVical is computed according the following 
formula: 
SVical = k x [(dZ/dtmax)/(Zmax-Zmin)] x W(TFITcal) 
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Where k is a constant, and the subscript “cal” indicates the parameters measured during 
the calibration phase. SVical represents the baseline reference. During the data 
acquisition phase, the variations of the parameters described above are analyzed and 
compared to those obtained during the calibration procedure. For instance, the 
designers demonstrated that the SV variations result mainly from a combination of 
contractility fluctuations (CTI or dZ/dtmax) and of TFIT variations whereby: 
SVi = SVical x ³√(CTI/CTIcal x TFITcal/TFIT). 
This concept is supported by a study by Moon et al (Moon et al., 1994), who 
showed that changes in SV, for example, during exercise, are correlated with variations 
in dZ/dt, but inversely correlated with variations in left ventricular ejection time. In all 
equations used by other impedance cardiograph devices, these two parameters appear 











Near infrared Spectroscopy (Study 1 and 2): The following text is an excerpt taken from 
the ISS OxiplexTS operation manual describing the theory of operation and the 
calculations used by this NIRS system:  
“The Near Infrared Spectroscopy (NIRS) Window: 
As light passes through tissue it is both absorbed and scattered. For light with 
wavelengths range from 670 nm to 900 nm (near infrared region, NIR) the absorption 
properties of tissue are such that a measurable amount of light can pass through large 
volumes of tissue. Below 650 nm the absorption of hemoglobin increases to the point 
that no measurable light can travel through the tissue. Above 900 nm the absorption of 
water makes detection of light passing through tissue difficult. Thus, between 670 and 




Figure 1.  The absorption spectra of major absorbers (Oxygenated Hemoglobin, De-Oxygenated Hemoglobin, and 
Water) in the region 600-1100 nm. 
 
Absorption 
A chromophore is substance which absorbs light. In the NIR region, there are 
only a handful of chromophores with significant absorption. The most significant 
absorbers are oxygenated hemoglobin (HbO2) and de-oxygenated hemoglobin (Hb). 
Water is also a significant absorber followed by lipids, oxidized cytochrome oxidase 
(CtOx), myoglobin, melanin, and bilirubin.      
 The ISS OxiplexTS is designed to measure only the concentrations of oxygenated 
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hemoglobin (HbO2) and de-oxygenated hemoglobin (Hb). It is assumed that, during the 
measurement time, the water concentration is constant, and that the other 
chromophores are not significant absorbers in the tissue. The presence of water is 
accounted for by assuming a known concentration of water in the tissue. The absorption 
spectrum of lipids is almost the same as water and can thus be included in the water 
correction. The absorption spectra of myoglobin is similar to that of hemoglobin, so any 
significant concentrations of these chromophores will be included in the hemoglobin 
concentration measurements.       
 The light absorbing properties of a material is expressed as Absorbance (A), 
which is related to fraction of incident light that passes through a material by the 
relationship 
 
A = − log (T)           [ 1 ] 
 
where T is the fraction of intensity transmitted. The absorption coefficient, UA , is the 
absorbance per unit distance.       
 Assuming only the presence of hemoglobin and water, the absorption coefficient 
at a particular wavelength λ is given as 
 




UA = Absorption coefficient (cm⁻¹) 
K = Extinction coefficient (μM M⁻¹ cm⁻¹) 
[HbO] = concentration of oxy-hemoglobin (μM) 
[Hb] = concentration of deoxy-hemoglobin (μM)  
[H2O] = concentration of water (μM) 
In equation [2] the extinction coefficients are known properties of the 
chromophores and of the water. Also, the water concentration is assumed to be 70% in 
tissues (the value can be changed in the Setup of OxiTS). The two unknowns are [Hb] 
and [HbO2].          
 In order to determine the concentrations of oxy- and deoxy-hemoglobin, the 
absorption coefficient UA is measured at two different wavelengths. The ISS OxiplexTS 
typically uses 690 nm and 830 nm as the measurement wavelengths.  
 
Scattering 
Unfortunately, the measurement of the absorption coefficient UA at a particular 
wavelength in tissue is complicated by the effects of scattering. Scattering occurs 
whenever a ray, or photon, of light crosses into a region with a different index of 
refraction. Or, simply, when bounces against objects that force a change in the direction 
of propagation. Tissues are highly inhomogeneous regions; the optical properties 
change on a small scale as each cell wall and tissue boundary encountered will have a 
different refractive index and will cause scattering. The effect of scattering is far more 
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significant than the effect of absorption when considering light transport through tissue 
in the near infrared. The scattering strength of a material at a specific wavelength is 
quantified using the scattering coefficient US, which like UA, is measured in cm⁻¹. 
In order to make accurate determinations of the absorption coefficient, the 
scattering must be accounted for. The ISS OxiplexTS measures the scattering coefficient 
directly and it is thus able to determine hemoglobin concentrations in any highly 
scattering medium. 
 
A Note about Absorption and Scattering Terminology 
The scattering coefficient US referred to in this manual is actually the reduced 
scattering coefficient μs' referred to in the literature. The term "reduced" and the prime 
symbol have been dropped for simplicity. Also, the symbol UA is utilized in this manual 
and in the OxiTS software to represent the absorption coefficient, whereas the symbol 
μa is used in the literature.  
 
Frequency-Domain Spectroscopy 
The measurement of the absorption and of the scattering coefficients allows for 
OxiplexTS to provide an absolute determination of the hemoglobin concentrations in 
tissue. The measurement is achieved by employing the frequency-domain spectroscopy 
approach, which is fast and accurate. Frequency-domain spectroscopy is a technique 
employed for the measurement of the decay times of fluorescence. Its extension and 
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implementation to the studies of tissues in 1993 has allowed for the determination of 
the absorption and scattering coefficients in tissues. 
In frequency domain spectroscopy, the light beam is modulated at a frequency f 
(the light sources used by the OxiplexTS are modulated at a frequency of 110 MHz). 
Mathematically, the light source intensity as a function of time is expressed as 
 
Io = IDCo + IACo (sin (2π ft – Φo)        [ 3 ] 
 
where: 
Io = source intensity 
IDCo  = average component of the light source intensity 
IACo  = alternating component of the light intensity 
f = modulation frequency 
Φo = phase of the light source 
 
As seen in equation [3] the light source intensity is described by three 
parameters: the average DC component, the alternating AC component, and the Phase 
component. In a highly scattering media, as the light travels away from the modulated 
light source it spreads out in all directions. The modulated light can be described as a 
photon density wave traveling away from the source. In a homogeneous media the 
photon density wave travels at a constant speed (slower than the speed of light), and 
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decreases in intensity as it moves away from the source. The phase shift of the photon 
density wave measured at a point distant from the source is a measure of the speed of 
the propagation of the wave. 
 
Figure 2 - The - light source modulation parameters are shown. AC is the amplitude of the modulation. DC 
is the average intensity. The phase shift between the two signals is also shown. 
 
The OxiplexTS determines the absorption coefficient and the scattering 
coefficient of the tissue by measuring how the AC (or DC), and Phase components 
change as a function of distance R between the source and detector locations. 
 
Equations 
Assuming the sensor geometry of Figure 6.2, and the light source modulation 
described by Equation [3], and further assuming US >> UA, then the propagation of the 
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light (photon density wave) through the tissue can be described by the following 
equations: 
 
In (R² • DC) =(R² • SDC) + KDC       [ 4 ] 
In (R² • AC) =(R² • SAC)        [ 5 ] 
(Φ) = (R • S Φ) + K Φ        [ 6 ]  
 
On the left side of the equality of each of these equations is a value which 
changes linearly with the source-detector separation distance R. As the Kn terms in the 
equations are constants, the equations describe straight lines in the form y = mx + b. 
The coefficients SDC, SAC and SΦ are the slopes of the lines when the equations 
are plotted against the distance R . Moreover, the slopes are functions of UA and UB, in 
addition to other known parameters such as modulation frequency and speed of light in 
the tissue. 
In theory the AC, DC and phase Φ components of the signal need only be 
measured at two distances to determine the three slopes. However, the ISS instrument 
measures these values at four distances, and the “best fit” of the lines are used to 
determine SDC, SAC and SΦ using four distances instead of two improves the signal-to-
noise (S/N) ratio of the measurement and its accuracy as well as the reliability 
performance of the device. The constants Kn are arbitrary; they are not calculated since 
they do not affect the determination of the slopes.     
172
 Once the three slopes have been determined at a particular wavelength, UA and 
US and can be calculated at that wavelength using any two of the slopes: for instance, 
SAC and SΦ ,or SDC and SΦ , or SAC and SDC.  In practice, using SAC and SDC  results in a lower 
S/N ratio; this couple is not utilized. The use of the pair SAC and SΦ  is preferred because 
the AC component of the signal is not susceptible to background light influences. When 
the background light is eliminated, the pair SDC and SΦ may give a slight improvement in 
accuracy when the absorption properties of the calibration is very difference from the 















Breath by Breath Oxygen Consumption (Study 2 and 3): Breath by breath measurement 
of alveolar gas exchange was determined according to the calculations and procedures 
as previously described by Beaver et al. (1981). For the purpose of this study subjects 
breathed through a two-way non rebreathing valve connected to a pneumotachometer 
(Hans Rudolph, Kansas City, MO). Oxygen and carbon dioxide concentration of inspired 
and expired gases were determined by a mass spectrometer (Perkin-Elmer MGA 1100, 
St. Louis, MO). Gas samples were collected at the mouthpiece via a 6 foot capillary tube 
connected directly to the mass spectrometer. Custom software (Beck Integrated 
Physiological Systems) was used to determine breath by breath oxygen consumption. 
The mass spectrometer was calibrated prior to each experimental trial using gases of 
known concentration. Volume was calibrated using a 3 l syringe (Hans Rudolph) at low, 










Open Circuit Acetylene Washin (Study 2 and 3). Cardiac output (CO) was determined by 
the open circuit acetylene washin technique using the iterative method (referred to as 
OpCirc 2 in (Johnson et al., 2000) for the calculation of CO as described by Johnson et al 
(Johnson et al., 2000). The following methodology is taken directly from Johnson et al. 

















Terms and Definitions: 
 




Tissue volume: static volume that acetylene dissolves in 
Pulmonary capillary blood flow                                                                      
Uptake volumes of acetylene and helium (ml, STPD), respectively 
for the nth breath of the washin maneuver. These are obtained by 
integrating the gas concentration x flow s time product for each 8-
ms sample over each breath 
Residual volumes of acetylene and helium respectively for the nth 
breath 
End-expiratory fractional concentration of acetylene and helium 
respectively , for the nth breath 
Mixed expired fractional concentration of helium,obtained by 
integrating helium concentration and expiratory flow 
Fractional concentrations of alveolar gas for acetylene and helium, 
respectively. In practice, alveolar gas concentrations were obtained 
from end-expiratory results 
Barometric pressure (mmHg) 
Tissue and blood solubilities of acetylene, respectively. Although 
these tow terms were carried through the derivation, in practice 
the same value, 0.74 ml•ml•tissue⁻¹•atm⁻¹, was used for both 
Inspiratory and expiratory times, respectively, of the nth breath 





“For the calculation of cardiac output using the iterative method the lungs are 
considered to be one well-mixed alveolar compartment separated from the inhaled gas 
bag by an anatomic dead space. Gas transport in each unit of time, ∆t (the 8-ms 
sampling period of the data), is governed by the following mass balance considerations 
at the alveolar level.  
The total acetylene volume in the alveolar compartment is given by VAcet = FA,Acet 
x (VA + αt,Acet x Vti). The change in the acetylene volume per unit time is equal to the 
rate of disappearance into the blood plus the amount entering the alveolar volume by 




where FDS’,Acet indicates the fractional concentration of acetylene at the alveolar end of 




where Insp is inspiratory and Exp is expiratory. 
This finite difference equation is used at each time sampling increment to 
update the fractional concentration of acetylene. The helium concentration is treated 
similarly, except that αt,He = 0 (negligible tissue solubility for helium).  
The process starts with a calculation of VSD, as above, and VA, as follows 
Equation 3: 
 
This equation is applied to helium data for all breaths where the ratio of FE/FI is ,95% to 
avoid unstable solutions.  
A computer algorithm then sets up a dead space volume that consists of an 
ordered list of 1-ml units, the total volume equaling VSD. The VA and each VSD element 
is initially filled with gas concentration equal to expired concentration of the breath 
immediately before the start of the washin maneuver, simulating end expiration. The 
computer then samples the first inspiratory data point, obtaining volume change, ∆V, 
and values for gas concentration at the mouth from the raw data stream. At the mouth 
end of the dead space, the first m = ∆V dead space elements are set to the measured 
gas concentration. At the alveolar end of the dead space, m elements are each added to 
the alveolar space, using Eq.2 to update the alveolar concentration and increasing 
alveolar gas volume by ∆V. As the process continues during inspiration, a front of gas 
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moves through the dead space elements until inspired gas appears at the alveolar end 
of the dead space. Further inspiration adds inspired gas to the alveolar compartment. 
During expiration, Eq. 2 is again applied and the dead space elements are filled from the 
alveolar end with the current value for alveolar gas concentration. This process 
continues until the entire data stream has been used, and end-tidal values for each of 
the breaths is obtained from the model. The sum of squared differences between 
measured and modeled end-tidal concentration is obtained for use in an iterative search 
procedure that finds the best Q˙ and Vti. 
Taylor minimization (Press, 1986) was used to find the best combination of Vti 
and Q˙ that minimized the sum of squared errors between modeled and actual end-tidal 
gas concentrations. Imagine a three-dimensional surface shaped like a large bowl with 
the value for sum squared errors as the height above a plane defining the ranges of 
values for Vti and Q˙. The algorithm finds the low point of this surface (bottom of bowl) 
by finding its local slope and descending the steepest path down the slope to the 
minimum. This process generally took 50–100 steps. A typical solution is shown in Fig. 
F.1. The solution for Vti was occasionally unphysiological, and we were unable to find 
methods resulting in consistently reasonable values for it. The solution for Q ˙ usually 
appeared reasonable despite the occasional unstable values for Vti. Thus Vti values 




Figure F.1. Model demonstrating the OpCirc2 method for calculation of QT. Thin line 
shows raw input data for acetylene concentration at the mouth. Thick black and thick 
gray lines show model results for mouth and alveolar concentrations, respectively (see 
APPENDIX  F for description of the model). In this study, the iterative methods (OpCirc2) 
modeled the entire alveolar gas concentration curves throughout inspiration and 
expiration. This is in contrast to the work of Stout et al.(Stout et al., 1975) and Gan et al. 
(Gan et al., 1993) who examined end-inspiratory and end-expiratory alveolar gas 







Blood volume and plasma volume: Changes in blood and plasma volume were 
calculated based on the procedures described Dill and Costill (Dill & Costill, 1974). 
Percent changes in blood volume (BV), red cell volume (CV), and plasma volume (PV) 
were calculated from values of hemoglobin (Hb) and hematocrit (Hct) using the 
following calculations where B and A refer to before exercise and at the time point during 
exercise for which the change is being determined, and BVB was taken as 100: 
BVA  = BVB (HbB/HbA) 
CVA = BVA (HCTA) 
PVA = BVA - CVA 
∆ BV, % = 100 (BVA – BVB)/ BVB 
∆ CV, % = 100 (CVA – CVB)/ CVB  
∆  PV, % = 100 (PVA – PVB)/ PVB 
The cyanomethemoglobin technique was used to calculate hemoglobin concentration 
based on the following procedure. 
1. Dispense 2.0 ml of total hemoglobin reagent (Pointe Scientific, Canton, MI) into 
test tubes labeled; blank, low, medium, high, time 0, time 5, etc… 
2. Place 0.01 ml (10μl) of standards (low = 8.1 g/dl, medium = 12.6 g/dl, high = 16.8 
g/dl, supplied by manufacturer) into appropriately marked test tubes.  
3. Place 0.01 ml (10μl) of fresh whole blood into appropriately labeled test tubes. 
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4. Allow tubes to stand for at least 3 minutes at room temperature. For this study 
samples were stored in a dark cabinet after collection and mixing with reagent 
for no longer than 7 days prior to analysis. 
5. Set spectrophotometer (Beckman DU-6, Beckman Coulter) to 540 nm and zero 
with the reagent blank.  
6. Read and record absorbance values of all tubes.  
7. Create standard curve using standards provided by Pointe Scientific. 
 
Hematocrit was determined by microcentrifugation according to the following 
procedure; 
1. Draw whole blood by capillary action into 2 heparinized mircohematocrit tubes 
(Fisherbrand).  
2. Fill tubes approximately 90% full.  
3. Wipe excess blood from the outside of the tubes and seal one end of the tube 
with clay. 
4. Place the tubes in the mircocentrifuge with the sealed ends against the rubber 
outer rim.  
5. Centrifuge for 15 minute at room temperature 
6. Read the red cells and total blood volume with a ruler under a microscope and 





Inertial load calculations: From Martin et al. (Martin et al., 1997) 
 
Angular Velocity: Determined from the time difference between consecutive edges of 
slot on the target disk (ω = Δθ/Δt where Δθ = angle between target disk slots in radians 
and Δt = time between target disk slots in seconds). 
Instantaneous Torque (Ti): Calculated as the angular force applied to the cranks, 
calculated every 3° of crank rotation as Ti = αIG, where I is the moment of inertia of the 
flywheel and G is the gear ratio, and α is the angular acceleration. 
Instantaneous Power (Pi): Calculated every 3° of crank rotation as Pi = αωI. 
Torque over each complete crank revolution (Trev): Calculated as the rate of change of 
angular momentum (Trev = I[ω(i+1) – ωi]/[t(i+1) – ti]), where ω(i+1) 
and t(i+1) are the angular velocity and time at the end of the crank revolution and ωi 
and ti are the angular velocity and time at the beginning of the crank revolution. 
Power over each complete crank revolution (Prev): Calculated as the rate of change in 
kinetic energy (Prev = ΔKE/Δt = 0.5 I[ω(i+1)² – ωi²]/[t(i+1) – ti]). 
Moment of inertia of the flywheel: Calculated as the sum of the component parts. All 
the parts are cylindrical shaped and have a moment of inertia (I) of I = m(ri² + ro²)/2 
where m is the mass of the cyclinder and ri and ro are the inner and outer radii of the 
cylinder. 
Inertial load: Defined as one-half the product of the flywheel moment of inertia and the 
overall gear ratio squared (inertial load = IG²/2). 
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APPENDIX I 














Rectal Tcore, º C 36.85 ± 0.19 37.10 ± 0.19* 37.58 ± 0.22* 37.78 ± 0.31* 37.97 ± 0.29* 38.08 ± 0.26 38.23 ± 0.35 38.32 ± 0.39
Esophageal Tcore, º C 37.24 ± 0.30† 37.29 ± 0.26† 37.53 ± 0.20* 37.79 ± 0.22* 37.99 ± .022* 38.28 ± 0.28* 38.30 ± 0.32 38.37 ± 0.28
Values are mean ± SD of 7 subjects. * indicates significant increase from previous value, † indicates signficant difference between measurements.
Rest 40% 50% 60% 70% 80% 90% 100%
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TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 69.0 108.3 131.5 149.9 165.2 160.9 160.1 166.3 164.9 172.6 174.5 180.0 189.7 193.1 194.8 196.2 197.4 198.6 201.1 203.3 206.0
BA 62.0 91.6 102.3 109.8 119.8 125.0 128.3 126.9 134.5 140.7 140.1 141.4 147.4 150.0 151.2 151.3 147.8 145.8 146.4 149.1 153.4
BM 51.0 107.0 120.8 137.3 153.7 156.8 160.5 161.7 166.1 166.7 165.4 173.1 179.0 179.7 177.0 175.1 174.2 175.5 177.7 178.9 180.5
DW 48.0 119.9 133.7 143.7 153.4 155.8 156.0 156.3 154.2 156.5 158.3 163.6 169.8 171.9 171.6 172.0 172.1 173.8 173.3 175.2 176.6
JG 74.0 116.3 137.8 149.5 160.8 165.0 165.1 169.4 170.9 171.0 173.1 179.4 184.4 185.7 185.8 186.4 186.3 186.4 186.3 186.9 186.4
JH 69.0 114.0 124.1 134.5 150.5 157.0 158.5 161.6 164.4 166.6 168.0 173.0 181.0 183.5 185.7 187.0 189.1 189.0 190.0 191.9 194.0
JW 76.0 105.7 119.9 130.3 141.9 146.7 138.9 140.1 146.6 149.3 136.9 134.5 144.0 154.5 164.6 168.7 172.9 175.6 177.3 179.6 181.4
KW 58.0 100.7 118.8 133.5 145.1 148.1 149.6 152.9 153.6 155.3 153.2 162.2 173.2 180.5 183.5 185.9 187.5 189.2 189.9 190.7 191.6
MT 72.0 122.2 141.2 155.7 169.5 164.9 160.2 147.8 161.8 168.6 164.5 172.2 180.1 182.4 183.7 183.9 183.5 183.7 183.8 185.9 190.1
NW 65.0 111.9 126.9 139.1 152.2 161.4 165.5 160.2 164.5 166.5 167.3 169.2 174.0 175.8 178.0 177.6 177.9 178.5 180.7 180.4 182.7
SD 61.0 114.8 127.7 138.4 158.6 156.0 155.6 160.2 166.0 165.3 165.1 168.4 175.5 178.8 180.7 181.6 181.9 182.6 183.7 184.9 186.8
SL 70.2 122.2 128.3 142.0 152.8 152.5 150.9 152.8 153.8 157.4 159.2 164.3 171.7 175.0 178.1 180.5 181.5 180.9 181.1 180.1 180.7
HEART RATE (bpm) ‐ POM; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 81.0 119.2 139.1 153.5 174.6 173.7 174.7 181.6 179.6 189.2 188.8 191.4 196.1 197.8 196.8 195.1 195.0 194.3 194.4 195.1 196.7
BA 65.0 89.4 102.4 115.3 121.6 133.3 133.3 133.8 136.5 138.0 140.2 141.4 148.6 145.9 135.8 132.3 133.1 134.7 136.7 137.3 142.2
BM 62 0 108 5 122 7 139 0 155 2 162 7 166 9 169 7 171 9 175 3 177 1 181 5 185 6 185 8 182 3 178 7 177 0 178 8 180 5 181 5 183 2. . . . . . . . . . . . . . . . . . . . .
DW 55.0 118.5 133.7 147.2 156.0 153.1 151.5 153.5 155.3 152.5 152.8 163.1 168.4 169.4 169.6 171.2 171.8 176.8 182.2 185.7 187.5
JG 57.0 114.3 129.7 144.1 157.9 157.2 158.0 158.7 159.1 163.5 166.9 172.6 177.2 178.7 179.8 177.4 180.2 177.3 177.5 178.6 182.5
JH 69.0 117.8 133.1 143.6 155.2 160.2 166.7 163.6 165.8 165.3 169.3 174.9 179.5 182.8 184.7 185.5 186.9 187.5 188.0 189.3 192.3
JW 65.0 98.4 109.4 117.8 135.2 132.4 139.6 144.1 139.8 148.3 143.3 151.3 161.7 164.9 169.0 171.9 174.8 177.1 181.3 185.2 190.7
KW 66.0 100.9 118.3 132.2 155.1 153.4 146.1 151.2 148.5 150.3 159.5 164.7 173.3 177.2 180.0 182.5 183.5 185.6 187.2 189.3 189.6
MT 70.0 117.9 133.3 151.9 165.3 164.9 165.0 160.8 161.2 165.3 167.6 174.6 182.8 182.2 180.4 181.6 180.0 179.9 181.1 185.4 188.9
NW 71.0 116.0 127.3 143.1 156.1 165.2 170.0 167.5 168.3 171.0 173.4 176.7 181.4 182.6 181.2 179.0 177.0 175.0 174.2 174.7 178.8
SD 69.0 119.9 130.5 145.7 160.7 160.4 164.3 164.3 166.8 169.5 175.5 179.1 183.4 184.8 186.3 187.8 187.9 189.4 190.0 191.3 195.0
SL 64.0 114.2 130.5 136.8 149.5 156.6 157.1 156.5 157.0 156.6 162.9 167.6 172.8 176.0 177.6 179.5 179.1 177.8 176.7 176.4 177.3
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STROKE VOLUME (ml/beat) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 66.0 89.7 91.0 94.1 97.1 97.5 97.2 97.5 96.6 95.6 93.3 94.2 90.8 95.6 94.7 96.4 95.9 94.7 97.1 95.8 98.7
BA 94.0 125.7 125.9 127.4 128.1 128.5 126.4 130.3 132.0 132.2 135.9 128.5 129.8 135.1 131.7 133.3 127.9 131.2 132.3 131.5 134.6
BM 101.0 123.5 127.2 135.4 136.5 132.3 135.5 135.8 134.8 132.2 129.2 133.6 134.1 134.9 132.8 135.3 132.5 134.2 133.7 135.3 134.3
DW 84.0 108.3 113.0 113.0 116.3 110.8 113.1 111.9 108.8 112.3 113.9 113.8 114.5 116.5 115.8 115.0 113.9 113.2 113.9 112.8 116.2
JG 92.0 114.2 113.0 116.9 118.0 120.1 130.5 125.1 130.1 121.4 122.5 122.5 122.3 124.4 116.7 130.3 124.4 129.5 122.8 125.6 126.3
JH 82.0 104.9 112.6 115.1 121.7 118.7 119.0 120.8 125.8 124.3 118.0 126.4 121.4 127.0 128.0 123.9 128.5 128.8 125.9 133.5 124.8
JW 99.0 132.4 129.6 133.5 135.4 141.7 144.3 143.8 139.0 140.9 135.3 152.5 141.9 149.0 162.7 160.2 172.1 168.6 185.9 182.4 155.2
KW 91.0 117.2 119.3 120.1 126.9 123.8 130.4 130.6 131.4 129.8 127.1 132.5 134.6 133.2 136.5 137.0 138.2 136.4 134.7 133.8 131.7
MT 97.0 123.3 127.6 130.8 132.3 131.1 133.5 121.2 130.8 135.1 132.5 135.1 135.8 137.1 136.4 135.9 135.3 134.5 133.4 135.4 133.4
NW 89.0 120.6 128.4 132.0 130.5 130.7 132.7 134.0 133.4 135.7 131.9 132.7 133.3 133.2 132.1 132.4 131.5 131.0 133.0 132.5 133.0
SD 70.0 98.9 99.8 102.9 96.3 99.5 98.8 99.3 100.4 103.2 99.8 103.6 102.5 104.5 104.7 106.2 105.9 106.0 108.2 107.4 105.9
SL 96.0 128.0 132.1 135.0 134.8 137.6 133.6 135.1 137.4 138.8 136.3 135.4 135.9 133.5 137.3 136.0 137.6 134.5 139.7 134.1 137.4
STROKE VOLUME (ml/beat) ‐ POM; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 68.0 97.1 96.1 103.0 106.9 106.0 102.8 106.1 105.3 107.2 103.5 103.6 106.3 105.0 106.9 107.2 104.9 104.0 104.0 106.1 107.6
BA 93.0 96.8 104.4 109.8 106.1 111.5 109.6 112.7 112.8 112.8 111.4 109.0 110.7 111.5 111.6 110.4 111.1 108.0 110.4 111.2 113.7
BM 84 0 107 1 111 2 113 5 117 2 117 6 115 9 117 2 117 6 116 2 116 4 120 6 118 9 121 2 119 8 117 7 114 7 119 7 119 1 119 6 121 9. . . . . . . . . . . . . . . . . . . . .
DW 82.0 111.3 109.4 110.8 111.7 112.3 110.6 109.3 116.4 106.8 107.7 109.7 109.5 114.8 119.2 115.0 115.6 116.3 122.9 123.1 122.7
JG 97.0 122.3 124.7 124.9 128.1 130.3 127.6 128.4 130.4 119.6 126.3 123.5 123.0 123.9 125.6 119.7 125.4 127.3 129.7 126.1 123.8
JH 90.0 118.0 126.6 133.2 133.4 136.9 134.0 135.3 138.3 133.5 137.7 140.3 138.3 142.4 139.0 138.2 136.4 138.2 134.2 140.8 146.2
JW 113.0 153.6 156.3 155.9 162.5 153.4 152.9 162.5 163.2 162.6 159.3 157.1 158.2 156.9 162.1 163.5 163.6 161.0 163.6 164.2 174.6
KW 95.0 126.2 125.5 134.4 139.1 137.4 143.0 139.1 145.0 140.8 141.9 143.6 142.9 146.7 149.2 148.3 146.2 140.8 150.2 144.5 146.1
MT 95.0 116.8 117.1 122.5 125.4 125.8 123.7 131.0 128.4 131.7 125.9 123.9 131.6 128.5 130.8 126.2 133.4 132.3 129.1 125.1 127.2
NW 85.0 113.3 114.9 118.4 120.4 122.7 120.6 116.4 116.6 121.5 120.9 122.2 122.9 123.8 122.7 121.4 121.3 121.3 123.1 121.1 119.7
SD 71.0 94.0 100.0 96.9 103.5 101.7 102.8 101.4 102.9 101.5 108.1 100.6 99.8 99.8 102.5 107.5 101.7 101.6 108.6 108.4 106.8
SL 93.0 131.1 134.3 135.2 136.2 143.2 139.2 140.4 139.0 139.2 142.0 140.2 140.6 138.6 141.6 146.6 136.6 139.2 136.8 134.5 133.2
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CARDIAC OUTPUT (l/min) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 4.6 9.7 12.0 14.1 16.0 15.7 15.6 16.2 15.9 16.5 16.3 16.9 17.2 18.5 18.4 18.9 18.9 18.8 19.5 19.5 20.3
BA 5.8 11.5 12.9 14.0 15.3 16.1 16.2 16.5 17.8 18.6 19.0 18.2 19.1 20.3 19.9 20.2 18.9 19.1 19.4 19.6 20.7
BM 5.2 13.2 15.4 18.6 21.0 20.7 21.7 22.0 22.4 22.0 21.4 23.1 24.0 24.2 23.5 23.7 23.1 23.6 23.8 24.2 24.2
DW 4.1 13.0 15.1 16.2 17.8 17.3 17.6 17.5 16.8 17.6 18.0 18.6 19.4 20.0 19.9 19.8 19.6 19.7 19.7 19.8 20.5
JG 6.9 13.3 15.6 17.5 19.0 19.8 21.5 21.2 22.2 20.8 21.2 22.0 22.6 23.1 21.7 24.3 23.2 24.1 22.9 23.5 23.5
JH 6.0 12.0 14.0 15.5 18.3 18.6 18.9 19.5 20.7 20.7 19.8 21.9 22.0 23.3 23.8 23.2 24.3 24.3 23.9 25.6 24.2
JW 7.5 14.0 15.5 17.4 19.2 20.8 20.0 20.2 20.4 21.0 18.8 20.5 20.4 23.0 26.8 27.0 29.8 29.6 32.9 31.9 28.2
KW 5.3 11.8 14.2 16.0 18.4 18.3 19.5 20.0 20.2 20.2 19.5 21.5 23.3 24.1 25.0 25.5 25.9 25.8 25.6 25.5 25.2
MT 6.9 15.1 18.0 20.4 22.4 21.6 21.4 18.0 21.2 22.8 21.8 23.3 24.5 25.0 25.1 25.0 24.8 24.7 24.5 25.2 25.4
NW 5.8 13.5 16.3 18.4 19.9 21.1 22.0 21.5 22.0 22.6 22.1 22.4 23.2 23.4 23.5 23.5 23.4 23.4 24.0 23.9 24.3
SD 4.2 11.4 12.7 14.2 15.3 15.5 15.4 15.9 16.7 17.1 16.5 17.4 17.9 18.6 18.9 19.3 19.3 19.3 19.9 19.8 19.8
SL 6.8 15.6 17.0 19.2 20.6 21.0 20.2 20.6 21.1 21.8 21.7 22.3 23.3 23.4 24.5 24.6 25.0 24.3 25.3 24.1 24.8
CARDIAC OUTPUT (l/min) ‐ POM; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 5.5 11.6 13.4 15.8 18.7 18.4 18.0 19.3 18.9 20.3 19.5 19.8 20.9 20.8 21.0 20.9 20.4 20.2 20.2 20.7 21.2
BA 6.0 8.7 10.7 12.7 12.9 14.9 14.6 15.1 15.4 15.6 15.6 15.4 16.5 16.3 15.2 14.6 14.8 14.6 15.1 15.3 16.2
BM 5 2 11 6 13 6 15 8 18 2 19 1 19 3 19 9 20 2 20 4 20 6 21 9 22 1 22 5 21 8 21 0 20 3 21 4 21 5 21 7 22 3. . . . . . . . . . . . . . . . . . . . .
DW 4.5 13.2 14.6 16.3 17.4 17.2 16.8 16.8 18.1 16.3 16.5 17.9 18.4 19.4 20.2 19.7 19.9 20.6 22.4 22.9 23.0
JG 5.5 14.0 16.2 18.0 20.2 20.5 20.2 20.4 20.7 19.6 21.1 21.3 21.8 22.2 22.6 21.2 22.6 22.6 23.0 22.5 22.6
JH 6.2 13.9 16.8 19.1 20.7 21.9 22.4 22.1 22.9 22.1 23.3 24.5 24.8 26.0 25.7 25.6 25.5 25.9 25.2 26.7 28.1
JW 7.3 15.1 17.1 18.4 22.0 20.3 21.4 23.4 22.8 24.1 22.8 23.8 25.6 25.9 27.4 28.1 28.6 28.5 29.7 30.4 32.1
KW 6.3 12.7 14.8 17.8 21.6 21.1 20.9 21.0 21.5 21.2 22.6 23.7 24.8 26.0 26.8 27.1 26.8 26.1 28.1 27.4 27.7
MT 6.7 13.8 15.6 18.6 20.7 20.7 20.4 21.1 20.7 21.8 21.1 21.6 24.1 23.4 23.6 22.9 24.0 23.8 23.4 23.2 24.0
NW 6.1 13.1 14.6 16.9 18.8 20.3 20.5 19.5 19.6 20.8 21.0 21.6 22.3 22.6 22.2 21.7 21.5 21.2 21.4 21.2 21.4
SD 4.9 11.3 13.0 14.1 16.6 16.3 16.9 16.7 17.2 17.2 19.0 18.0 18.3 18.4 19.1 20.2 19.1 19.3 20.6 20.7 20.8
SL 6.0 15.0 17.5 18.5 20.4 22.4 21.9 22.0 21.8 21.8 23.1 23.5 24.3 24.4 25.1 26.3 24.5 24.7 24.2 23.7 23.6
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SYSTOLIC BLOOD PRESSURE (mmHg) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 114 152 161 171 186 176 183 176 191 192 193 203 194
BA 124 166 173 181 187 190 188 188 202 207 200 194 203
BM 129 173 195 206 227 236 230 223 232 230 210 224 220
DW 120 163 171 175 191 185 187 189 211 197 192 188 202
JG 126 180 206 217 205 212 221 214 230 262 206 246 222
JH 126 126 148 163 172 186 173 178 193 210 188 204 199
JW 122 169 175 174 191 190 188 186 203 217 246 253 223
KW 112 159 171 170 172 187 178 177 190 203 196 196 173
MT 131 143 162 172 187 196 177 189 198 202 202 206 213
NW 119 129 177 178 193 195 180 184 194 185 176 180 183
SD 126 173 184 193 215 204 201 188 205 210 214 219 224
SL 120 168 163 180 191 192 204 208 217 221 222 225 214
SYSTOLIC BLOOD PRESSURE (mmHg) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 126 178 191 169 184 176 165 159 177 184 186 170 169
BA 128 157 178 169 186 195 189 194 204 209 194 203 206
BM 123 123 194 203 225 210 212 207 207 198 197 200 199
DW 124 154 174 191 196 186 194 225 207 202 207 187 216
JG 128 170 193 211 213 210 203 217 224 205 221 211 208
JH 119 137 147 158 187 191 184 185 197 213 207 216 202
JW 135 160 169 182 192 192 186 197 191 209 202 238 243
KW 123 145 162 164 174 170 171 163 178 200 197 193 202
MT 126 165 167 177 191 156 177 181 184 182 187 193 188
NW 115 157 168 169 197 194 182 177 178 182 178 164 174
SD 129 184 195 204 212 210 203 202 207 216 222 216 222
SL 132 159 172 184 208 198 197 192 206 210 212 198 208
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DIASTOLIC BLOOD PRESSURE (mmHg) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 92 86 95 86 84 66 69 57 88 95 86 89 76
BA 87 84 79 82 78 73 79 80 78 82 84 83 64
BM 85 70 82 71 67 85 70 80 71 73 76 75 71
DW 82 81 78 61 59 71 72 80 81 75 67 86 82
JG 72 80 79 80 79 83 77 69 69 77 47 43 53
JH 84 81 78 62 70 70 66 79 69 76 72 77 82
JW 85 100 86 84 78 73 77 76 67 97 74 96 70
KW 71 100 76 81 86 89 89 90 93 88 81 83 80
MT 89 63 59 52 46 53 69 60 80 74 72 69 74
NW 89 89 87 83 75 76 76 72 67 68 71 68 64
SD 78 95 87 83 79 85 84 88 94 91 91 87 98
SL 82 58 55 56 54 57 54 64 68 62 65 67 48
DIASTOLIC BLOOD PRESSURE (mmHg) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 97 93 82 71 70 81 109 107 97 96 92 76 82
BA 90 76 83 73 73 77 79 78 63 86 80 87 84
BM 88 83 80 85 78 79 80 82 73 69 81 66 65
DW 86 76 75 80 74 84 80 79 69 90 86 84 82
JG 64 64 63 74 55 63 65 81 68 75 80 74 81
JH 81 74 60 63 61 69 63 68 63 70 63 75 69
JW 86 97 71 76 84 77 71 78 84 76 78 88 91
KW 81 71 91 86 80 76 76 74 79 79 86 73 75
MT 80 62 62 56 61 67 62 53 53 52 56 53 87
NW 80 85 85 79 75 81 70 80 63 69 78 69 75
SD 94 99 98 84 87 83 85 98 94 96 96 88 94
SL 90 84 67 59 53 54 56 57 66 59 66 57 56
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MEAN ARTERIAL BLOOD PRESSURE (mmHg) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 99 108 117 114 118 103 107 97 122 127 122 127 115
BA 99 111 110 115 114 112 115 116 119 124 123 120 110
BM 100 104 120 116 120 135 123 128 125 125 121 125 121
DW 95 108 109 99 103 109 110 116 124 116 109 120 122
JG 90 113 121 126 121 126 125 117 123 139 100 111 109
JH 98 96 101 96 104 109 102 112 110 121 111 119 121
JW 97 123 116 114 116 112 114 113 112 137 131 148 121
KW 85 120 108 111 115 122 119 119 126 126 120 121 111
MT 103 90 93 92 93 101 105 103 119 117 115 115 120
NW 99 102 117 115 114 116 111 109 109 107 106 105 104
SD 94 121 119 120 124 125 123 121 131 131 132 131 140
SL 95 95 91 97 100 102 104 112 118 115 117 120 103
MEAN ARTERIAL BLOOD PRESSURE (mmHg) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 30 45 50 52 54 56 58 60
AW 107 121 118 104 108 113 128 124 124 125 123 107 111
BA 103 103 115 105 111 116 116 117 110 127 118 126 125
BM 100 96 118 124 127 123 124 124 118 112 120 111 110
DW 99 102 108 117 115 118 118 128 115 127 126 118 127
JG 85 99 106 120 108 112 111 126 120 118 127 120 123
JH 94 95 89 95 103 110 103 107 108 118 111 122 113
JW 102 118 104 111 120 115 109 118 120 120 119 138 141
KW 95 96 115 112 111 107 108 104 112 119 123 113 117
MT 95 96 97 96 104 97 100 96 97 95 100 100 121
NW 92 109 113 109 116 119 107 112 101 106 111 101 108
SD 106 127 130 124 129 125 124 133 132 136 138 131 137
SL 104 109 102 101 105 102 103 102 113 109 115 104 107
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VENTILATION (l/min) ‐ PLACEBO; DAY ‐ 1
TIME 5 10 15 20
AW 35 45 56 68
BA 37 43 52 62
BM 35 45 55 67
DW 39 50 57 69
JG 39 52 58 69
JH 29 37 43 51
JW 35 48 55 67
KW 36 55 62 73
MT 29 41 49 63
NW 35 47 57 66
SD 41 54 62 78
SL 38 46 56 70
VENTILATION (l/min) ‐ POMS; DAY ‐ 1
TIME 5 10 15 20
AW 36 47 54 69
BA 34 47 54 62
BM 34 44 54 69
DW 43 50 62 73
JG 38 46 58 69
JH 29 34 44 52
JW 34 43 50 65
KW 39 52 65 84
MT 33 41 53 66
NW 39 49 59 70
SD 43 52 65 78
SL 38 48 54 68
OXYGEN CONSUMPTIONS (l/min) ‐ PLACEBO; 
TIME 5 10 15 20
AW 1790 2332 2836 3346
BA 1852 2267 2688 3199
BM 1664 2111 2587 3036
DW 1915 2389 2727 3208
JG 1909 2502 2804 3266
JH 1677 2098 2454 3061
JW 1741 2436 2761 3199
KW 1932 2891 3225 3724
MT 1531 2059 2468 2960
NW 1789 2342 2818 3314
SD 2090 2590 3042 3623
SL 1795 2150 2708 3319
OXYGEN CONSUMPTION (l/min) ‐ POMS; DAY
TIME 5 10 15 20
AW 1895 2394 2857 3332
BA 1761 2440 2706 3260
BM 1713 2199 2611 3119
DW 2044 2456 3032 3592
JG 1958 2301 2826 3294
JH 1704 2148 2607 3012
JW 1738 2172 2670 3162
KW 1938 2671 3261 3981
MT 1650 2016 2561 2966
NW 2103 2457 3066 3424
SD 2180 2585 3154 3558
SL 1905 2409 2721 3184
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RESPIRATORY EXCHANGE RATIO ‐ PLACEBO; D
TIME 5 10 15 20
AW 0.87 0.90 0.89 0.91
BA 0.84 0.83 0.84 0.84
BM 0.86 0.88 0.88 0.90
DW 0.81 0.83 0.86 0.87
JG 0.84 0.86 0.86 0.87
JH 0.83 0.89 0.89 0.89
JW 0.87 0.91 0.90 0.93
KW 0 81 0 85 0 86 0 84. . . .
MT 0.90 0.93 0.94 0.97
NW 0.80 0.82 0.82 0.84
SD 0.81 0.84 0.83 0.87
SL 0.87 0.89 0.89 0.89
RESPIRATORY EXCHANGE RATIO ‐ POMS; DAY
TIME 5 10 15 20
AW 0.84 0.89 0.89 0.92
BA 0.82 0.85 0.86 0.83
BM 0.84 0.87 0.88 0.90
DW 0.84 0.83 0.84 0.85
JG 0.82 0.86 0.86 0.86
JH 0.79 0.82 0.84 0.86
JW 0.86 0.89 0.89 0.91
KW 0.86 0.86 0.87 0.89
MT 0.91 0.92 0.96 0.97
NW 0.83 0.85 0.85 0.88
SD 0.84 0.84 0.85 0.88
SL 0 83 0 83 0 84 0 87. . . .
GROSS EFFICIECNY (%) ‐ PLACEBO; DAY ‐ 1
TIME 5 10 15 20
AW 18.2% 20.6% 21.8% 22.1%
BA 13.9% 17.8% 20.2% 21.4%
BM 17.7% 20.1% 21.4% 22.3%
DW 16.8% 18.6% 20.7% 21.4%
JG 18.3% 18.2% 20.1% 20.6%
JH 15.0% 17.1% 19.1% 19.1%
JW 15.3% 16.1% 18.8% 20.0%
KW 14.9% 16.0% 19.8% 22.0%
MT 17.5% 19.1% 21.0% 21.6%
NW 14.8% 17.6% 19.9% 21.4%
SD 16.2% 17.7% 19.2% 19.3%
SL 15.8% 18.6% 19.1% 19.2%
GROSS EFFICIENCY (%) ‐ POMS; DAY ‐ 1
TIME 5 10 15 20
AW 17 3% 20 1% 21 7% 22 2%. . . .
BA 14.7% 16.4% 19.9% 21.1%
BM 17.2% 19.3% 21.2% 21.7%
DW 15.6% 18.1% 18.7% 19.2%
JG 17.9% 19.8% 20.0% 20.4%
JH 14.9% 17.0% 18.2% 19.5%
JW 15.4% 18.1% 19.5% 20.4%
KW 14.7% 17.3% 19.5% 20.3%
MT 16.2% 19.5% 20.2% 21.6%
NW 12.5% 16.7% 18.2% 20.5%
SD 15.5% 17.7% 18.4% 19.6%
SL 15.1% 16.8% 19.2% 20.1%
193
CORE TEMPERATURE (ºC) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 37.17 37.21 37.30 37.43 37.61 37.75 37.85 37.93 38.02 38.07 38.15 38.16 38.19 38.22 38.25 38.29 38.33 38.38 38.42 38.43 38.45
BA 37.67 37.80 37.92 38.04 38.18 38.32 38.41 38.27 38.41 38.50 38.58 38.59 38.61 38.64 38.67 38.70 38.72 38.75 38.77 38.79 38.81
BM 36.88 36.98 37.25 37.49 37.76 37.99 38.17 38.30 38.38 38.47 38.53 38.54 38.56 38.61 38.67 38.73 38.78 38.83 38.85 38.87 38.90
DW 36.94 37.01 37.28 37.57 37.82 38.04 38.15 38.24 38.30 38.33 38.29 38.29 38.30 38.33 38.37 38.42 38.47 38.52 38.56 38.60 38.64
JG 37.28 37.41 37.61 37.82 38.07 38.33 38.52 38.65 38.75 38.81 38.86 38.87 38.90 38.93 38.98 39.03 39.09 39.16 39.22 39.30 39.38
JH 37.25 37.30 37.46 37.68 37.94 38.19 38.41 38.55 38.66 38.75 38.81 38.82 38.84 38.89 38.94 39.01 39.09 39.18 39.26 39.35 39.44
JW 37.61 37.62 37.67 37.74 37.84 37.97 38.07 38.12 38.14 38.20 38.16 38.16 38.17 38.19 38.22 38.27 38.32 38.38 38.45 38.52 38.60
KW 37.12 37.14 37.24 37.38 37.56 37.78 37.95 38.11 38.26 38.38 38.46 38.47 38.50 38.54 38.59 38.66 38.72 38.79 38.86 38.94 39.02
MT 37.81 37.94 37.97 38.10 38.28 38.45 38.57 38.65 38.78 38.83 38.86 38.87 38.89 38.92 38.96 39.00 39.04 39.07 39.10 39.13 39.16
NW 37.33 37.40 37.44 37.53 37.68 37.90 38.15 38.34 38.44 38.49 38.54 38.55 38.56 38.58 38.62 38.66 38.70 38.75 38.79 38.83 38.88
SD 36.99 37.00 37.15 37.29 37.47 37.64 37.75 37.82 37.87 37.97 38.02 38.02 38.06 38.11 38.16 38.21 38.25 38.29 38.32 38.35 38.38
SL 37.53 37.59 37.69 37.81 37.94 38.15 38.23 38.30 38.39 38.45 38.56 38.62 38.69 38.76 38.85 38.93 39.03 39.03 39.07 39.11 39.16
CORE TEMPERATURE (ºC) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 37.24 37.25 37.34 37.46 37.63 37.80 37.93 38.04 38.14 38.25 38.36 38.37 38.39 38.42 38.44 38.47 38.49 38.52 38.55 38.57 38.60
BA 37.53 37.51 37.62 37.81 37.99 38.15 38.32 38.43 38.48 38.48 38.49 38.49 38.50 38.51 38.52 38.51 38.48 38.46 38.45 38.45 38.45
BM 37 16 37 25 37 51 37 78 38 05 38 31 38 53 38 72 38 82 38 97 39 05 39 09 39 15 39 19 39 24 39 28 39 32 39 34 39 38 39 41 39 42. . . . . . . . . . . . . . . . . . . . .
DW 36.97 37.05 37.26 37.54 37.76 37.91 38.03 38.10 38.11 38.19 38.26 38.27 38.27 38.29 38.32 38.34 38.40 38.47 38.55 38.63 38.73
JG 37.08 37.17 37.34 37.52 37.79 38.06 38.24 38.38 38.46 38.50 38.58 38.59 38.61 38.66 38.71 38.77 38.83 38.89 38.94 38.99 39.04
JH 37.07 37.10 37.25 37.43 37.62 37.87 38.12 38.29 38.40 38.48 38.56 38.58 38.60 38.65 38.71 38.79 38.87 38.95 39.03 39.11 39.20
JW 37.49 37.58 37.71 37.77 37.88 37.90 38.04 38.15 38.25 38.30 38.37 38.38 38.42 38.48 38.54 38.61 38.67 38.73 38.80 38.88 38.97
KW 37.13 37.18 37.25 37.33 37.43 37.60 37.75 37.95 38.08 38.22 38.28 38.28 38.33 38.36 38.40 38.44 38.48 38.52 38.55 38.58 38.63
MT 37.59 37.66 37.80 37.99 38.18 38.34 38.44 38.53 38.60 38.66 38.82 38.85 38.88 38.90 38.93 38.96 38.99 38.96 38.82 38.80 38.85
NW 37.55 37.51 37.55 37.68 37.86 38.10 38.33 38.41 38.53 38.76 38.85 38.89 38.94 38.96 38.98 38.99 39.01 39.03 39.02 38.90 38.86
SD 37.08 37.09 37.18 37.30 37.46 37.63 37.76 37.87 37.98 38.06 38.15 38.17 38.21 38.24 38.29 38.35 38.42 38.48 38.55 38.62 38.68
SL 37.31 37.35 37.49 37.64 37.81 38.00 38.20 38.35 38.48 38.60 38.64 38.65 38.66 38.69 38.72 38.77 38.82 38.88 38.94 39.00 39.06
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SKIN TEMPERATURE (ºC) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 31.42 31.52 31.41 31.57 30.90 30.60 30.54 30.17 30.01 30.84 30.46 30.30 30.28 30.31 30.23 30.00 29.86 29.81 29.87 29.88 29.79
BA 29.69 32.54 32.62 32.46 32.53 32.05 31.69 31.90 31.97 31.11 31.19 31.32 31.45 31.42 31.29 31.18 31.08 30.98 30.97 30.94 30.87
BM 32.20 31.84 31.40 31.96 31.67 31.83 31.47 31.65 31.86 30.25 29.91 29.83 30.19 30.15 30.09 30.15 30.23 30.30 30.77 30.98 30.60
DW 33.16 32.70 32.00 32.67 32.42 32.10 31.98 32.10 30.89 30.07 30.76 30.93 31.06 31.07 31.11 31.14 31.08 31.02 30.83 30.79 30.74
JG 32.19 31.91 32.52 32.74 32.98 32.76 32.40 32.10 32.32 32.09 32.63 32.92 32.61 31.94 31.80 31.73 31.71 32.01 32.31 32.65 32.80
JH 33.03 32.42 32.34 31.43 31.00 30.91 31.43 31.35 30.76 31.05 30.88 30.93 30.87 30.83 30.80 30.67 30.74 30.97 31.22 30.91 30.38
JW 31.89 32.58 32.87 32.59 33.00 32.17 31.72 31.61 31.52 31.75 31.73 31.73 31.82 31.96 32.04 31.89 31.79 31.64 31.53 31.82 31.93
KW 31.49 31.97 32.29 32.79 32.04 32.41 32.33 32.69 32.68 31.46 31.63 31.75 31.96 31.97 31.57 31.01 30.63 30.83 31.50 31.72 31.92
MT 32.67 33.27 32.56 32.37 32.22 32.63 32.54 32.03 32.13 31.91 31.24 31.04 31.14 31.63 31.66 31.49 31.42 31.28 31.27 31.70 32.09
NW 31.84 32.13 32.53 31.80 32.03 31.54 31.03 31.03 30.62 30.46 29.91 29.86 30.04 30.22 30.15 30.01 29.89 29.85 29.77 29.71 29.77
SD 32.39 31.73 32.16 32.71 32.57 31.72 31.76 30.90 31.49 32.21 31.07 31.58 31.67 31.60 31.55 31.61 31.85 32.18 31.77 31.37 31.28
SL 32.03 32.09 32.29 32.58 32.34 31.86 31.41 31.29 31.92 31.20 30.95 30.71 30.64 30.77 30.69 30.50 30.36 30.45 30.46 30.50 30.45
SKIN TEMPERATURE (ºC) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 31.22 31.13 31.48 30.99 31.41 30.57 30.05 29.95 29.87 29.57 29.37 29.47 29.73 29.62 29.47 29.41 29.58 29.81 29.76 29.66 29.65
BA 31.88 31.88 32.09 32.41 31.94 31.23 30.92 30.98 30.91 30.59 31.25 30.90 30.70 30.51 30.74 30.98 30.77 30.62 30.45 30.35 30.68
BM 32 23 32 47 32 51 32 14 31 94 31 97 31 67 31 00 31 04 30 76 30 45 30 26 30 06 29 88 29 80 30 03 30 20 30 12 29 97 29 86 29 85. . . . . . . . . . . . . . . . . . . . .
DW 33.55 32.50 31.82 32.04 32.55 31.55 31.62 31.67 31.52 31.03 31.37 31.42 31.43 31.48 31.61 31.51 31.08 30.72 30.49 30.67 30.92
JG 32.28 32.98 32.87 31.86 32.09 32.80 32.28 32.02 31.73 33.23 32.48 32.74 32.35 32.10 31.89 32.01 32.47 32.81 32.89 32.81 32.69
JH 33.12 32.98 32.81 32.38 31.86 31.40 31.82 31.10 31.15 30.70 30.88 30.62 30.53 30.41 30.82 31.14 30.63 30.08 30.12 30.67 31.04
JW 32.50 32.78 32.77 32.37 32.62 31.56 32.21 31.80 31.21 32.17 31.59 31.63 31.93 31.92 31.81 31.70 31.64 31.57 31.66 31.86 31.72
KW 32.49 31.63 31.46 31.60 31.44 31.24 30.98 30.59 31.36 31.23 31.42 30.42 30.43 30.34 30.34 30.40 30.30 30.20 30.13 29.99 29.92
MT 33.82 32.92 31.95 32.04 32.25 32.66 32.80 32.15 32.92 33.21 33.31 33.35 33.28 33.24 33.17 33.08 32.45 32.02 32.03 31.22 31.13
NW 32.95 32.99 32.69 32.13 31.86 31.76 30.73 30.57 31.00 30.95 30.11 30.01 29.92 29.86 29.89 29.95 29.92 29.87 29.70 28.56 27.83
SD 32.24 31.77 31.70 32.13 32.32 31.30 31.29 31.45 31.58 31.26 31.04 30.99 30.96 30.95 30.96 31.07 31.01 30.91 30.75 30.59 30.50
SL 32.41 32.36 32.32 32.26 32.35 31.81 32.17 31.77 31.61 31.63 31.73 31.60 31.52 31.40 31.24 31.11 31.18 31.30 31.21 31.15 31.08
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BODY TEMPERATURE (ºC) ‐ PLACEBO; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 36.42 36.47 36.54 36.67 36.74 36.82 36.90 36.92 36.98 37.13 37.15 37.14 37.16 37.19 37.21 37.22 37.23 37.26 37.31 37.32 37.33
BA 36.63 37.11 37.23 37.31 37.44 37.51 37.54 37.44 37.57 37.54 37.62 37.65 37.68 37.70 37.71 37.72 37.73 37.74 37.76 37.77 37.78
BM 36.27 36.31 36.49 36.77 36.97 37.19 37.30 37.44 37.53 37.40 37.41 37.41 37.47 37.51 37.55 37.62 37.67 37.72 37.80 37.85 37.82
DW 36.45 36.45 36.60 36.93 37.12 37.27 37.35 37.44 37.34 37.26 37.31 37.34 37.36 37.39 37.43 37.48 37.51 37.55 37.55 37.58 37.61
JG 36.62 36.69 36.94 37.16 37.41 37.60 37.72 37.80 37.91 37.93 38.05 38.10 38.08 38.03 38.04 38.08 38.13 38.23 38.33 38.43 38.52
JH 36.70 36.67 36.79 36.86 37.04 37.24 37.50 37.61 37.64 37.75 37.78 37.80 37.81 37.84 37.88 37.93 38.00 38.11 38.22 38.26 38.26
JW 36.87 36.97 37.05 37.07 37.21 37.21 37.25 37.27 37.28 37.36 37.32 37.33 37.34 37.38 37.41 37.44 37.47 37.51 37.55 37.65 37.73
KW 36.39 36.47 36.60 36.78 36.84 37.08 37.22 37.41 37.54 37.48 37.57 37.60 37.65 37.69 37.68 37.66 37.67 37.76 37.90 38.00 38.10
MT 37.14 37.33 37.27 37.35 37.49 37.69 37.78 37.79 37.92 37.93 37.87 37.85 37.88 37.97 38.01 38.02 38.05 38.06 38.08 38.16 38.24
NW 36.62 36.71 36.80 36.78 36.94 37.07 37.22 37.39 37.42 37.44 37.42 37.42 37.45 37.50 37.52 37.53 37.56 37.59 37.61 37.64 37.69
SD 36.39 36.31 36.50 36.69 36.83 36.87 36.97 36.92 37.05 37.22 37.11 37.19 37.23 37.26 37.30 37.35 37.42 37.50 37.47 37.45 37.46
SL 36.82 36.87 36.99 37.13 37.21 37.33 37.34 37.39 37.54 37.51 37.57 37.59 37.64 37.73 37.79 37.84 37.90 37.91 37.95 37.99 38.02
BODY TEMPERATURE (ºC) ‐ POMS; DAY ‐ 1
TIME 0 5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
AW 36.45 36.45 36.57 36.61 36.82 36.86 36.90 36.99 37.07 37.12 37.19 37.21 37.27 37.28 37.28 37.29 37.34 37.39 37.40 37.41 37.43
BA 36.79 36.78 36.90 37.10 37.20 37.25 37.36 37.46 37.49 37.46 37.55 37.50 37.48 37.47 37.51 37.53 37.48 37.44 37.41 37.40 37.44
BM 36 52 36 63 36 86 37 05 37 26 37 48 37 64 37 71 37 81 37 91 37 94 37 94 37 97 37 98 38 01 38 08 38 13 38 15 38 16 38 16 38 18. . . . . . . . . . . . . . . . . . . . .
DW 36.53 36.46 36.55 36.83 37.09 37.09 37.19 37.26 37.25 37.26 37.36 37.38 37.38 37.41 37.45 37.45 37.44 37.46 37.50 37.60 37.71
JG 36.46 36.63 36.76 36.79 37.05 37.38 37.47 37.55 37.58 37.82 37.79 37.83 37.80 37.80 37.82 37.89 38.00 38.10 38.15 38.19 38.22
JH 36.56 36.56 36.67 36.77 36.87 37.03 37.30 37.35 37.46 37.46 37.56 37.55 37.55 37.58 37.69 37.79 37.79 37.80 37.87 38.02 38.14
JW 36.84 36.96 37.07 37.07 37.20 37.07 37.28 37.32 37.34 37.51 37.49 37.50 37.58 37.63 37.66 37.71 37.75 37.80 37.87 37.97 38.02
KW 36.52 36.46 36.50 36.59 36.65 36.77 36.87 37.00 37.20 37.31 37.39 37.26 37.30 37.32 37.35 37.39 37.42 37.44 37.45 37.46 37.50
MT 37.10 37.04 37.04 37.22 37.41 37.60 37.71 37.71 37.87 37.95 38.10 38.14 38.15 38.17 38.18 38.20 38.14 38.06 37.94 37.82 37.85
NW 36.95 36.92 36.92 36.96 37.08 37.28 37.34 37.39 37.55 37.74 37.71 37.74 37.77 37.78 37.80 37.82 37.83 37.84 37.81 37.56 37.42
SD 36.45 36.40 36.47 36.63 36.79 36.81 36.91 37.03 37.15 37.17 37.23 37.24 37.26 37.29 37.34 37.40 37.45 37.50 37.53 37.57 37.62
SL 36.67 36.70 36.82 36.94 37.10 37.19 37.42 37.49 37.59 37.69 37.74 37.74 37.74 37.74 37.75 37.77 37.83 37.90 37.94 37.98 38.03
196
BLOOD LACTATE (mmol/l) ‐ PLACEBO; DAY ‐ 1
TIME 5 30 60 5 30 60
AW 1.9 1.9 10.0 2.1 4.2 4.6
BA 0.8 1.4 4.3 0.8 1.6 2.7
BM 1.0 3.3 5.6 0.9 3.4 5.2
DW 1.3 2.1 5.9 2.1 2.0 9.7
JG 1.3 4.0 8.2 1.2 2.0 6.3
PLACEBO POMS
JH 1.0 2.3 11.6 1.1 2.8 11.1
JW 1.0 1.9 10.6 1.6 2.4 14.1
KW 1.3 2.6 9.2 1.6 1.8 8.2
MT 1.8 2.1 8.3 1.2 2.0 6.9
NW 1.4 3.9 7.3 1.3 3.4 8.0
SD 1.4 2.2 6.0 1.7 3.1 7.4
SL 1.6 3.7 11.1 1.0 3.8 12.4
RATING OF PERCEIVED EXERTION ; DAY ‐ 1
TIME 30 45 30 45
AW 12.5 12.5 12.5 16.0
BA 13.0 13.0 14.0 16.0
BM 12.0 14.0 12.5 12.5
DW 14 0 15 0 14 0 14 0
PLACEBO POMS
. . . .
JG 13.0 13.0 14.0 14.0
JH 12.0 12.0 12.0 13.5
JW 12.0 12.0 12.0 12.0
KW 14.0 14.0 13.5 15.0
MT 14.5 13.5 13.5 15.5
NW 13.0 14.0 15.0 14.0
SD 16.0 16.5 14.0 14.0





























5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 57.4 57.0 54.0 47.8 46.0 46.6 46.8 47.5 50.5 52.4 50.5 49.5 48.5 48.1 47.8 47.8 48.4 47.6 47.0 47.6
JH 56.6 54.9 53.5 52.4 51.1 52.8 49.5 48.9 49.3 51.2 49.7 48.3 46.4 45.7 45.8 44.8 44.7 44.4 44.4 44.9
KW 64.7 63.7 60.6 57.1 64.0 61.8 62.1 63.0 61.7 60.0 59.4 58.8 58.4 58.0 57.8 57.7 57.4 57.4 57.9 57.7
MT 60.3 57.7 50.7 53.1 52.6 51.5 57.4 55.0 53.5 55.0 53.7 51.6 52.0 50.4 51.1 50.9 52.1 52.5 52.3 52.8
SD 65.6 64.5 61.4 59.1 60.4 59.6 60.7 58.2 57.2 55.7 56.1 54.9 55.7 56.8 56.4 56.7 56.8 56.1 56.5 57.1
OXYGEN SATURATION (%) ‐ POMS; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 63.0 60.3 57.1 54.9 54.8 54.1 53.4 53.6 54.0 52.8 52.4 50.9 49.8 48.3 48.8 48.8 49.2 49.7 48.9 49.7
JH 60 2 56 2 56 1 54 5 52 6 51 0 50 5 50 6 53 6 52 5 53 2 53 5 54 4 53 7 50 8 51 4 50 2 50 3 51 0 49 5. . . . . . . . . . . . . . . . . . . .
KW 56.2 54.3 50.6 51.4 50.7 48.5 48.0 49.2 50.8 50.7 50.8 49.3 50.1 49.9 50.5 50.2 50.9 50.5 50.9 50.7
MT 58.9 58.7 55.8 57.6 57.7 57.2 61.5 58.7 55.4 56.9 57.8 55.8 57.2 55.5 56.1 53.6 54.7 53.9 56.0 56.5
SD 70.4 74.4 71.2 66.7 64.6 63.5 63.8 63.0 62.4 62.6 62.2 61.6 60.6 60.2 59.0 58.6 57.9 56.7 55.6 54.5
TOTAL HEMOGLOBIN CONTENT (µM) ‐ PLACEBO; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 60.2 62.8 62.2 60.3 60.0 60.0 60.6 61.2 62.8 64.4 64.5 63.9 63.6 63.2 63.2 62.8 62.9 62.8 62.9 63.2
JH 63.1 65.9 66.3 67.3 68.6 68.9 68.2 68.8 68.2 70.2 70.5 70.8 69.5 69.3 70.2 69.5 69.4 69.8 69.5 70.2
KW 59.4 61.8 62.7 63.5 73.2 72.7 74.3 75.8 73.6 71.8 72.1 71.7 70.7 70.1 70.5 70.5 70.0 69.6 70.0 70.3
MT 57.2 55.9 52.8 53.6 53.1 53.6 53.4 51.4 52.9 53.2 54.2 54.8 54.0 53.1 52.5 53.0 53.2 54.2 52.5 53.6
SD 70.6 74.4 74.8 76.2 75.7 77.8 78.3 77.0 77.1 74.5 75.3 74.9 75.2 76.2 76.6 76.4 77.6 77.8 77.7 78.0
TOTAL HEMOGLOBIN CONTENT (µM) ‐ POMS; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 66.7 70.8 69.4 68.7 70.5 70.5 70.8 70.9 71.7 69.9 71.2 69.8 68.6 68.7 68.3 69.4 69.8 70.1 69.2 69.9
JH 69.2 69.8 72.1 72.7 73.5 75.3 76.3 76.8 76.1 75.1 76.4 76.3 77.1 76.4 75.0 75.9 75.8 76.1 77.0 76.0
KW 62.0 65.2 65.7 68.3 65.1 63.4 64.7 65.9 65.1 64.5 65.5 65.8 67.0 66.6 67.3 67.2 67.5 66.9 67.7 69.2
MT 56.7 57.4 58.2 58.4 56.5 59.3 57.4 56.8 59.1 59.6 56.4 56.9 55.8 56.5 56.7 58.9 57.5 59.4 59.5 60.6
SD 63.9 72.8 74.0 70.6 67.9 67.0 67.7 66.8 66.6 66.5 66.3 65.9 65.7 66.0 64.8 64.8 64.2 64.7 63.5 62.5
OXYGENATED HEMOGLOBIN (µM) ‐ PLACEBO; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 34.5 35.8 33.6 28.9 27.6 28.0 28.3 29.1 31.7 33.7 32.6 31.7 30.8 30.4 30.2 30.0 30.5 29.9 29.6 30.0
JH 35.7 36.2 35.5 35.2 35.1 36.3 33.8 33.7 33.6 35.9 35.1 34.2 32.3 31.7 32.2 31.1 31.1 31.0 30.9 31.5
KW 38.4 39.4 38.0 36.3 46.9 44.9 46.2 47.7 45.4 43.1 42.8 42.1 41.3 40.6 40.7 40.7 40.2 40.0 40.5 40.6
MT 34.5 32.3 26.8 28.5 28.0 27.6 30.7 28.3 28.3 29.2 29.1 28.3 28.1 26.7 26.8 27.0 27.7 28.4 27.5 28.3
SD 46.4 48.0 45.9 45.0 45.7 46.4 47.5 44.8 44.1 41.5 42.2 41.1 41.9 43.3 43.2 43.3 44.1 43.7 43.9 44.6
OXYGENATED HEMOGLOBIN (µM) ‐ POMS; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 42.0 42.7 39.6 37.7 38.7 38.2 37.8 38.0 38.7 36.9 37.3 35.5 34.2 33.2 33.3 33.8 34.4 34.8 33.8 34.8
JH 41.6 39.2 40.5 39.6 38.7 38.4 38.5 38.9 40.7 39.4 40.6 40.8 41.9 41.1 38.1 39.0 38.0 38.3 39.2 37.6
KW 34.9 35.4 33.2 35.1 33.1 30.7 31.1 32.4 33.0 32.7 33.3 32.4 33.5 33.2 34.0 33.7 34.3 33.8 34.4 35.1
MT 33.4 33.7 32.5 33.6 32.6 34.0 35.2 33.4 32.7 33.9 32.6 31.7 31.9 31.3 31.8 31.6 31.4 32.0 33.3 34.2
SD 45.0 54.2 52.7 47.1 43.9 42.5 43.2 42.0 41.6 41.6 41.3 40.6 39.8 39.7 38.2 38.0 37.1 36.7 35.3 34.0
DEOXYGENATED HEMOGLOBIN (µM) ‐ PLACEBO; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 25.7 27.0 28.6 31.5 32.5 32.0 32.3 32.1 31.1 30.6 31.9 32.3 32.8 32.8 33.0 32.8 32.5 32.9 33.3 33.1
JH 27.4 29.7 30.8 32.1 33.5 32.5 34.4 35.1 34.6 34.2 35.4 36.6 37.3 37.6 38.0 38.3 38.4 38.8 38.6 38.7
KW 21.0 22.4 24.7 27.3 26.3 27.7 28.2 28.1 28.2 28.7 29.3 29.5 29.4 29.4 29.8 29.8 29.8 29.6 29.5 29.7
MT 22.7 23.6 26.0 25.1 25.1 26.0 22.7 23.1 24.6 23.9 25.1 26.5 25.9 26.4 25.7 26.0 25.5 25.8 25.0 25.3
SD 24.3 26.4 28.8 31.1 30.0 31.4 30.8 32.1 33.0 33.0 33.1 33.8 33.4 32.9 33.4 33.1 33.5 34.0 33.7 33.5
DEOXYGENATED HEMOGLOBIN (µM) ‐ POMS; DAY ‐ 1
5 10 15 20 25 30 35 40 45 50 51 52 53 54 55 56 57 58 59 60
JG 24.7 28.1 29.7 31.0 31.8 32.3 33.0 32.9 33.0 33.0 33.9 34.3 34.4 35.5 35.0 35.6 35.5 35.3 35.4 35.1
JH 27.5 30.6 31.7 33.1 34.9 36.9 37.7 37.9 35.3 35.7 35.7 35.5 35.2 35.3 36.9 36.8 37.7 37.8 37.7 38.4
KW 27.2 29.8 32.5 33.2 32.1 32.7 33.6 33.5 32.0 31.8 32.2 33.4 33.5 33.4 33.3 33.5 33.2 33.1 33.3 34.1
MT 23.3 23.7 25.7 24.8 23.9 25.4 22.1 23.5 26.4 25.7 23.8 25.2 23.9 25.2 24.9 27.3 26.0 27.4 26.2 26.4
SD 18.9 18.6 21.3 23.5 24.0 24.5 24.5 24.7 25.0 24.9 25.0 25.3 25.9 26.3 26.6 26.8 27.0 28.0 28.3 28.4
198
MAXIMAL NUEROMUSCULAR POWER; DAY ‐ 1
Subject  PLACEBO POMS PLACEBO POMS PLACEBO POMS
AW 1797.6 1723.6 1084.7 1091.3 127.9 123.9
BA 1965.6 1885.8 1294.5 1191.6 127.7 125.9
BM 1401.6 1470.7 876.3 891.2 115.1 120.8
DW 1733.0 1671.0 1068.5 978.9 114.9 113.6
JG 1927.1 1904.3 1155.2 1164.8 124.4 130.3
JH 1982.9 2079.7 1223.9 1258.2 112.5 115.5
JW 2290.0 2440.1 1323.5 1401.8 113.6 119.3
KW 2768.7 2739.7 1740.1 1768.1 106.5 100.4
MT 1691.2 1857.6 1073.7 1119.7 134.8 130.6
NW 1976.7 2007.1 1225.0 1257.0 127.9 129.6
SD 2576.5 2420.0 1504.5 1370.6 129.0 122.7




TIME 0 10 20 30 40 50 60 70 80 90 100
AW 183.4 187.0 187.6 188.6 192.3 196.4 197.2 197.9 198.4 197.9 198.4
BA 120.9 124.0 130.5 135.4 138.6 139.5 141.4 143.5 145.5 147.3 147.6
BM 158.0 160.0 165.8 170.9 172.6 173.7 176.0 177.9 179.7 180.7 181.2
DW 154.3 160.3 167.8 171.6 175.8 179.0 179.8 181.1 182.6 183.0 184.3
JG 156.3 159.9 164.0 168.0 171.0 172.4 172.9 174.3 175.9 176.4 173.9
JH 151.8 161.4 171.5 177.1 180.2 182.0 183.9 185.4 187.0 187.7 187.7
JW 140.4 149.2 158.5 164.1 168.0 171.0 174.0 177.4 179.9 185.6 187.2
KW 156.3 162.8 171.8 177.1 180.3 181.5 182.4 184.0 185.5 187.0 188.6
MT 160.3 160.3 167.9 170.5 173.9 176.3 178.2 180.0 180.5 181.1 180.9
NW 152.2 157.8 164.1 166.7 170.1 170.8 173.3 175.2 177.3 178.3 180.4
SD 164.1 167.7 173.3 175.7 176.8 180.3 182.3 183.3 183.1 183.6 184.2
SL 156.1 158.9 165.3 168.4 171.0 173.1 174.5 175.8 177.2 179.0 180.3
HEART RATE (bpm) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 189.3 192.5 193.9 197.4 200.0 201.7 202.7 204.1 204.7 206.6 206.5
BA 128.2 127.4 131.9 137.3 139.9 143.1 145.9 147.9 149.4 150.6 150.3
BM 156.9 162.3 169.8 173.0 175.3 176.5 177.6 180.2 181.1 181.7 182.6
DW 147.3 154.4 162.9 169.2 171.5 174.1 175.9 179.0 179.8 180.8 182.8
JG 156.6 159.3 164.0 167.5 170.0 170.7 170.9 172.1 174.0 175.2 174.4
JH 154.1 161.9 170.1 174.9 177.1 179.8 182.7 184.2 186.1 186.7 187.5
JW 145.4 149.7 158.7 163.6 167.9 170.1 172.4 175.5 178.9 182.7 185.7
KW 151.9 157.4 163.8 170.2 173.0 175.2 176.4 177.7 176.5 179.4 182.1
MT 166.9 170.7 173.7 178.7 181.0 182.1 184.3 184.0 184.1 184.0 185.3
NW 157.1 161.8 167.9 170.5 172.4 174.3 175.9 178.2 179.7 181.4 182.4
SD 163.1 165.2 170.7 172.4 174.7 175.7 177.8 177.2 177.2 177.7 177.9
SL 154.7 157.9 163.2 168.0 170.1 173.1 174.9 176.2 177.1 179.2 180.3
STROKE VOLUME (ml/beat) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 119.9 112.5 114.2 113.2 111.8 117.4 112.9 108.3 110.7 113.0 115.7
BA 140.0 137.4 140.3 140.3 141.6 143.0 145.3 142.8 137.7 134.2 141.2
BM 139.0 139.6 143.0 141.6 140.6 139.7 138.4 135.4 138.7 129.4 134.8
DW 117.6 129.6 128.9 132.6 135.3 134.3 131.3 134.2 127.9 132.0 129.3
JG 116.4 122.6 117.4 119.9 122.8 117.7 116.2 114.3 117.9 111.8 121.6
JH 109.8 114.4 113.4 112.5 110.9 115.3 116.8 107.2 112.6 114.8 109.3
JW 154.0 153.1 149.5 157.5 161.1 156.3 158.2 157.8 163.8 176.1 166.3
KW 131.5 129.5 129.1 131.3 132.4 129.9 130.3 128.3 126.3 128.8 131.9
MT 132.3 137.7 137.2 137.4 132.1 128.0 132.7 137.2 136.0 135.0 134.9
NW 130.5 137.6 137.5 133.6 137.6 136.6 133.8 135.7 132.8 135.0 134.5
SD 109.1 105.0 107.2 105.9 104.2 106.2 107.8 106.4 112.1 109.1 107.0
SL 127.1 134.8 135.7 137.7 134.9 139.4 138.5 135.7 138.5 135.8 139.3
STROKE VOLUME (ml/beat) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 107.7 100.1 98.5 100.2 99.3 101.1 104.4 102.3 103.6 99.1 98.4
BA 131.8 132.1 133.7 130.9 137.7 135.9 132.7 126.1 134.9 136.8 135.9
BM 140.3 142.2 149.3 144.5 146.1 148.4 142.5 141.0 147.6 143.0 134.4
DW 120.2 130.7 128.9 127.8 127.8 129.1 127.8 125.3 127.6 133.9 134.5
JG 131.7 125.1 120.2 134.6 132.4 130.1 125.0 124.8 132.9 126.1 124.3
JH 137.2 137.4 138.1 138.2 143.8 146.0 143.7 145.8 143.9 144.2 145.8
JW 133.2 142.3 143.5 141.6 140.5 144.3 135.7 146.3 141.5 150.9 150.4
KW 147.5 149.4 154.1 153.7 152.2 154.0 153.6 152.3 148.0 149.6 149.6
MT 123.6 126.2 122.9 126.4 119.9 125.8 128.5 128.7 122.0 122.9 119.2
NW 140.4 144.7 145.5 145.5 146.1 147.2 146.4 143.1 143.0 147.0 145.0
SD 105.6 109.9 108.0 105.3 104.1 104.7 109.6 107.6 108.8 106.2 109.5
SL 135.7 142.9 143.4 144.0 145.1 143.4 145.9 149.3 141.0 144.9 145.6
200
CARDIAC OUTPUT (l/min) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 22.0 21.0 21.4 21.3 21.5 23.1 22.3 21.4 22.0 22.4 23.0
BA 16.9 17.0 18.3 19.0 19.6 20.0 20.5 20.5 20.0 19.8 20.8
BM 22.0 22.3 23.7 24.2 24.3 24.3 24.4 24.1 24.9 23.4 24.4
DW 18.1 20.8 21.6 22.8 23.8 24.0 23.6 24.3 23.3 24.1 23.8
JG 18.2 19.6 19.3 20.1 21.0 20.3 20.1 19.9 20.7 19.7 21.1
JH 16.7 18.5 19.4 19.9 20.0 21.0 21.5 19.9 21.1 21.5 20.5
JW 21.6 22.8 23.7 25.9 27.1 26.7 27.5 28.0 29.4 32.1 30.5
KW 20.6 21.1 22.2 23.3 23.9 23.6 23.8 23.6 23.4 24.1 24.9
MT 21.2 22.1 23.0 23.4 23.0 22.6 23.6 24.7 24.6 24.5 24.4
NW 19.9 21.7 22.6 22.3 23.4 23.3 23.2 23.8 23.5 24.1 24.3
SD 17.9 17.6 18.6 18.6 18.4 19.1 19.6 19.5 20.5 20.0 19.7
SL 19.8 21.4 22.4 23.2 23.1 24.1 24.2 23.9 24.6 24.3 25.1
CARDIAC OUTPUT (l/min) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 20.4 19.3 19.1 19.8 19.8 20.4 21.2 20.9 21.2 20.5 20.3
BA 16.9 16.8 17.6 18.0 19.3 19.4 19.4 18.6 20.2 20.6 20.4
BM 22.0 23.1 25.3 25.0 25.6 26.2 25.3 25.4 26.7 26.0 24.5
DW 17.7 20.2 21.0 21.6 21.9 22.5 22.5 22.4 22.9 24.2 24.6
JG 20.6 19.9 19.7 22.5 22.5 22.2 21.4 21.5 23.1 22.1 21.7
JH 21.1 22.2 23.5 24.2 25.5 26.3 26.2 26.8 26.8 26.9 27.3
JW 19.4 21.3 22.8 23.2 23.6 24.5 23.4 25.7 25.3 27.6 27.9
KW 22.4 23.5 25.2 26.2 26.3 27.0 27.1 27.1 26.1 26.8 27.2
MT 20.6 21.5 21.3 22.6 21.7 22.9 23.7 23.7 22.5 22.6 22.1
NW 22.1 23.4 24.4 24.8 25.2 25.7 25.7 25.5 25.7 26.7 26.5
SD 17.2 18.1 18.4 18.2 18.2 18.4 19.5 19.1 19.3 18.9 19.5
SL 21.0 22.6 23.4 24.2 24.7 24.8 25.5 26.3 25.0 26.0 26.3
VENTILATION (l/min) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 85.3 85.2 80.3 100.4 98.8 106.8 109.5 121.4 119.2 117.9 116.8
BA 62.1 64.2 70.6 83.0 84.2 97.3 99.8 107.6 116.3 134.7 122.9
BM 72.0 89.2 107.0 124.1 124.3 133.7 138.7 146.6 140.1 141.1 124.2
DW 68.8 75.4 94.3 98.9 106.9 113.9 120.7 121.1 128.3 127.3 128.1
JG 66.2 85.1 106.1 115.7 117.8 120.3 121.0 119.2 125.3 109.0 110.7
JH 64.5 84.8 100.4 107.9 110.9 115.7 113.0 120.0 118.4 107.0 112.7
JW 64.4 77.2 93.3 103.5 113.7 119.8 117.1 124.1 127.6 124.6 126.2
KW 87.0 105.2 121.1 127.0 128.8 136.3 132.1 133.3 140.4 144.4 148.9
MT 67.1 71.7 72.2 86.9 98.4 98.4 98.6 107.2 108.3 109.7 105.4
NW 68.2 84.5 95.8 106.8 107.1 114.5 115.2 115.2 121.9 120.8 105.4
SD 76.3 85.6 89.6 105.1 104.3 104.6 110.9 111.8 110.9 125.9 118.8
VENTILATION (l/min) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 73.4 92.4 103.4 100.9 114.3 121.7 121.3 124.0 126.1 125.3 125.1
BA 67.7 75.1 86.3 87.7 100.5 113.5 125.6 129.9 132.7 146.1 119.1
BM 71.8 89.7 106.9 117.1 120.9 121.6 130.2 133.4 136.7 136.8 128.4
DW 66.2 78.5 101.1 117.9 114.1 124.8 116.2 119.3 121.4 127.9 124.4
JG 78.5 84.5 86.5 104.5 108.4 105.4 112.4 116.8 120.8 128.5 127.3
JH 71.9 95.6 109.1 109.0 119.4 122.6 125.3 125.6 121.5 120.5 121.0
JW 68.5 85.6 93.9 108.8 116.8 121.3 125.6 126.3 123.4 118.8 115.0
KW 120.6 119.5 128.2 135.2 141.5 142.9 145.1 137.7 146.4 149.1 145.5
MT 68.5 73.2 83.3 94.2 95.0 104.0 102.0 94.9 97.1 104.1 103.4
NW 65.6 82.9 95.4 102.5 107.9 109.5 116.6 113.8 116.7 115.3 111.8
SD 82.6 84.5 94.1 100.1 106.5 115.3 118.6 117.6 116.7 119.3 121.8
SL 69.3 78.8 90.9 104.1 114.4 118.9 126.4 128.2 140.1 144.9 145.1
201
OXYGEN CONSUMPTIONS (l/min) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 3712 3763 3593 4019 4049 4084 4163 4375 4367 4341 4330
BA 3298 3443 3683 3839 3902 4020 3850 3951 4039 4303 4134
BM 3248 3667 3871 4148 4145 4257 4328 4404 4183 4088 3663
DW 3116 3426 3802 3843 4016 4116 4157 4188 4289 4145 4138
JG 2979 3528 3939 4090 4156 4132 4122 4118 4065 3707 3646
JH 3241 3786 4023 4193 4294 4431 4405 4559 4486 4235 4360
JW 3286 3637 3867 4098 4370 4427 4335 4646 4589 4373 4493
KW 3962 4413 4833 4987 4914 5187 4911 4964 5151 5320 5285
MT 3237 3308 3111 3536 3891 3878 3828 4301 4216 4401 4145
NW 3545 3971 4120 4615 4663 4715 4403 4356 4787 4596 3862
SD 3587 3881 3808 4334 4169 4101 4228 4303 4220 4749 4497
OXYGEN CONSUMPTION (l/min) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 3147 3830 3949 3910 4138 4196 4217 4242 4278 4281 4263
BA 3090 3544 3805 3782 3968 4089 4371 4319 4116 4301 3896
BM 3122 3376 3571 3687 3945 3990 3903 4051 4152 4128 3896
DW 2979 3395 3898 4082 4070 4242 4028 4163 4038 4186 4143
JG 3340 3433 3270 3808 4051 3841 4021 3998 4096 4391 4317
JH 3295 3818 4135 4173 4357 4491 4512 4495 4350 4495 4422
JW 3555 3940 3896 4520 4702 4781 4909 4842 4787 4615 4482
KW 4392 4482 4948 5100 5253 5304 5330 5128 5179 5185 4872
MT 3369 3323 3660 3732 3852 4004 4051 3659 3823 3961 3832
NW 3486 4006 4228 4367 4444 4470 4488 4441 4395 4175 3871
SD 3906 3891 4171 4316 4366 4612 4528 4564 4563 4573 4633
SL 3140 3367 3533 3708 3899 3986 3924 4084 4194 4085 3923
RESPIRATORY EXCHANGE RATION ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 0.95 0.95 0.98 1.03 1.03 1.06 1.05 1.07 1.05 1.04 1.03
BA 0.84 0.83 0.86 0.80 0.96 0.99 1.03 1.03 1.03 1.04 1.02
BM 0.90 0.96 1.05 1.10 1.07 1.06 1.04 1.04 1.02 1.02 1.02
DW 0.94 0.98 1.08 1.11 1.11 1.09 1.08 1.07 1.05 1.04 1.03
JG 0.91 0.98 1.09 1.08 1.07 1.05 1.03 1.01 1.01 1.01 1.02
JH 0.99 1.10 1.16 1.13 1.08 1.04 1.00 1.00 0.97 0.97 0.97
JW 0.89 0.99 1.09 1.10 1.08 1.07 1.06 1.03 1.06 1.06 1.05
KW 0.91 0.97 1.02 1.01 1.00 0.98 0.97 0.96 0.94 0.97 0.98
MT 0.97 0.99 1.05 1.07 1.08 1.06 1.07 1.05 1.04 1.02 1.02
NW 0.86 0.94 0.98 1.01 0.99 1.02 1.02 1.01 0.98 1.00 1.03
SD 0.87 0.93 0.96 0.94 0.93 0.92 0.91 0.90 0.89 0.89 0.88
RESPIRATORY EXCHANGE RATIO ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 0.92 0.95 1.01 1.01 1.06 1.07 1.06 1.05 1.05 1.04 1.03
BA 0.96 0.89 0.94 1.00 1.01 1.05 1.06 1.08 1.07 1.06 1.06
BM 0.94 0.89 1.07 1.06 1.03 1.02 1.04 1.03 1.00 1.00 0.99
DW 0.91 0.95 1.06 1.11 1.07 1.06 1.04 1.01 1.01 1.01 1.00
JG 0.87 0.90 0.95 0.98 0.95 0.99 0.98 1.00 0.98 0.97 0.98
JH 0.98 1.11 1.12 1.07 1.06 1.02 1.00 0.99 0.96 0.95 0.95
JW 0.87 0.97 1.05 1.05 1.05 1.03 1.01 1.01 0.99 0.99 1.00
KW 0.94 0.95 0.95 0.97 0.99 0.98 0.97 0.96 0.98 0.97 1.00
MT 0.93 0.99 1.04 1.08 1.07 1.06 1.04 1.00 0.98 0.98 0.98
NW 0.87 0.97 1.03 1.03 1.01 0.99 0.99 0.98 0.98 0.99 1.03
SD 0.87 0.91 0.96 0.97 0.99 0.99 1.00 0.96 0.93 0.95 0.96
SL 0.93 0.98 1.07 1.11 1.11 1.08 1.08 1.03 1.04 1.04 1.04
202
CORE TEMPERATURE(ºC) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
BA 37.91 37.91 37.92 37.94 37.95 37.97 37.99 38.01 38.03 38.05 38.07
BM 37.60 37.62 37.65 37.69 37.74 37.79 37.84 37.89 37.94 38.00 38.05
DW 37.71 37.72 37.76 37.81 37.87 37.94 38.02 38.08 38.15 38.23 38.31
JG 37.52 37.54 37.57 37.60 37.63 37.67 37.71 37.74 37.78 37.83 37.88
JH 37.75 37.82 37.88 37.98 38.10 38.25 38.40 38.56 38.74 38.91 39.06
JW 37.65 37.66 37.69 37.73 37.79 37.85 37.92 37.99 38.07 38.14 38.22
KW 37.89 37.93 37.96 38.00 38.03 38.07 38.11 38.14 38.19 38.24 38.29
MT 37.97 38.00 38.02 38.04 38.07 38.10 38.13 38.16 38.19 38.22 38.26
NW 37.51 37.54 37.57 37.63 37.68 37.75 37.83 37.91 37.98 38.07 38.16
SD 37.37 37.40 37.46 37.53 37.60 37.68 37.77 37.85 37.94 38.03 38.12
SL 37.94 37.95 37.98 38.00 38.03 38.07 38.11 38.15 38.20 38.25 38.31
CORE TEMPERATURE(ºC) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 37.93 37.94 37.96 37.98 38.01 38.03 38.06 38.08 38.11 38.13 38.17
BA 38.02 38.03 38.04 38.06 38.08 38.11 38.13 38.16 38.19 38.21 38.24
BM 37.85 37.87 37.91 37.94 37.98 38.03 38.08 38.14 38.20 38.26 38.34
DW 37.39 37.40 37.44 37.49 37.55 37.61 37.68 37.75 37.83 37.91 37.98
JG 37.94 37.95 37.98 38.00 38.03 38.05 38.08 38.10 38.14 38.17 38.20
JH 37.82 37.91 38.00 38.13 38.29 38.46 38.64 38.82 38.97 39.12 39.26
JW 37.68 37.71 37.74 37.80 37.88 37.96 38.05 38.15 38.25 38.34 38.46
KW 37.57 37.61 37.64 37.69 37.74 37.79 37.85 37.91 37.98 38.05 38.12
NW 37.61 37.63 37.67 37.75 37.84 37.95 38.06 38.17 38.27 38.38 38.49
SD 37.40 37.41 37.43 37.46 37.51 37.55 37.60 37.66 37.71 37.77 37.82
SL 37.80 37.81 37.83 37.86 37.89 37.93 37.98 38.03 38.08 38.15 38.22
SKIN TEMPERATURE(ºC) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
BA 32.44 32.43 32.44 32.44 32.44 32.42 32.48 32.60 32.67 32.63 32.52
BM 32.27 32.25 32.24 32.20 32.12 31.99 31.85 31.73 31.65 31.74 31.94
DW 32.43 32.54 32.58 32.48 32.37 32.23 32.12 32.12 32.26 32.42 32.42
JG 32.08 32.01 31.99 32.06 31.98 31.91 32.08 32.33 32.40 32.34 32.31
JH 32.08 32.02 31.96 31.84 31.68 31.48 31.18 31.14 31.37 31.73 31.77
JW 32.64 32.60 32.51 32.39 32.29 32.20 32.06 32.01 31.95 31.91 31.87
KW 31.56 31.61 31.61 31.48 31.33 31.14 31.52 31.65 31.30 31.18 31.18
MT 32.18 32.08 32.05 32.05 32.04 32.05 32.00 31.89 31.74 31.65 31.55
NW 32.50 32.48 32.43 32.38 32.35 32.22 32.07 31.37 31.12 31.44 31.84
SD 31.95 32.14 32.35 32.10 31.68 31.43 31.53 31.87 31.85 31.69 31.43
SL 32.76 32.85 32.90 32.81 32.65 32.57 32.47 32.39 32.34 32.26 32.23
SKIN TEMPERATURE(ºC) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 31.10 31.10 31.02 30.77 30.58 30.36 30.11 30.00 29.88 29.83 29.90
BA 31.51 31.49 31.45 31.49 31.55 31.58 31.62 31.62 31.67 31.86 32.11
BM 31.92 31.89 31.86 31.91 32.00 32.14 32.15 32.06 31.99 31.91 31.82
DW 32.53 32.70 32.79 32.77 32.64 32.46 32.33 32.32 32.56 32.85 32.94
JG 32.52 32.62 32.79 32.95 33.06 33.16 33.26 33.31 33.19 32.97 32.79
JH 32.27 32.37 32.22 32.05 31.85 31.69 31.51 31.11 31.12 31.39 31.39
JW 33.11 33.04 32.83 32.57 32.31 32.18 32.13 31.99 31.92 31.79 31.57
KW 31.78 32.20 32.47 32.23 31.68 31.32 31.48 31.84 32.00 31.96 31.76
NW 31.61 31.84 31.93 31.70 31.48 31.22 31.45 31.82 31.71 31.45 31.24
SD 30.84 30.83 30.74 30.57 30.60 30.75 30.88 30.90 30.83 30.67 30.54
SL 32.58 32.55 32.46 32.35 32.19 32.09 31.90 31.73 31.57 31.42 31.26
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BODY TEMPERATURE(ºC) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
BA 37.20 37.20 37.21 37.22 37.23 37.25 37.27 37.31 37.33 37.34 37.35
BM 36.91 36.92 36.94 36.98 37.01 37.03 37.06 37.09 37.12 37.18 37.26
DW 37.03 37.05 37.09 37.12 37.16 37.20 37.25 37.30 37.39 37.48 37.54
JG 36.81 36.82 36.85 36.88 36.90 36.92 36.98 37.04 37.08 37.12 37.16
JH 37.01 37.06 37.11 37.18 37.27 37.37 37.46 37.60 37.79 37.97 38.11
JW 37.00 37.00 37.02 37.04 37.07 37.11 37.15 37.21 37.27 37.33 37.40
KW 37.07 37.11 37.14 37.15 37.16 37.17 37.25 37.30 37.30 37.32 37.37
MT 37.22 37.23 37.25 37.26 37.28 37.31 37.33 37.34 37.35 37.36 37.38
NW 36.86 36.88 36.90 36.95 36.99 37.03 37.08 37.06 37.09 37.21 37.34
SD 36.66 36.72 36.80 36.82 36.83 36.87 36.96 37.08 37.15 37.21 37.25
SL 37.27 37.29 37.32 37.33 37.33 37.35 37.38 37.40 37.44 37.47 37.52
BODY TEMPERATURE(ºC) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
AW 37.04 37.05 37.06 37.04 37.04 37.03 37.02 37.03 37.04 37.05 37.09
BA 37.18 37.18 37.19 37.21 37.23 37.26 37.29 37.31 37.34 37.39 37.44
BM 37.07 37.09 37.12 37.16 37.21 37.26 37.31 37.35 37.39 37.44 37.49
DW 36.75 36.79 36.84 36.88 36.91 36.94 36.98 37.04 37.14 37.25 37.33
JG 37.23 37.26 37.30 37.34 37.38 37.41 37.45 37.48 37.49 37.49 37.50
JH 37.10 37.19 37.25 37.34 37.45 37.58 37.71 37.82 37.95 38.11 38.24
JW 37.09 37.10 37.10 37.12 37.16 37.21 37.28 37.35 37.42 37.49 37.56
KW 36.82 36.90 36.97 36.98 36.95 36.95 37.02 37.12 37.20 37.26 37.29
NW 36.83 36.88 36.93 36.96 37.02 37.08 37.20 37.34 37.42 37.48 37.54
SD 36.54 36.56 36.56 36.57 36.61 36.67 36.73 36.78 36.81 36.84 36.88
SL 37.12 37.12 37.14 37.14 37.15 37.17 37.19 37.21 37.24 37.28 37.32
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OXYGEN SATURATION (%) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 60.1 60.5 59.8 60.0 60.1 59.4 59.2 59.0 59.1 58.0 58.0
JH 53.7 50.7 49.4 51.0 51.8 51.7 54.0 54.6 53.6 52.9 53.9
KW 54.7 55.8 56.4 57.3 57.0 57.3 56.1 54.5 54.5 53.9 53.1
MT 69.8 68.6 68.2 69.3 66.8 66.0 65.2 65.2 64.9 65.1 64.3
SD 55.8 54.8 55.2 54.1 53.5 52.9 52.2 52.3 50.3 49.2 50.4
OXYGEN SATURATION (%) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 59.5 57.4 57.2 56.4 55.6 54.7 54.7 54.6 53.1 53.4 52.1
JH 54.3 53.5 54.4 55.3 53.2 51.4 52.3 52.3 52.1 52.2 51.4
KW 64.5 64.2 65.3 64.4 65.0 64.7 65.3 66.1 65.8 64.3 64.3
MT 69.3 69.7 69.2 69.5 69.5 69.5 69.9 69.7 68.7 69.0 68.9
SD 67.0 65.7 65.3 64.7 65.2 63.9 64.0 63.4 62.7 61.3 61.4
TOTAL HEMOGLOBIN CONTENT (µm) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 72.6 72.0 72.1 71.5 71.8 72.0 71.2 71.7 72.6 71.5 72.0
JH 65.4 64.8 64.4 65.5 65.3 65.7 66.3 66.8 66.5 66.4 67.0
KW 58.9 59.3 59.3 59.4 59.4 59.5 58.7 57.7 58.0 58.7 60.8
MT 59.5 59.3 59.2 59.5 59.2 57.7 57.7 58.6 59.2 59.0 58.9
SD 64.5 64.8 65.8 64.9 64.9 65.6 66.0 65.8 65.5 65.3 66.3
TOTAL HEMOGLOBIN CONTENT (µm) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 69.6 68.4 67.9 68.3 67.6 66.3 66.9 66.9 65.2 64.7 64.9
JH 62.2 62.8 63.9 65.2 63.7 63.3 64.4 64.1 64.4 65.1 65.5
KW 67.4 67.5 69.1 68.7 69.4 68.8 68.5 69.1 69.6 69.9 70.8
MT 58.8 58.8 58.4 57.9 59.0 58.0 59.1 58.4 59.7 59.3 59.9
SD 75.6 74.8 74.7 74.4 74.6 73.5 73.6 74.7 75.2 74.4 74.7
OXYGENATED HEMOGLOBIN (µm) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 43.6 43.6 43.1 42.9 43.2 42.7 42.2 42.3 42.9 41.5 41.7
JH 35.1 32.9 31.8 33.4 33.8 34.0 35.8 36.5 35.6 35.1 36.1
KW 32.2 33.1 33.5 34.1 33.9 34.1 33.0 31.4 31.6 31.6 32.2
MT 41.5 40.7 40.4 41.2 39.5 38.1 37.6 38.1 38.4 38.4 37.9
SD 36.0 35.5 36.3 35.1 34.7 34.7 34.4 34.4 33.0 32.1 33.4
OXYGENATED HEMOGLOBIN (µm) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 41.4 39.2 38.9 38.5 37.6 36.3 36.6 36.5 34.6 34.5 33.8
JH 33.7 33.6 34.7 36.0 33.9 32.5 33.7 33.5 33.5 33.9 33.7
KW 43.5 43.3 45.1 44.2 45.0 44.6 44.7 45.7 45.9 45.0 45.5
MT 40.7 40.9 40.4 40.3 41.0 40.3 41.3 40.7 41.0 40.9 41.2
SD 50.6 49.2 48.8 48.1 48.6 46.9 47.1 47.3 47.2 45.6 45.9
DEOXYGENATED HEMOGLOBIN (µm) ‐ PLACEBO; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 28.9 28.5 29.0 28.6 28.6 29.2 29.0 29.4 29.7 30.0 30.3
JH 30.3 31.9 32.6 32.1 31.5 31.7 30.5 30.3 30.9 31.3 30.9
KW 26.7 26.2 25.9 25.4 25.5 25.4 25.8 26.3 26.4 27.1 28.6
MT 18.0 18.6 18.8 18.3 19.7 19.6 20.1 20.4 20.8 20.6 21.0
SD 28.5 29.3 29.4 29.8 30.2 30.9 31.6 31.4 32.6 33.2 32.9
DEOXYGENATED HEMOGLOBIN (µm) ‐ POMS; DAY ‐ 2
TIME 0 10 20 30 40 50 60 70 80 90 100
JG 28.2 29.2 29.1 29.8 30.0 30.0 30.3 30.4 30.6 30.1 31.1
JH 28.5 29.2 29.2 29.2 29.8 30.8 30.7 30.6 30.8 31.1 31.8
KW 23.9 24.2 24.0 24.5 24.3 24.3 23.8 23.4 23.8 24.9 25.3
MT 18.1 17.9 18.0 17.7 18.0 17.6 17.8 17.7 18.7 18.4 18.7
SD 25.0 25.6 25.9 26.3 26.0 26.6 26.5 27.4 28.0 28.8 28.8
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TIME TO FATIGUE ‐ DAY2















Subject  PLACEBO POMS PLACEBO POMS PLACEBO POMS
AW 1840.2 1804.8 1120.8 1111.6 123.2 123.7
BA 1985.0 1847.9 1238.9 1166.3 118.2 116.4
BM 1431.2 1443.7 882.7 877.2 109.0 115.5
DW 1838.5 1681.9 1109.1 1012.2 110.5 114.7
JG 1891.2 1852.5 1131.6 1122.8 128.8 128.6
JH 2129.2 2042.6 1225.6 1200.7 120.9 104.5
JW 2114.0 2514.2 1249.9 1444.5 118.4 103.4
KW 2749.0 2868.4 1759.6 1838.9 107.8 109.6
MT 1731.7 1760.7 1104.9 1055.5 139.7 127.1
NW 2008.3 1969.1 1283.1 1223.9 115.5 121.3
SD 2385.7 2550.2 1395.5 1491.1 126.5 120.0





















% VO2max rest 40 50 60 70 80 90 100
RDS 0 141 188 236 283 330 378 425
AS 0 135 178 222 265 308 352 395
TT 0 125 165 204 244 284 323 363
RD 0 112 150 187 224 261 298 335
FC 0 127 168 208 244 290 330 371
DC 0 158 205 252 300 346 393 440
JL 0 127 168 208 249 289 330 370
DG 0 138 181 224 270 320 353 396
JH 0 110 145 180 215 250 285 320
TB 0 144 189 235 280 325 370 415
RECTAL TEMPERATURE (ºC)
% VO2max rest 40 50 60 70 80 90 100
RDS 36.87 37.03 37.34 37.56 37.75 37.94 37.99 37.93
AS 37.52 37.54 37.72 38.00 38.21 38.84 38.66 38.65
TT 37.01 37.03 37.30 37.54 37.70 38.22 38.22 38.28
RD 37.47 37.51 37.63 37.79 37.93 38.13 38.06 38.14
FC 37.36 37.33 37.54 37.85 38.07 38.44 38.46 38.55
DC 37.02 37.04 37.25 37.51 37.66 37.95 37.85 37.90
JL 37.28 37.29 37.45 37.64 37.81 38.03 37.81 38.01
DG 37.64 37.61 37.72 37.95 38.17 38.20 38.49 38.66
JH 36.94 36.90 37.01 37.29 37.53 38.08 38.08 38.25
TB 37.15 37.15 37.38 37.64 37.83 38.19 38.03 38.20
OXYGEN CONSUMPTION (l/min)
% VO2max rest 40 50 60 70 80 90 100
RDS 0.422 2.070 2.510 3.000 3.444 4.075 4.456 4.875
AS 0.531 2.146 2.602 3.058 3.524 4.376 4.640 4.846
TT 0.441 2.192 2.560 2.896 3.456 3.784 4.258 4.580
RD 0.356 1.878 2.158 2.603 3.099 3.633 3.816 4.128
FC 0.382 1.774 2.186 2.646 3.059 3.606 3.974 4.332
DC 0.371 2.106 2.574 2.950 3.590 4.284 4.517 4.815
JL 0.433 1.912 2.280 2.665 3.157 3.672 4.283 4.415
DG 0.437 1.960 2.491 2.902 3.415 4.313 4.364 4.741
JH 0.380 1.859 2.201 2.593 3.002 3.336 3.581 3.749
TB 0.404 2.077 2.453 2.897 3.376 4.063 4.244 4.590
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VENTILATION (l/min)
% VO2max rest 40 50 60 70 80 90 100
RDS 13.5 47.4 56.5 67.3 80.1 105.8 119.9 138.0
AS 21.0 58.5 71.0 83.7 100.3 148.7 163.6 183.4
TT 17.2 53.6 63.8 72.6 90.3 104.5 127.7 152.0
RD 12.4 50.6 60.9 81.4 103.2 143.3 142.2 162.8
FC 13.5 41.2 50.0 61.1 72.2 92.2 110.8 133.1
DC 14.3 51.3 62.7 71.7 89.5 112.9 120.4 133.0
JL 13.9 44.0 52.0 59.1 70.8 95.4 130.8 145.2
DG 20.1 47.4 61.2 70.4 85.1 140.3 135.9 164.5
JH 15.9 47.5 58.1 69.4 85.9 108.4 132.0 146.6
TB 14.1 49.2 56.7 67.2 77.9 98.4 105.5 124.4
HEART RATE (bpm)
% VO2max rest 40 50 60 70 80 90 100
RDS 75.2 122.5 136.7 149.2 161.6 173.1 176.9 183.8
AS 64.1 116.1 128.6 137.6 147.4 165.3 170.5 174.5
TT 53.5 113.0 128.7 140.7 157.0 172.2 180.3 187.4
RD 71.1 113.3 122.1 132.8 146.8 180.4 176.1 191.7
FC 85.2 130.3 138.3 148.7 155.2 168.3 173.8 180.7
DC 53.2 102.3 107.7 115.8 130.8 154.9 156.2 163.9
JL 73.5 115.0 124.2 134.3 147.7 164.7 173.5 176.3
DG 76.6 119.3 129.0 138.2 150.6 177.0 173.1 186.5
JH 88.0 127.0 139.5 147.3 156.8 169.7 174.8 179.6
TB 54.8 102.9 112.0 120.5 133.3 156.6 156.8 166.5
CARDIAC OUTPUT (l/min)
% VO2max rest 40 50 60 70 80 90 100
RDS 7.4 17.9 20.6 21.8 23.9 25.2 27.4 29.3
AS 7.9 17.6 20.0 21.7 23.1 26.0 26.4 27.7
TT 7.1 15.8 20.0 20.5 23.9 24.3 24.3 26.6
RD 7.1 13.1 15.8 17.6 21.6 22.7 23.2 22.0
FC 9.9 17.4 19.1 20.9 22.5 23.7 24.0 24.6
DC 7.7 17.5 19.4 21.4 23.9 25.6 26.0 24.5
JL 7.8 14.6 16.3 17.9 19.7 21.6 22.9 23.1
DG 7.3 15.8 17.4 18.7 20.0 21.3 21.8 23.2
JH 6.7 14.8 16.8 17.9 19.8 19.7 20.7 20.6
TB 6.8 15.6 17.0 18.5 20.4 20.9 21.9 24.1
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STROKE VOLUME (ml/beat)
% VO2max rest 40 50 60 70 80 90 100
RDS 99.8 146.9 151.0 146.8 147.9 145.4 155.0 159.4
AS 123.7 151.8 155.3 157.9 156.9 157.5 155.0 158.9
TT 133.7 138.6 156.1 146.6 152.8 141.5 135.1 142.1
RD 99.8 116.5 129.6 132.9 147.0 126.0 131.4 115.1
FC 116.0 133.4 138.3 140.5 145.2 141.2 137.9 136.1
DC 145.5 171.5 179.8 184.8 183.0 165.3 166.7 149.6
JL 106.1 126.8 131.6 133.2 133.7 131.3 131.9 131.1
DG 95.6 132.4 134.5 135.4 133.1 121.2 126.3 124.5
JH 75.9 116.4 120.7 121.7 126.2 116.3 118.3 115.2
TB 123.8 151.7 151.4 153.6 152.7 133.4 141.1 144.6
ARTERIAL ‐ VENOUS OXYGEN DIFFERENCE (ml/dl)
% VO2max rest 40 50 60 70 80 90 100
RDS 5.7 11.5 12.2 13.8 14.4 16.2 16.3 16.5
AS 6.7 12.2 13.1 14.1 15.2 16.9 17.6 17.5
TT 6.2 14.6 12.8 14.2 14.5 15.6 17.6 17.3
RD 5.0 14.7 13.7 14.8 14.4 16.2 16.5 19.5
FC 3.9 10.2 11.4 12.7 13.6 15.3 16.6 17.6
DC 4.8 12.0 13.3 13.8 15.0 16.8 17.4 19.8
JL 5.6 13.1 14.0 14.9 16.0 17.0 18.8 19.2
DG 6.0 12.4 14.4 15.5 17.0 20.2 20.0 20.5
JH 5.7 12.6 13.1 14.5 15.2 16.9 17.4 18.3
TB 6.0 13.3 14.5 15.7 16.6 19.5 19.2 19.1
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BASELINE DEOXYGENATED HEMOGLOBIN  (µm) ‐ VASTUS LATERALIS
% VO2max 40 50 60 70 80 90 100
RDS 17.4 17.4 17.6 17.3 16.8 17.6 16.5
AS 45.0 44.3 45.2 45.4 47.8 46.1 45.6
TT 34.2 34.8 33.8 34.0 32.5 31.8 32.7
RD 40.1 39.4 40.7 40.2 42.9 41.3 42.6
FC 38.6 38.6 38.0 39.3 39.4 39.7 40.0
DC 28.0 27.3 28.0 28.8 27.8 28.2 27.8
JL 35.3 34.9 35.9 35.0 37.8 38.6 38.2
JH 44.5 43.3 44.0 46.2 48.4 48.5 49.5
TB 37.0 37.0 37.3 36.6 39.6 37.6 38.9
NORMALIZED DEOXYGENATED HEMOGLOBIN (%) ‐ VASTUS LATERALIS
% VO2max 40 50 60 70 80 90 100
RDS 42.1 47.8 69.3 90.6 94.7 81.7 100.0
AS 19.7 33.4 51.6 71.7 85.8 100.0 99.7
TT 27.8 45.7 69.2 82.7 90.9 100.0 90.4
RD 26.6 48.4 55.8 80.6 86.9 94.5 100.0
FC 46.1 50.3 71.2 80.7 95.7 93.2 100.0
DC 35.5 52.7 65.9 56.3 76.2 81.8 100.0
JL 37.0 55.0 70.1 89.5 89.8 100.0 97.0
JH 14.6 28.9 45.6 63.1 82.6 93.6 100.0
TB 29.8 47.5 60.6 78.4 85.9 100.0 70.4
NORMALIZED CAPILLARY BLOOD FLOW (%) ‐ VASTUS LATERALIS
% VO2max 40 50 60 70 80 90 100
RDS 51.5 61.2 67.8 72.7 85.0 96.8 100.0
AS 60.4 68.9 75.2 80.2 94.7 95.6 100.0
TT 60.6 65.8 68.1 77.5 82.5 90.1 100.0
RD 63.6 65.3 76.1 81.2 92.7 94.5 100.0
FC 50.1 60.6 67.6 75.5 84.5 93.9 100.0
DC 58.1 65.0 70.1 89.2 97.1 100.0 98.9
JL 56.2 61.5 67.3 73.6 85.5 95.9 100.0
JH 71.2 78.6 85.7 92.2 94.9 97.7 100.0
TB 54.7 59.2 65.9 71.1 83.1 82.1 100.0
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BASELINE DEOXYGENATED HEMOGLOBIN  (µm) ‐ GASTROCNEMIUS
% VO2max 40 50 60 70 80 90 100
RDS 7.2 7.2 7.5 7.4 7.2 6.9 7.3
AS 26.1 25.7 26.8 25.7 29.7 28.2 27.5
TT 11.5 11.3 11.6 11.4 11.4 11.6 10.9
RD 23.7 23.7 23.5 23.9 24.1 24.1 24.3
FC 30.8 31.1 30.5 30.7 33.3 34.2 33.9
DC 16.1 16.4 15.8 16.2 18.1 16.8 16.6
JL 14.6 14.3 14.5 15.0 16.9 18.2 16.8
JH 21.3 20.9 21.4 21.6 23.1 23.8 22.2
TB 18.9 17.8 19.5 19.3 23.5 21.4 18.1
NORMALIZED DEOXYGENATED HEMOGLOBIN (%) ‐ GASTROCNEMIUS
% VO2max 40 50 60 70 80 90 100
RDS 27.0 71.9 63.2 81.8 95.2 100.0 86.1
AS 53.4 56.6 75.6 94.2 75.7 95.4 100.0
TT 40.5 38.9 52.4 71.3 79.5 83.2 100.0
RD 44.3 44.1 57.0 58.8 81.5 86.0 100.0
FC 47.1 43.1 60.1 86.9 89.3 84.1 100.0
DC 59.7 53.4 71.6 73.0 94.6 89.3 100.0
JL 53.7 58.2 60.9 67.6 67.8 78.9 100.0
JH 43.1 58.0 65.8 71.4 72.4 73.4 100.0
TB 2.6 56.8 53.0 76.6 84.7 97.6 100.0
NORMALIZED DEOXYGENATED HEMOGLOBIN (%) ‐ GASTROCNEMIUS
% VO2max 40 50 60 70 80 90 100
RDS 52.2 53.9 66.3 71.6 81.3 87.6 100.0
AS 52.4 62.8 68.7 74.1 98.3 97.2 100.0
TT 59.4 69.8 74.9 83.3 88.5 98.4 100.0
RD 58.0 66.7 75.7 89.3 94.8 97.7 100.0
FC 49.8 62.5 70.6 73.9 86.4 96.9 100.0
DC 52.1 65.5 69.0 83.5 90.9 97.9 100.0
JL 49.8 58.2 67.2 77.3 89.9 100.0 94.8
JH 58.9 65.4 74.6 84.5 93.5 100.0 94.8
TB 71.5 63.8 76.7 80.7 93.9 93.3 100.0
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APPENDIX L 



















TIME 0 5 10 15 20 30 40 50 60
AP 68.0 132.4 138.0 137.8 145.1 142.6 143.1 146.6 154.3
AT 83.5 142.2 162.3 162.9 164.2 168.6 170.8 171.2 172.6
CC 77.7 146.6 154.1 155.1 156.1 157.1 161.8 159.9 163.6
DD 62.0 111.1 120.2 123.2 122.3 131.0 135.9 136.8 137.4
JC 68.1 115.6 121.7 127.8 125.6 134.0 137.2 139.3 142.7
JK 63.8 123.4 130.4 133.5 137.3 140.5 140.7 142.6 144.0
JM 80.8 134.7 142.0 144.6 148.8 152.5 153.7 160.3 161.4
JR 75.3 128.5 138.4 143.7 148.0 152.2 157.0 159.1 160.0
MC 69.1 135.6 148.1 152.8 155.0 159.0 161.3 162.7 163.2
TT 77.3 137.2 142.6 144.5 146.9 150.1 154.3 155.6 156.9
NY 75.1 123.8 130.1 132.5 134.6 137.0 140.1 142.8 144.6
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 65.2 129.7 131.7 129.9 127.0 131.2 129.8 131.9 130.0
AT 86.6 153.0 159.0 159.3 160.4 154.5 156.8 157.2 156.9
CC 75.0 143.8 147.1 147.3 146.2 144.7 144.0 142.4 141.6
DD 63.7 112.2 116.7 117.2 114.6 112.3 113.9 114.5 113.8
JC 66.0 122.5 127.4 130.5 129.1 128.8 130.8 131.0 134.7
JK 67.9 129.5 135.6 133.6 130.9 130.7 128.5 129.8 128.3
JM 81.4 130.1 136.9 139.1 139.2 138.6 137.9 140.6 140.0
JR 63.8 116.1 125.0 125.6 125.4 125.7 123.6 123.3 124.7
MC 65.1 133.0 139.2 143.2 137.5 139.5 135.3 132.9 134.4
TT 72.7 137.1 142.5 142.3 143.5 150.7 150.0 149.4 152.3
NY 73.1 128.0 129.9 129.8 131.9 128.1 134.6 132.3 131.7
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 68.2 130.3 138.5 143.6 150.8 155.7 160.3 165.0 171.8
AT 84.1 155.3 167.8 175.2 178.2 185.8 190.9 194.5 197.6
CC 85.3 153.4 164.4 168.1 171.7 174.7 181.7 183.0 183.8
DD 65.5 115.3 129.8 135.0 142.8 150.3 159.9 163.8 166.3
JC 74.4 123.5 138.3 144.5 153.0 159.0 171.1 175.9 182.9
JK 82.1 134.2 150.6 154.5 158.7 161.5 168.8 174.8 176.7
JM 80.7 138.2 152.4 160.8 163.9 177.3 184.1 188.3 193.4
JR 69.6 141.8 150.7 156.6 158.7 166.7 169.4 172.4 173.9
MC 69.0 134.3 149.8 153.3 156.2 166.9 171.4 176.5 177.0
TT 82.3 144.9 156.1 155.9 162.3 173.5 170.5 171.5 175.6
NY 76.4 134.5 142.5 150.5 155.7 168.4 171.6 179.5 182.5
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 68.9 130.5 135.7 133.8 135.2 135.2 137.1 140.5 143.3
AT 89.1 166.7 171.2 171.2 170.5 173.0 174.4 172.0 178.3
CC 85.0 152.5 163.3 165.3 166.9 164.3 166.2 164.5 164.9
DD 72.0 117.3 126.0 126.4 127.6 130.0 127.5 131.5 133.2
JC 70.0 125.0 140.6 142.3 142.9 145.8 154.5 155.6 159.4
JK 78.3 132.4 143.4 144.1 144.4 140.8 143.4 145.6 149.2
JM 81.6 136.6 146.8 153.4 154.1 154.5 160.5 159.4 159.7
JR 63.8 122.7 128.4 130.0 135.1 140.0 136.8 139.6 140.1
MC 66.1 136.6 147.4 150.0 152.6 152.7 146.7 144.6 147.3
TT 77.1 143.3 146.9 149.7 153.7 159.1 156.0 166.9 167.4




TIME 0 5 10 15 20 30 40 50 60
AP 90.4 135.2 141.7 136.2 141.2 140.6 132.4 135.5 122.8
AT 94.1 129.5 114.2 122.3 121.5 113.7 107.6 108.0 111.9
CC 103.3 124.7 120.0 121.1 117.8 123.4 113.4 121.5 119.5
DD 95.2 150.6 143.2 132.5 139.3 135.7 126.3 125.3 116.9
JC 104.9 160.3 164.6 153.3 154.9 151.5 152.9 148.5 146.1
JK 111.2 131.0 123.7 114.2 114.8 115.4 120.7 125.4 110.8
JM 75.3 108.8 110.7 108.9 107.6 105.1 101.4 97.0 96.2
JR 99.1 150.4 140.2 143.5 141.0 137.8 133.1 138.3 136.1
MC 133.3 168.5 152.6 144.4 147.7 146.0 143.0 141.3 140.5
TT 88.2 144.1 130.8 137.9 136.8 136.2 132.4 130.1 129.3
NY 72.5 134.9 141.7 132.7 124.6 128.3 124.6 128.8 123.6
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 96.0 134.4 133.0 127.1 142.9 131.1 144.7 131.4 124.3
AT 85.6 124.8 113.3 123.1 116.8 131.1 118.7 115.8 128.3
CC 114.0 137.7 132.7 131.6 132.8 136.9 141.5 145.5 142.8
DD 87.7 137.8 127.8 144.0 130.9 133.2 138.2 129.7 125.9
JC 103.7 146.2 146.5 133.5 146.5 149.5 149.7 159.5 158.3
JK 97.9 125.2 114.2 121.9 120.7 119.0 124.8 128.8 130.4
JM 78.3 130.3 125.6 117.4 126.0 127.7 116.6 118.3 117.9
JR 99.4 160.0 166.2 165.6 168.0 179.5 175.6 167.0 178.7
MC 142.8 159.3 143.9 146.2 161.4 168.3 162.2 163.2 175.6
TT 98.8 144.7 140.9 129.9 131.8 134.9 142.9 142.7 124.3
NY 82.0 132.5 133.9 135.5 130.3 145.3 123.8 133.7 130.1
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 92.2 133.6 128.1 139.7 125.9 115.8 122.6 124.3 107.0
AT 90.9 120.0 114.8 112.8 102.3 104.5 104.0 102.9 91.3
CC 95.9 122.2 120.2 115.5 118.8 122.1 117.4 120.8 118.5
DD 96.5 142.7 134.2 126.7 126.2 115.0 107.1 104.2 97.0
JC 94.7 164.0 143.1 145.2 129.5 138.6 130.6 125.8 125.3
JK 89.0 115.5 118.5 111.3 116.4 113.3 107.8 101.8 101.4
JM 78.3 125.2 113.6 112.9 102.6 101.5 101.2 93.6 95.7
JR 95.2 145.8 145.5 142.6 144.8 139.5 135.7 130.4 126.8
MC 129.6 165.9 156.4 146.3 146.9 139.7 146.0 143.3 130.5
TT 87.1 156.3 116.3 125.5 121.6 108.6 121.2 116.5 123.5
NY 81.7 139.4 122.0 126.8 122.0 111.2 108.2 105.2 102.0
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 97.0 134.0 139.0 141.5 142.1 152.8 148.0 148.4 141.5
AT 92.3 118.0 105.0 125.6 118.8 119.0 116.9 119.4 122.3
CC 96.9 122.9 130.1 128.4 126.2 125.7 123.2 134.9 130.6
DD 96.4 128.3 120.8 139.3 125.9 135.4 144.0 129.2 120.7
JC 97.7 158.4 141.5 142.2 135.3 143.4 137.5 139.8 134.2
JK 94.3 131.6 126.9 128.5 132.2 129.1 135.7 130.1 126.6
JM 73.3 101.4 94.6 93.2 95.4 101.9 94.8 95.6 99.8
JR 111.3 196.8 167.1 175.7 166.6 162.9 163.7 172.2 177.5
MC 144.2 158.0 164.4 161.1 154.9 166.8 160.4 175.8 160.2
TT 91.4 134.8 122.3 129.6 124.8 125.2 122.2 115.3 115.6




TIME 0 5 10 15 20 30 40 50 60
AP 6.2 17.9 19.6 18.8 20.5 20.1 19.0 19.9 19.0
AT 7.9 18.4 18.5 19.9 20.0 19.2 18.4 18.5 19.3
CC 8.0 18.3 18.5 18.8 18.4 19.4 18.4 19.4 19.5
DD 5.9 16.7 17.2 16.3 17.0 17.8 17.2 17.2 16.1
JC 7.1 18.5 20.0 19.6 19.5 20.3 21.0 20.7 20.8
JK 7.1 16.2 16.1 15.3 15.8 16.2 17.0 17.9 16.0
JM 6.1 14.7 15.7 15.8 16.0 16.0 15.6 15.6 15.5
JR 7.5 19.3 19.4 20.6 20.9 21.0 20.9 22.0 21.8
MC 9.2 22.9 22.6 22.1 22.9 23.2 23.1 23.0 22.9
TT 6.8 19.8 18.7 19.9 20.1 20.4 20.4 20.2 20.3
NY 5.4 16.7 18.4 17.6 16.8 17.6 17.5 18.4 17.9
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 6.3 17.4 17.5 16.5 18.2 17.2 18.8 17.3 16.2
AT 7.4 19.1 18.0 19.6 18.7 20.3 18.6 18.2 20.1
CC 8.6 19.8 19.5 19.4 19.4 19.8 20.4 20.7 20.2
DD 5.6 15.5 14.9 16.9 15.0 15.0 15.7 14.9 14.3
JC 6.8 17.9 18.7 17.4 18.9 19.3 19.6 20.9 21.3
JK 6.6 16.2 15.5 16.3 15.8 15.6 16.0 16.7 16.7
JM 6.4 16.9 17.2 16.3 17.5 17.7 16.1 16.6 16.5
JR 6.3 18.6 20.8 20.8 21.1 22.6 21.7 20.6 22.3
MC 9.3 21.2 20.0 20.9 22.2 23.5 22.0 21.7 23.6
TT 7.1 19.8 20.1 18.5 18.9 20.3 21.4 21.3 18.9
NY 6.0 17.0 17.4 17.6 17.2 18.6 16.7 17.7 17.1
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 6.3 17.4 17.7 20.1 19.0 18.0 19.7 20.5 18.4
AT 7.7 18.6 19.3 19.8 18.2 19.4 19.9 20.0 18.0
CC 8.2 18.8 19.8 19.4 20.4 21.3 21.3 22.1 21.8
DD 6.3 16.5 17.4 17.1 18.0 17.3 17.1 17.1 16.1
JC 7.1 20.3 19.8 21.0 19.8 22.0 22.4 22.1 22.9
JK 7.3 15.5 17.9 17.2 18.5 18.3 18.2 17.8 17.9
JM 6.3 17.3 17.3 18.2 16.8 18.0 18.6 17.6 18.5
JR 6.6 20.7 21.9 22.3 23.0 23.2 23.0 22.5 22.1
MC 8.9 22.3 23.4 22.4 22.9 23.3 25.0 25.3 23.1
TT 7.2 22.6 18.2 19.6 19.7 18.8 20.7 20.0 21.7
NY 6.2 18.8 17.4 19.1 19.0 18.7 18.6 18.9 18.6
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 6.7 17.5 18.9 18.9 19.2 20.7 20.3 20.9 20.3
AT 8.2 19.7 18.0 21.5 20.3 20.6 20.4 20.5 21.8
CC 8.2 18.7 21.2 21.2 21.1 20.7 20.5 22.2 21.6
DD 6.9 15.0 15.2 17.6 16.1 17.6 18.4 17.0 16.1
JC 6.8 19.8 19.9 20.2 19.3 20.9 21.2 21.8 21.4
JK 7.4 17.4 18.2 18.5 19.1 18.2 19.5 19.0 18.9
JM 6.0 15.0 15.4 15.9 15.2 15.6 15.5 16.2 16.4
JR 7.1 24.2 21.5 22.8 22.5 22.8 22.4 24.0 24.9
MC 9.5 21.6 24.2 24.2 23.6 25.5 23.5 25.4 23.6
TT 7.0 19.3 18.0 19.4 19.2 19.9 19.1 19.2 19.4




TIME 0 5 10 15 20 30 40 50 60
AP 14.14 6.09 5.88 5.33 5.01 5.03 5.31 5.22 5.11
AT 13.08 6.08 5.77 5.57 5.89 5.79 6.22 6.25 5.86
CC 12.19 5.29 5.20 5.35 5.31 4.56 4.72 5.14 4.72
DD 13.26 6.34 6.93 6.52 6.35 6.05 5.90 5.76 6.60
JC 12.55 5.16 4.89 4.72 5.05 4.69 4.97 5.13 4.72
JK 13.57 6.45 7.12 6.79 6.43 6.41 5.71 5.56 5.55
JM 17.73 7.83 7.45 6.77 7.31 7.23 6.87 6.89 6.53
JR 13.24 6.92 5.72 5.36 5.55 5.14 5.20 5.75 5.23
MC 9.71 5.01 4.76 4.92 4.82 4.45 4.75 4.97 4.43
TT 14.20 5.66 5.81 5.19 5.51 5.69 5.05 5.24 4.72
NY 15.73 5.98 6.07 6.23 5.94 5.49 5.59 5.86 5.30
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 13.74 5.81 5.71 5.86 5.45 5.48 4.92 5.67 5.61
AT 13.73 6.40 5.92 5.94 5.85 5.65 6.20 6.22 5.34
CC 11.97 5.23 5.25 5.34 5.20 4.91 4.48 4.62 4.22
DD 16.17 6.66 6.97 6.68 6.92 6.36 6.02 6.42 6.11
JC 14.34 5.73 5.69 6.22 5.73 5.42 5.37 4.70 4.57
JK 14.29 7.33 7.98 6.85 7.22 6.84 6.45 6.54 6.11
JM 16.70 6.83 6.99 7.34 6.90 6.17 6.29 6.30 6.06
JR 17.24 6.41 6.02 6.00 5.51 5.21 4.98 4.83 4.59
MC 10.83 5.22 6.18 5.92 5.70 5.70 5.55 5.37 5.78
TT 12.16 5.45 4.90 5.22 5.42 4.61 4.15 4.83 4.77
NY 15.21 6.00 6.36 5.69 5.62 5.69 6.11 5.92 6.31
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 14.14 6.09 5.88 5.33 5.01 5.03 5.31 5.22 5.11
AT 12.66 6.06 4.79 5.09 5.66 4.92 5.23 4.35 5.37
CC 12.07 5.19 5.38 5.20 5.30 5.42 4.41 4.37 4.36
DD 15.34 6.55 5.87 5.84 6.00 5.42 5.69 5.57 5.90
JC 13.61 4.64 4.43 4.21 4.36 3.94 3.84 3.95 3.81
JK 13.12 6.57 6.29 5.87 5.81 5.52 5.24 5.90 5.39
JM 14.81 5.97 5.96 5.51 6.09 5.48 5.25 5.35 5.19
JR 14.80 5.28 5.45 5.02 4.54 4.94 4.74 4.60 4.55
MC 10.52 4.83 5.02 4.75 4.59 4.56 4.16 4.38 4.09
TT 13.56 4.94 5.62 5.31 5.40 5.12 4.45 4.50 4.50
NY 14.80 5.51 6.31 5.83 5.91 5.59 5.24 5.19 4.90
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 12.72 5.41 4.92 5.05 5.12 4.41 4.73 5.33 4.62
AT 11.77 5.18 5.98 4.99 5.40 4.94 4.98 4.92 4.66
CC 12.65 4.85 4.83 4.88 4.62 4.32 4.46 4.35 4.19
DD 12.05 6.71 6.30 5.83 5.51 5.65 5.70 5.64 5.94
JC 13.49 4.73 4.70 4.45 4.56 3.85 3.88 3.91 3.73
JK 13.56 6.27 5.96 5.47 5.50 5.85 5.09 5.05 5.06
JM 16.51 7.54 7.12 6.88 6.75 6.38 6.18 5.05 5.47
JR 12.81 4.48 5.35 4.97 7.26 4.81 4.42 3.90 3.89
MC 10.31 4.73 4.46 4.20 4.35 4.13 4.15 4.12 4.26
TT 13.59 5.10 5.28 5.15 4.94 4.65 4.74 4.27 4.16




TIME 0 5 10 15 20 30 40 50 60
AP 35.80 35.74 36.01 36.37 36.56 36.87 37.00 37.09 37.22
AT 36.40 36.34 36.55 36.65 36.77 36.88 36.97 37.13 37.12
CC 36.67 36.62 36.90 37.10 37.18 37.29 37.34 37.39 37.47
DD 35.83 35.82 35.96 36.17 36.30 36.50 36.60 36.62 36.63
JC 36.23 36.20 36.27 36.50 36.62 36.83 36.97 36.99 37.07
JK 36.50 36.50 36.82 37.17 37.40 37.65 37.76 37.79 37.80
JM 36.35 36.35 36.48 36.67 36.75 36.94 37.08 37.14 37.26
MC 36.12 36.06 36.22 36.47 36.52 36.71 36.84 36.91 37.03
TT 36.18 36.13 36.30 36.55 36.81 37.22 37.46 37.69 37.82
JR 36.12 36.05 36.10 36.36 36.43 36.64 36.76 36.85 36.88
NY 36.47 36.34 36.38 36.56 36.69 36.90 37.02 37.07 37.15
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 35.72 35.80 36.13 36.47 36.60 36.85 36.98 37.05 37.28
AT 36.42 36.33 36.38 36.53 36.63 36.79 37.02 37.12 37.33
CC 36.56 36.58 36.86 37.04 37.06 37.26 37.34 37.36 37.36
DD 35.75 35.75 35.90 36.11 36.24 36.51 36.63 36.70 36.81
JC 36.28 36.20 36.34 36.56 36.64 36.84 37.00 37.14 37.31
JK 36.59 36.57 36.74 36.96 37.15 37.40 37.58 37.69 37.77
JM 36.26 36.22 36.35 36.55 36.62 36.81 36.91 37.02 37.14
MC 36.09 35.95 36.10 36.39 36.46 36.70 36.86 36.92 37.02
TT 35.72 35.69 35.90 36.20 36.48 36.83 37.09 37.26 37.44
JR 35.91 35.92 36.04 36.24 36.35 36.57 36.82 36.99 37.15
NY 36.39 36.33 36.37 36.54 36.71 36.94 37.09 37.19 37.33
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 36.45 36.49 36.57 36.74 36.95 37.35 37.77 38.13 38.36
AT 37.13 37.28 37.46 37.64 37.81 38.11 38.39 38.70 38.98
CC 37.14 37.23 37.35 37.48 37.63 37.93 38.20 38.40 38.62
DD 36.11 36.15 36.48 36.59 36.72 36.96 37.20 37.39 37.59
JC 36.69 36.72 36.96 37.15 37.33 37.73 37.99 38.33 38.68
JK 37.23 37.35 37.64 37.77 37.88 38.19 38.51 38.79 39.06
JM 36.82 36.83 36.92 37.03 37.13 37.38 37.72 38.06 38.44
MC 36.73 36.67 36.76 36.87 36.99 37.14 37.41 37.68 38.00
TT 36.54 36.63 37.06 37.41 37.69 38.16 38.73 39.11 39.11
JR 36.55 36.69 36.92 37.00 37.19 37.51 37.88 38.28 38.63
NY 36.79 36.76 36.99 37.19 37.34 37.67 38.00 38.27 38.54
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 36.29 36.40 36.65 36.93 37.18 37.67 38.04 38.26 38.44
AT 37.23 37.27 37.37 37.49 37.65 37.90 38.16 38.57 38.94
CC 37.26 37.31 37.47 37.56 37.70 37.95 38.26 38.43 38.69
DD 36.50 36.48 36.63 36.71 36.83 37.09 37.33 37.53 37.70
JC 36.77 36.75 36.81 36.89 37.03 37.26 37.54 37.95 38.36
JK 37.23 37.39 37.79 37.95 38.01 38.28 38.51 38.72 38.93
JM 36.66 36.69 36.79 36.89 37.00 37.25 37.56 37.77 38.04
MC 36.71 36.67 36.75 36.82 36.86 37.10 37.39 37.68 37.97
TT 36.32 36.38 36.77 37.09 37.38 37.79 38.24 38.60 38.99
JR 36.93 36.87 36.98 37.01 37.16 37.36 37.62 37.95 38.33




TIME 0 5 10 15 20 30 40 50 60
AP 36.70 36.68 36.95 37.20 37.38 37.67 37.82 37.94 38.03
AT 37.16 37.09 37.21 37.28 37.45 37.60 37.69 37.95 37.97
CC 37.40 37.43 37.68 37.86 37.99 38.15 38.21 38.30 38.34
DD 36.66 36.66 36.75 36.89 37.00 37.21 37.34 37.42 37.40
JC 37.04 37.06 37.12 37.27 37.42 37.68 37.87 37.98 38.06
JK 37.31 37.34 37.62 37.97 38.18 38.44 38.57 38.62 38.64
JM 37.16 37.18 37.26 37.37 37.49 37.70 37.85 37.95 38.06
JR 36.99 36.97 36.99 37.18 37.26 37.51 37.63 37.75 37.76
MC 37.07 37.07 37.17 37.27 37.37 37.58 37.78 37.94 38.06
TT 36.91 36.94 37.09 37.34 37.60 38.02 38.29 38.54 38.67
NY 37.23 37.18 37.21 37.33 37.43 37.64 37.77 37.87 37.89
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 36.53 36.69 37.05 37.28 37.40 37.68 37.87 37.92 38.11
AT 37.16 37.12 37.08 37.22 37.35 37.54 37.80 38.04 38.19
CC 37.36 37.44 37.69 37.87 38.00 38.18 38.29 38.37 38.44
DD 36.57 36.59 36.70 36.84 36.99 37.26 37.41 37.51 37.59
JC 37.12 37.06 37.17 37.31 37.44 37.71 37.93 38.12 38.26
JK 37.44 37.46 37.59 37.81 38.01 38.29 38.47 38.60 38.69
JM 37.10 37.10 37.18 37.31 37.41 37.61 37.77 37.90 37.99
JR 36.77 36.81 36.89 37.01 37.13 37.39 37.64 37.84 38.00
MC 37.02 36.91 37.00 37.13 37.27 37.53 37.80 37.93 38.01
TT 36.49 36.55 36.72 37.02 37.27 37.60 37.89 38.11 38.26
NY 37.27 37.23 37.27 37.41 37.53 37.75 37.91 38.04 38.16
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 36.80 36.81 36.89 37.05 37.23 37.63 38.06 38.51 38.86
AT 37.38 37.47 37.64 37.90 38.10 38.48 38.80 39.22 39.52
CC 37.42 37.45 37.58 37.74 37.89 38.22 38.53 38.83 39.12
DD 36.31 36.34 36.57 36.73 36.86 37.12 37.35 37.59 37.85
JC 36.97 36.98 37.18 37.38 37.58 38.03 38.37 38.75 39.07
JK 37.45 37.44 37.63 37.84 38.04 38.44 38.78 39.10 39.40
JM 37.01 37.03 37.08 37.16 37.26 37.53 37.87 38.25 38.67
JR 36.99 37.02 37.12 37.24 37.40 37.76 38.16 38.59 39.01
MC 37.13 37.10 37.14 37.22 37.31 37.57 37.86 38.16 38.46
TT 36.78 36.84 37.21 37.59 37.91 38.44 39.04 39.46 39.48
NY 37.10 37.06 37.23 37.43 37.59 37.92 38.24 38.59 38.92
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 36.73 36.83 37.05 37.30 37.53 38.07 38.45 38.73 38.99
AT 37.49 37.46 37.57 37.73 37.93 38.33 38.70 39.15 39.51
CC 37.43 37.45 37.61 37.77 37.92 38.23 38.56 38.89 39.22
DD 36.77 36.71 36.76 36.88 37.02 37.29 37.54 37.83 38.01
JC 37.04 37.02 37.04 37.11 37.23 37.52 37.88 38.30 38.73
JK 37.40 37.47 37.82 38.08 38.24 38.54 38.79 39.04 39.30
JM 36.94 36.96 37.01 37.09 37.21 37.50 37.81 38.14 38.45
JR 37.12 37.10 37.13 37.21 37.32 37.60 37.93 38.34 38.67
MC 37.14 37.11 37.15 37.22 37.32 37.61 37.93 38.23 38.54
TT 36.58 36.62 36.93 37.27 37.57 38.01 38.47 38.84 39.29




TIME 0 5 10 15 20 30 40 50 60
AP 29.82 29.47 29.70 30.81 31.07 31.54 31.50 31.43 31.74
AT 31.34 31.31 32.13 32.43 32.23 32.11 32.14 31.65 31.44
CC 31.79 31.19 31.69 32.00 31.72 31.54 31.55 31.34 31.66
DD 30.29 30.19 30.66 31.33 31.59 31.73 31.61 31.30 31.41
JC 30.79 30.46 30.59 31.38 31.33 31.14 30.92 30.35 30.41
JK 31.07 30.94 31.50 31.85 32.16 32.31 32.30 32.20 32.20
JM 30.96 30.77 31.32 31.96 31.80 31.83 31.88 31.68 31.88
JR 30.31 29.86 30.14 30.82 30.88 30.83 30.93 30.81 30.97
MC 29.71 29.31 29.85 31.11 30.81 30.85 30.54 29.97 30.12
TT 31.32 30.72 31.00 31.26 31.49 31.86 31.90 32.05 32.14
NY 31.42 30.70 30.79 31.40 31.70 31.97 31.99 31.68 32.25
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 30.34 29.81 29.99 31.00 31.21 31.31 31.04 31.28 31.71
AT 31.41 31.05 31.75 31.94 31.82 31.79 31.86 31.00 31.61
CC 31.24 30.88 31.32 31.43 30.79 31.10 31.01 30.56 30.08
DD 30.30 30.11 30.53 31.19 31.26 31.49 31.41 31.32 31.61
JC 30.70 30.39 30.73 31.54 31.23 31.07 30.72 30.61 30.96
JK 30.88 30.66 31.01 31.25 31.38 31.50 31.63 31.54 31.57
JM 30.66 30.27 30.74 31.44 31.31 31.45 31.10 31.17 31.47
JR 30.13 30.00 30.32 31.08 31.12 31.08 31.34 31.29 31.46
MC 29.85 29.57 30.12 31.40 31.10 31.11 30.59 30.20 30.35
TT 30.54 29.96 30.36 30.76 31.25 31.67 31.75 31.64 31.92
NY 30.54 30.27 30.32 30.74 31.24 31.54 31.64 31.50 31.79
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 34.04 34.36 34.42 34.67 35.04 35.46 35.86 35.59 34.97
AT 35.48 36.06 36.23 35.87 35.85 35.60 35.64 35.20 35.34
CC 35.32 35.78 35.76 35.73 35.86 35.98 35.99 35.46 35.26
DD 34.75 34.90 35.81 35.63 35.83 35.92 36.24 36.07 35.88
JC 34.86 35.00 35.48 35.60 35.65 35.73 35.42 35.51 36.08
JK 35.77 36.70 37.73 37.31 36.80 36.50 36.74 36.71 36.76
JM 35.59 35.46 35.87 36.18 36.24 36.36 36.68 36.79 36.86
JR 33.63 34.45 35.58 35.36 35.76 35.81 35.97 36.24 36.15
MC 34.10 33.77 34.23 34.52 34.81 34.29 34.39 34.46 34.95
TT 34.93 35.24 36.07 36.15 36.23 36.34 36.61 36.76 36.76
NY 34.66 34.74 35.35 35.62 35.70 36.00 36.40 36.18 36.00
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 33.35 33.50 33.98 34.43 34.84 35.02 35.29 35.13 34.78
AT 35.52 35.95 36.05 35.89 35.76 35.01 34.56 34.69 35.11
CC 36.10 36.33 36.49 36.20 36.20 36.05 36.26 35.31 35.08
DD 34.67 34.92 35.74 35.55 35.56 35.74 35.94 35.48 35.57
JC 34.99 34.96 35.23 35.41 35.71 35.54 35.23 35.57 35.89
JK 36.09 36.83 37.63 37.11 36.46 36.59 36.65 36.60 36.43
JM 34.77 34.84 35.30 35.52 35.57 35.55 35.94 35.26 35.35
JR 35.64 35.36 35.96 35.69 36.06 35.76 35.59 35.31 36.05
MC 33.79 33.66 34.08 34.14 33.80 33.68 33.81 33.99 34.22
TT 34.55 34.78 35.72 35.89 36.10 36.33 36.69 36.94 36.97




TIME 0 5 10 15 20 30 40 50 60
AP 125 168.5 176.5 173.5 167 162.5 158 167 168
AT 138.5 188 196 199 204 200.5 209 207.5 207
CC 130.5 160 179 188.5 178.5 175.5 191 187.5 190.5
DD 126 170 201.5 196.5 198.5 204 194.5 189 191
JC 126 164.5 174 162.5 171.5 169 174 179 179
JK 128 166.5 198 191 193 187 187 185 181.5
JM 134.5 180 191.5 190 193 190.5 183.5 190.5 179
MC 118.5 166 178.5 180.5 186.5 182.5 188.5 188.5 180
TT 124.5 170 166 171.5 163 182 174 174.5 160
JR 133.5 171.5 156 204 192.5 194 198.5 182 202
NY 109 153 161.5 166.5 162 159.5 156.5 163 158.5
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 114 147 152 148.5 144.5 144.5 140.5 147.5 141
AT 136.5 181 189.5 200 195 192.5 198 193.5 188
CC 139 183 185 193.5 196 182 183 179.5 171
DD 120 166.5 180 177 168.5 168 165 160 159.5
JC 126.5 165 173 181.5 180.5 178 170 175 170.5
JK 129 180 211 195.5 192 196 185 189.5 186
JM 134.5 186.5 189 195.5 198 183 164 163.5 163.5
MC 139 179 193.5 194.5 187.5 185 188 178.5 184
TT 111 156 142 169 173.5 154.5 158.5 166 160
JR 142 178.5 211 215.5 204 205 189.5 186.5 175.5
NY 110.5 153.5 168.5 156 163 157.5 155.5 156.5 162
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 113.5 153 150.5 146 162 170 153.5 157 154.5
AT 135.5 182 176 199.5 200.5 198 205 182 197
CC 138 181 197.5 196 195 205.5 193 186.5 188
DD 128 173 178.5 185.5 194 179.5 182 182.5 186
JC 122 167 175 178.5 174.5 183 182 174.5 176
JK 134.5 182.5 191 188 194.5 194.5 189 197.5 188
JM 128.5 170 182.5 185.5 187 181.5 180 179.5 176
MC 125 146.5 182 182 187.5 190.5 194 192 185
TT 132 167.5 165 167 169 165.5 177.5 177 177
JR 145 196.5 214 220.5 203.5 207 225 190 197.5
NY 116 160 162.5 163.5 163.5 155.5 157.5 157.5 158
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 117 145.5 144.5 144.5 154 138.5 148 155.5 146.5
AT 133.5 173 205 196 207.5 206.5 201 201.5 193
CC 142.5 171.5 189.5 188.5 193 194 189 188.5 183.5
DD 124 163.5 186 182 187 193 178 172 170.5
JC 125.5 164 179 176 180.5 167.5 170 178 168.5
JK 133.5 185.5 186 185.5 190.5 196.5 185.5 195.5 183
JM 132.5 176 180.5 178.5 176 177 170.5 154.5 165
MC 132 169 170.5 175.5 175.5 178 178.5 178 173
TT 127 159 161.5 174 173 167.5 168.5 162 152.5
JR 128 174 194 192 200.5 201 196 186.5 197.5




TIME 0 5 10 15 20 30 40 50 60
AP 68.0 78.0 81.0 66.5 68.0 67.0 73.5 71.5 67.5
AT 85.0 69.0 62.5 65.0 69.5 73.5 67.5 70.5 62.5
CC 81.5 70.0 61.0 58.5 57.5 44.0 46.0 58.0 45.0
DD 54.5 64.5 63.0 68.5 61.0 60.0 65.0 67.0 62.5
JC 71.5 68.5 67.5 64.0 67.0 66.5 73.5 72.0 63.0
JK 80.5 70.5 74.0 62.0 64.0 65.5 56.5 56.0 58.0
JM 94.5 88.5 80.0 74.0 79.0 78.5 69.0 75.5 70.5
MC 75.0 87.0 72.0 71.5 69.5 57.0 65.0 62.5 60.5
TT 83.0 88.0 79.5 73.5 84.0 84.0 72.5 75.5 60.0
JR 81.5 93.5 94.5 68.0 73.0 68.5 69.0 74.0 73.0
NY 74.0 74.5 77.5 76.0 73.5 70.5 76.0 78.5 69.0
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 72.0 79.5 74.0 72.0 73.0 69.0 66.5 75.0 71.0
AT 84.5 90.0 74.0 77.5 75.5 73.0 76.0 76.0 71.5
CC 84.0 57.5 56.5 53.5 51.5 48.5 41.0 47.5 39.5
DD 75.5 72.0 71.0 76.0 67.0 61.0 64.0 63.0 58.5
JC 84.0 76.5 82.0 86.0 73.0 73.0 77.5 64.5 62.0
JK 78.0 88.0 85.5 77.0 77.0 68.0 68.5 71.5 66.5
JM 92.5 79.5 82.5 82.0 76.5 74.0 74.5 76.0 72.0
MC 81.5 81.5 96.5 97.0 92.0 101.5 89.5 88.0 90.5
TT 74.0 90.0 89.0 71.5 63.5 72.0 58.0 71.5 55.5
JR 93.0 89.5 80.0 80.5 74.5 71.0 69.5 54.0 63.5
NY 81.5 82.5 86.5 83.0 79.0 82.5 84.0 82.0 87.0
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 69.5 70.5 69.5 58.0 56.5 53.0 51.0 49.5 59.5
AT 77.5 76.5 48.0 52.0 56.5 51.0 52.0 48.0 51.5
CC 79.0 53.5 55.0 54.5 61.0 71.0 46.0 47.5 45.0
DD 81.5 64.0 64.0 54.0 59.5 50.0 54.0 53.5 52.5
JC 83.0 63.5 50.0 48.5 50.5 41.0 40.5 51.0 48.0
JK 76.5 69.5 72.5 59.5 67.0 58.0 55.5 59.5 61.0
JM 76.0 69.0 69.5 69.0 70.0 63.0 61.0 59.5 53.5
MC 78.5 86.5 77.5 67.5 66.0 63.0 51.0 53.5 42.5
TT 80.5 79.0 77.0 78.5 80.0 72.5 51.0 54.5 54.5
JR 74.5 66.0 71.0 58.5 53.0 63.0 50.5 49.5 52.5
NY 80.5 80.0 85.0 84.0 84.5 74.0 73.5 68.0 65.0
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 69.0 73.5 70.5 73.0 70.5 66.0 69.5 65.0 58.5
AT 78.5 65.0 63.0 61.0 62.0 53.0 51.0 55.0 51.5
CC 85.0 49.5 50.5 53.5 46.5 35.0 42.5 47.0 42.5
DD 63.5 63.0 53.5 58.5 57.0 54.0 55.5 57.5 58.0
JC 75.5 64.0 56.5 52.5 51.5 45.5 43.0 43.0 43.0
JK 83.5 75.5 72.0 61.5 63.0 64.5 60.0 49.5 54.0
JM 82.0 82.0 74.0 74.5 73.0 66.5 65.5 55.0 60.5
MC 81.5 70.5 72.0 69.5 66.0 66.5 58.0 60.0 61.0
TT 80.0 80.5 62.5 67.5 63.5 58.5 56.5 50.5 43.5
JR 72.5 75.5 78.5 73.5 73.5 64.5 53.0 47.5 43.0




TIME 0 5 10 15 20 30 40 50 60
AP 87.0 108.2 112.8 102.2 101.0 98.8 101.7 103.3 101.0
AT 102.8 108.7 107.0 109.7 114.3 115.8 114.7 116.2 110.7
CC 97.8 100.0 100.3 101.8 97.8 87.8 94.3 101.2 93.5
DD 78.3 99.7 109.2 111.2 106.8 108.0 108.2 107.7 105.3
JC 89.7 100.5 103.0 100.8 101.8 100.7 107.0 107.7 101.7
JK 96.3 102.5 115.3 105.0 107.0 106.0 100.0 99.0 99.2
JM 107.8 119.0 117.2 112.7 117.0 115.8 107.2 113.8 106.7
JR 98.8 119.5 115.0 113.3 112.8 110.3 112.2 110.0 116.0
MC 89.5 113.3 107.5 107.8 108.5 98.8 106.2 104.5 100.3
TT 96.8 115.3 108.3 106.2 110.3 116.7 106.3 108.5 93.3
NY 85.7 100.7 105.5 106.2 103.0 100.2 102.8 106.7 98.8
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 86.0 102.0 100.0 97.5 96.8 94.2 91.2 99.2 94.3
AT 101.8 120.3 112.5 118.3 115.3 112.8 116.7 115.2 110.3
CC 102.3 99.3 99.3 100.2 99.7 93.0 88.3 91.5 83.3
DD 90.3 103.5 107.3 109.7 100.8 96.7 97.7 95.3 92.2
JC 98.2 106.0 112.3 111.2 108.8 108.0 108.3 101.3 98.2
JK 95.0 118.7 127.3 116.5 115.3 110.7 107.3 110.8 106.3
JM 106.5 115.2 118.0 119.8 117.0 110.3 104.3 105.2 102.5
JR 98.0 119.3 119.3 123.4 120.3 114.6 110.3 104.1 103.5
MC 100.7 114.0 128.8 129.5 123.8 129.3 122.3 118.2 121.7
TT 86.3 112.0 106.7 104.0 100.2 99.5 91.5 103.0 90.3
NY 91.2 106.2 113.8 107.3 107.0 107.5 107.8 106.8 112.0
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 84.2 98.0 96.5 87.3 91.7 92.0 85.2 85.3 91.2
AT 96.8 111.7 90.7 101.2 104.5 100.0 103.0 92.7 100.0
CC 98.7 96.0 102.5 101.7 105.7 115.8 95.0 93.8 92.7
DD 97.0 100.3 102.2 97.8 104.3 93.2 96.7 96.5 97.0
JC 96.0 98.0 91.7 91.8 91.8 88.3 87.7 92.2 90.7
JK 95.8 107.2 112.0 102.3 109.5 103.5 100.0 105.5 103.3
JM 93.5 102.7 107.2 107.8 109.0 102.5 100.7 99.5 94.3
JR 98.0 109.5 118.7 112.5 103.2 111.0 108.7 96.3 100.8
MC 94.0 106.5 112.3 105.7 106.5 105.5 98.7 99.7 90.0
TT 97.7 108.5 106.3 108.0 109.7 103.5 93.2 95.3 95.3
NY 92.3 106.7 110.8 110.5 110.8 101.2 101.5 97.8 96.0
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 85.0 97.5 95.2 96.8 98.3 90.2 95.7 95.2 87.8
AT 96.8 101.0 110.3 106.0 110.5 104.2 101.0 103.8 98.7
CC 104.2 90.2 96.8 98.5 95.3 88.0 91.3 94.2 89.5
DD 83.7 96.5 97.7 99.7 100.3 100.3 96.3 95.7 95.5
JC 92.2 97.3 97.3 93.7 94.5 86.2 85.3 88.0 84.8
JK 100.2 112.2 110.0 102.8 105.5 108.5 101.8 98.2 97.0
JM 98.8 113.3 109.5 109.2 107.3 103.3 100.5 88.2 95.3
JR 91.0 108.3 117.0 113.0 115.8 110.0 100.7 93.8 94.5
MC 98.3 103.3 104.8 104.8 102.5 103.7 98.2 99.3 98.3
TT 95.7 106.7 95.5 103.0 100.0 94.8 93.8 87.7 79.8




TIME 0 5 10 15 20 30 40 50 60
AP 0.240 2.057 2.139 2.090 2.240 2.080 2.015 2.145 2.184
AT 0.396 2.011 2.018 1.989 2.053 2.035 2.121 2.131 2.065
CC 0.324 2.268 2.340 2.351 2.387 2.502 2.512 2.404 2.437
DD 0.352 1.840 1.938 1.873 1.950 1.996 2.004 1.968 1.977
JC 0.552 2.329 2.422 2.459 2.478 2.517 2.579 2.575 2.633
JK 0.312 2.028 2.009 2.082 2.116 2.104 2.131 2.176 2.151
JM 0.311 1.998 2.084 2.090 2.084 2.033 2.027 2.109 2.093
MC 0.526 2.781 2.795 2.773 2.900 2.878 2.853 2.891 2.900
TT 0.288 1.935 2.035 2.058 2.070 2.119 2.173 2.159 2.181
JR 0.404 2.370 2.428 2.560 2.665 2.621 2.676 2.680 2.649
NY 0.299 1.706 1.843 1.856 1.850 1.901 1.898 1.903 1.903
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 0.282 2.012 1.963 1.936 2.005 2.050 2.137 2.178 2.054
AT 0.391 1.990 2.024 2.132 2.179 2.191 2.188 2.235 2.197
CC 0.408 2.236 2.223 2.249 2.303 2.313 2.358 2.303 2.337
DD 0.405 1.814 1.806 1.870 2.016 1.964 1.984 1.975 1.934
JC 0.463 2.427 2.414 2.422 2.427 2.484 2.590 2.648 2.716
JK 0.209 2.000 2.160 2.116 2.133 2.193 2.147 2.181 2.161
JM 0.390 2.035 2.047 2.077 2.145 2.123 2.150 2.207 2.112
MC 0.610 2.591 2.580 2.679 2.709 2.818 2.752 2.802 2.746
TT 0.289 2.004 2.129 2.115 2.154 2.171 2.232 2.229 2.186
JR 0.503 2.292 2.361 2.455 2.526 2.636 2.607 2.609 2.606
NY 0.066 1.720 1.646 1.626 1.677 1.585 1.633 1.704 1.618
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 0.272 1.944 1.944 1.943 2.031 2.033 2.016 2.019 2.012
AT 0.255 1.963 1.978 1.996 2.129 2.102 2.093 2.119 2.181
CC 0.393 2.152 2.238 2.305 2.371 2.436 2.471 2.473 2.482
DD 0.225 1.704 1.808 1.803 1.906 1.923 1.938 1.917 1.924
JC 0.436 2.355 2.449 2.440 2.500 2.548 2.598 2.640 2.657
JK 0.407 2.086 2.142 2.105 2.229 2.132 2.200 2.316 2.272
JM 0.336 1.982 2.084 2.087 2.122 2.183 2.127 2.243 2.383
MC 0.700 2.597 2.735 2.682 2.842 2.879 2.957 2.853 2.891
TT 0.229 2.007 2.117 2.107 2.174 2.174 2.133 2.211 2.210
JR 0.529 2.339 2.412 2.514 2.638 2.648 2.694 2.728 2.712
NY 0.072 1.636 1.569 1.612 1.712 1.745 1.599 1.687 1.595
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 0.241 2.083 2.077 2.065 2.157 2.149 2.198 2.218 2.278
AT 0.379 1.875 1.880 1.929 2.023 2.049 2.164 2.051 2.020
CC 0.385 2.107 2.176 2.228 2.384 2.382 2.391 2.434 2.488
DD 0.293 1.772 1.769 1.867 1.962 1.921 1.904 1.906 1.923
JC 0.297 2.307 2.410 2.525 2.551 2.579 2.593 2.597 2.629
JK 0.342 1.977 1.955 2.049 2.163 2.134 2.167 2.183 2.213
JM 0.302 1.927 1.913 1.929 1.938 1.982 1.976 2.014 2.052
MC 0.479 2.589 2.625 2.648 2.774 2.745 2.633 2.775 2.741
TT 0.217 1.880 1.999 2.004 2.011 2.048 2.021 2.066 2.073
JR 0.474 2.319 2.383 2.407 2.519 2.642 2.602 2.666 2.693




TIME 0 5 10 15 20 30 40 50 60
AP 9.20 60.79 63.24 69.48 66.97 61.48 58.64 64.97 59.85
AT 15.35 57.76 59.82 57.83 62.22 61.15 62.71 61.18 58.87
CC 14.63 63.43 70.66 69.06 70.06 74.17 74.13 67.42 65.89
DD 13.10 50.21 55.30 54.63 55.15 54.92 55.20 56.74 53.40
JC 20.55 66.46 71.82 72.66 76.12 76.07 77.77 82.38 84.92
JK 14.32 58.84 54.66 56.16 54.78 62.19 59.72 57.71 59.23
JM 13.40 58.81 60.21 59.23 58.82 54.81 54.86 59.38 62.41
MC 25.35 89.36 89.93 87.32 96.22 91.70 93.08 94.37 90.34
TT 12.31 67.39 68.83 69.23 68.73 70.71 72.77 72.86 73.06
JR 13.85 61.40 64.63 69.06 72.64 70.73 75.74 75.10 74.41
NY 14.09 54.40 55.99 59.42 58.55 60.31 59.27 59.87 61.62
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 11.06 53.98 52.27 51.48 58.75 53.84 60.98 58.86 55.26
AT 14.21 61.04 57.99 66.22 68.73 67.52 64.52 65.39 62.07
CC 17.38 62.03 59.13 60.77 63.85 65.37 66.33 64.70 67.60
DD 14.03 50.42 47.02 51.04 52.71 56.15 53.09 54.21 57.65
JC 21.58 68.80 70.00 67.41 69.90 73.66 73.55 82.11 88.85
JK 11.49 50.97 56.69 57.92 58.24 63.08 64.85 62.05 64.59
JM 14.70 56.70 58.13 58.02 62.33 60.79 62.86 64.89 62.73
MC 25.07 77.50 74.64 81.83 84.04 85.48 85.21 84.30 79.96
TT 12.30 69.75 72.33 74.58 73.10 74.05 73.83 71.57 72.40
JR 15.75 57.61 61.87 61.70 65.07 69.05 65.24 62.42 70.82
NY 10.95 52.81 54.88 55.45 57.64 54.18 56.04 59.58 56.85
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 11.75 56.98 56.06 60.92 59.73 57.33 61.57 61.77 58.99
AT 11.69 57.23 61.12 62.44 65.24 64.94 64.78 63.48 68.25
CC 15.14 56.87 62.08 67.31 71.39 75.54 77.83 75.75 77.68
DD 9.45 51.57 54.73 55.00 58.38 58.33 59.99 61.09 54.99
JC 20.41 68.61 74.98 75.02 79.17 79.31 83.64 86.00 89.21
JK 16.91 54.56 58.50 57.44 64.58 60.30 63.84 65.14 62.38
JM 15.11 56.74 60.33 61.64 61.72 64.44 61.56 69.62 88.71
MC 30.64 79.84 85.32 82.77 92.86 99.52 103.82 108.13 103.72
TT 11.02 70.17 76.52 75.54 75.58 75.58 72.49 87.68 87.68
JR 16.21 67.28 68.43 78.42 83.03 80.07 86.20 94.54 92.23
NY 11.30 54.36 55.63 60.27 62.77 65.57 60.51 67.19 65.73
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 11.09 59.73 63.74 64.69 67.23 68.20 71.93 70.18 74.56
AT 14.07 57.99 55.09 60.92 64.67 62.68 67.84 63.23 62.22
CC 16.57 55.40 60.05 64.91 70.62 68.92 68.51 69.04 73.79
DD 12.67 48.08 52.80 52.66 55.12 54.33 53.95 56.08 53.48
JC 14.53 66.25 70.06 73.33 77.46 72.73 77.62 76.11 81.08
JK 13.96 50.14 52.72 52.76 60.14 62.76 59.56 59.46 63.07
JM 13.01 55.55 53.80 55.72 57.35 58.10 60.01 63.13 68.00
MC 29.87 73.36 83.03 82.31 91.65 90.80 85.21 90.44 95.54
TT 10.81 62.45 61.07 59.69 62.34 64.09 61.87 58.86 68.86
JR 21.88 63.55 62.92 68.29 67.99 75.20 71.49 76.74 81.24




TIME 5 10 15 20 30 40 50 60
AP 13 13 13 13 13 13 13 13
AT 12 13 13 13 13 13 13 13
CC 12 13 13 13 13 13 12 12
DD 12 13 14 14 15 15 16 15
JC 12 12 12 12 13 13 14 15
JK 12 12 12 12 12 12 12 13
JM 12 12 13 13 13 13 13 14
MC 12 12 12 12 13 13 13 14
TT 11 12 12 12 12 12 13 15
JR 8 9 11 11 12 13 14 14
NY 12 12 12 12.5 12.5 13 13 14
Normothermia + Beta Blockade
TIME 5 10 15 20 30 40 50 60
AP 13 13 13 13 13 13 13 13
AT 13 13 13 13 13 14 14 14
CC 12 12 12 12 12 12 13 13
DD 12 13 13 15 14 15 15 16
JC 12 12 13 13 13 14 14 15
JK 12 12 12 12 12 12 13 14
JM 13 13 14 14 14 15 15 15
MC 12 12 12 13 13 14 14 14
TT 13 13 13 14 14 14 15 17
JR 8 9 11 12 12 12 13 13
NY 12 12 12 13 13 13 14 14.5
Hyperthermia + Placebo
TIME 5 10 15 20 30 40 50 60
AP 14 14 14 14 15 15 15 15
AT 12.5 13 13 13 13 13 13 13
CC 12 13 13 13 13 13 13 13
DD 13 13 14 14 15 15 15 16
JC 12 12 13 13 14 15 17 18
JK 12 12 13 13 14 15 15 17
JM 12 12 13 13 14 14 15 16
MC 12 13 13 13 15 16 17 17
TT 12 12 13 13 14 16 17 17
JR 9 10 10 11 12 14 15 16
NY 12 12 12 12 13 13 14 14
Hyperthermia + Beta Blockade
TIME 5 10 15 20 30 40 50 60
AP 14 14 15 16 16.5 17 17 18
AT 13 13 13 13 13 14 14 13
CC 13 13 13 13 13 14 14 14
DD 13 14 14 15 15 16 16 16
JC 12 12 13 13 14 15 16 18
JK 11 11 12 12 13 13 13 15
JM 13 13 13 13 13 14 14 15
MC 13 13 13 13 14 15 16 16
TT 12 12 13 13 13 15 16 18
JR 9 9 11 11 14 14 16 16




TIME 0 12 35 55
AP 1.3 8.1 11.7 9.4
AT 2.9 15.3 14.2 15.2
CC 2.9 11.7 11.9 11.6
DD 1.0 7.1 7.2 8.6
JC 1.9 5.8 7.8 6.9
JK 1.8 9.1 5.2 5.9
JM 2.1 5.6 5.6 5.9
JR 0.6 5.8 6.1 7.0
MC 1.8 10.1 11.8 11.8
TT 1.3 4.5 14.3 17.2
NY 1.1 5.6 6.7 6.7
Normothermia + Beta Blockade
TIME 0 12 35 55
AP 1.0 7.2 9.9 10.6
AT 3.7 12.5 10.5 18.3
CC 3.5 13.9 15.5 16.3
DD 0.7 7.3 9.1 10.8
JC 2.1 9.2 9.7 12.8
JK 1.9 9.0 7.7 6.2
JM 1.7 6.8 8.5 6.2
JR 2.3 6.7 8.5 11.7
MC 1.7 14.8 11.2 9.7
TT 1.2 4.9 15.4 17.7
NY 1.3 8.0 7.8 8.2
Hyperthermia + Placebo
TIME 0 12 35 55
AP 1.0 9.5 11.1 11.3
AT 1.7 16.2 24.9 19.2
CC 3.4 20.4 22.4 25.0
DD 1.5 13.9 18.6 19.7
JC 2.8 10.2 14.8 14.4
JK 1.1 12.8 18.6 14.1
JM 2.4 20.4 17.2 14.1
JR 2.4 10.9 8.8 9.8
MC 4.1 18.3 21.1 16.5
TT 1.3 16.8 16.7 16.0
NY 1.0 8.3 10.1 9.2
Hyperthermia + Beta Blockade
TIME 0 12 35 55
AP 1.5 13.5 15.1 13.2
AT 4.2 23.9 23.1 23.0
CC 3.4 18.2 17.2 18.1
DD 1.6 12.4 12.7 11.4
JC 2.0 10.0 11.2 12.6
JK 1.3 18.3 19.9 13.5
JM 2.0 9.4 13.1 11.1
JR 2.5 12.9 13.8 12.9
MC 4.0 17.2 20.2 18.6
TT 0.7 13.4 15.4 17.7




TIME 0 5 10 15 20 30 40 50 60
AP 24.9 49.9 71.4 114.0 100.0 104.7 99.6 108.0 102.7
AT 32.6 59.6 192.1 173.4 180.5 192.4 179.5 171.8 172.5
CC 44.4 68.5 111.5 130.4 121.4 125.5 183.1 160.1 137.1
DD 28.6 38.5 70.9 104.2 98.4 109.8 108.3 100.9 101.8
JC 23.2 36.3 84.1 94.1 94.7 95.5 100.8 112.3 138.4
JK 20.2 24.1 31.8 58.7 51.9 49.0 61.3 61.0 72.8
JM 16.6 31.6 65.0 71.3 73.1 73.0 81.3 67.5 75.5
JR 27.8 45.9 83.0 101.0 90.6 105.0 100.7 103.2 91.4
MC 22.3 32.6 81.5 88.7 86.7 83.1 79.8 76.3 77.8
TT 21.0 27.0 49.6 97.8 113.0 191.4 187.1 192.6 187.6
Normothermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 18.5 36.0 90.3 118.1 111.4 120.0 108.0 107.4 93.8
AT 30.0 68.3 164.7 153.6 155.5 134.5 143.9 141.4 141.1
CC 34.5 44.5 80.5 84.0 80.9 96.6 98.0 92.9 90.5
DD 27.7 29.1 54.8 68.0 82.9 81.4 78.8 87.1 118.6
JC 26.5 27.0 83.6 82.1 79.2 76.5 75.8 95.3 100.6
JK 18.7 25.9 36.2 62.7 57.0 58.1 69.8 72.1 69.3
JM 17.7 24.5 60.2 66.8 68.2 66.9 73.0 68.8 66.9
JR 32.9 59.9 150.2 175.6 180.7 170.2 167.2 165.1 158.3
MC 21.0 28.9 120.8 114.7 128.2 126.7 115.2 124.9 107.7
TT 19.2 32.3 49.0 78.4 100.6 116.3 140.8 132.9 118.4
Hyperthermia + Placebo
TIME 0 5 10 15 20 30 40 50 60
AP 32.0 53.7 144.3 133.0 140.0 127.9 131.3 141.7 130.7
AT 46.4 131.7 184.8 170.5 205.3 178.0 172.9 161.8 171.6
CC 42.0 157.7 202.6 229.5 210.2 236.1 230.8 220.2 218.9
DD 23.9 26.6 64.2 69.7 75.5 83.4 90.1 89.6 89.0
JC 48.6 126.1 288.5 266.5 237.8 311.5 306.3 189.5 173.9
JK 12.4 40.9 97.8 101.2 100.6 105.9 130.0 105.9 103.4
JM 24.7 46.6 74.7 72.9 88.9 81.4 84.6 80.4 88.0
JR 45.9 183.7 214.8 202.7 181.0 190.0 185.0 161.8 168.1
MC 40.9 100.6 120.0 124.5 132.1 133.7 128.3 128.9 129.5
TT 29.3 41.7 82.7 106.6 141.8 148.0 144.5 142.0 176.9
Hyperthermia + Beta Blockade
TIME 0 5 10 15 20 30 40 50 60
AP 17.6 47.5 75.2 75.0 80.7 80.0 90.5 91.4 95.4
AT 37.6 189.9 186.7 193.3 191.0 166.3 186.3 160.7 176.0
CC 291.8 346.0 344.1 302.5 287.4 246.3 243.5 237.1 243.9
DD 33.5 55.4 123.3 124.9 102.6 134.7 104.8 98.5 101.7
JC 38.6 54.0 115.0 123.4 126.7 204.7 225.1 189.5 173.9
JK 41.0 67.4 121.9 108.6 272.9 118.2 110.4 116.6 137.8
JM 36.1 76.6 105.0 123.3 112.3 93.4 94.3 125.2 117.8
JR 3.6 163.8 199.7 201.1 198.8 201.3 201.8 184.0 188.2
MC 36.0 51.1 104.5 96.2 118.4 136.6 158.9 164.6 176.9
TT 29.3 41.7 82.7 106.6 141.8 148.0 144.5 142.0 176.9
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